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ABSTRACT 
It is common knowledge and has been shown in studies that alcoholism clusters in 
families. However, the model of inheritance in vulnerability to alcoholism is believed 
to be complex and polygenic, different subtypes of the disorder probably having 
different genetic aetiologies with a varying environmental impact on the 
development. Already in the 1980s C.R. Cloninger proposed his dichotomy of two 
subtypes in alcoholism: late-onset, socially dependent type 1, and early-onset, 
antisocial, impulsive violent type 2. The genes involved in serotonin and dopamine 
neurotransmission of the brain have been extensively studied, because these 
transmitters are believed to be crucial in mediating the acute effects of alcohol. 
However, the results of these studies have been equivocal, as alcoholics have most 
often been studied as one group suffering from a homogenous disorder. 
 Here, alcoholic subjects were classified as type 1 or type 2, and the COMT 
(coding cerebral dopamine inactivation) and 5-HTTLPR (coding serotonin 
transporter synthesis) genotypes thereafter compared between these groups and 
healthy controls (and the general population) in studies I–III. In studies IV–V, COMT 
and (DRD2) TaqI A (possibly affecting dopamine DRD2 receptor availability in the 
human brain) genotypes were studied among a large sample of non-alcoholic 
socially drinking males. 
 Type 1 alcoholism (including the majority of alcoholics) in these studies showed 
an association with dopaminergic polymorphism COMT (L allele), but not with 
serotonergic 5-HTTLPR. Type 2 alcoholism (with ASP and habitual impulsive violent 
behaviour) showed an association with serotonergic polymorphism 5-HTTLPR (S 
allele), but not with dopaminergic COMT. The results are consistent with the 
dichotomy of dopaminergic and serotonergic deficits in these subtypes of 
alcoholism, previously suggested by Cloninger before the era of molecular genetics. 
Dopaminergic polymorphisms COMT and TaqI A showed an association with 
alcohol consumption among socially drinking males, indicating the role of 
dopamine-mediated reward mechanisms in regulating non-alcoholic drinking 
patterns, as well. Careful diagnostic procedures, classification and subtyping of 
alcoholic study subjects are essential considering the heterogenous nature of this 
disorder. Comorbid disorders should be screened for to support the formulation of 
clinical subtypes. This is crucial concerning both research and individual treatment 
planning. 
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TIIVISTELMÄ  
Perinteisesti on tiedetty, ja tutkimukset ovat sen myöhemmin osoittaneet, että alkoholismia 
esiintyy suvuittain. Riski sairastua alkoholismiin periytyy, mutta on polygeenisesti (useiden 
geenien ja näiden yhdistelmien välityksellä) säädelty. Ympäristövaikutuksilla on vaihteleva 
osuus häiriön synnyssä, riippuen myös alkoholismin alatyypistä. Jo 1980-luvulla C.R. 
Cloninger ehdotti alkoholismin jakoa kahteen alatyyppiin: myöhemmällä iällä alkavaan 
sosiaaliseen tyyppi 1:een ja varhain alkavaan antisosiaaliseen tyyppi 2:een, jossa esiintyy 
impulsiivista väkivaltaisuutta. Aivojen välittäjäaineista serotoniinin ja dopamiinin on uskottu 
olevan keskeisiä alkoholin akuutin keskushermostovaikutuksen ja nousuhumalaan liittyvän 
mielihyvän aiheuttajina. Näiden välittäjäaineiden aineenvaihduntaa säätelevien geenien 
osuutta alkoholismialttiuteen on tutkittu paljon. Tulokset ovat kuitenkin olleet ristiriitaisia, 
kun alkoholisteja on useimmiten tutkittu yhtenäisenä ryhmänä, luokittelematta eri 
alatyyppeihin. 
 Näissä tutkimuksissa alkoholismista kärsivät tutkimushenkilöt on luokiteltu tyyppi 1- ja 
tyyppi 2-alkoholisteiksi. COMT- ja 5-HTTLPR-genotyyppejä verrattiin näiden kahden 
alkoholistiryhmän, terveiden kontrollihenkilöiden (ja yleisväestön) välillä tutkimuksissa I–III. 
COMT-geeni koodaa entsyymiä, joka säätelee dopamiinin inaktivaatiota aivoissa, ja 5-
HTTLPR-geeni koodaa serotoniinitransportterin synteesiä. Tutkimuksissa IV–V selvitettiin 
suuressa joukossa sosiaalisesti juovia miehiä, vaikuttaako COMT- tai (DRD2) TaqI A–
genotyyppi alkoholin kulutukseen. TaqI A-geeni säätelee mahdollisesti aivojen dopamiinin 
aineenvaihduntaa. 
 Tyyppi 1-alkoholisteilla havaittiin assosiaatio dopaminergisen COMT-polymorfismin L-
alleeliin mutta ei assosiaatiota serotonergiseen 5-HTTLPR-genotyyppiin. Tyyppi 2-
alkoholisteilla puolestaan havaittiin assosiaatio 5-HTTLPR-polymorfismin S-alleelin kanssa 
mutta ei COMT-polymorfismin kanssa. Löydökset tukevat Cloningerin aiempaa oletusta 
näiden alkoholismin alatyyppien taustalta löytyvästä dopaminergisestä (tyyppi 1) tai 
serotonergisestä häiriöstä (tyyppi 2). Dopaminergisillä polymorfismeilla COMT- ja Taq1 A 
osoitettiin assosiaatio sosiaalisesti alkoholia käyttävien miesten viikoittain käyttämiin 
alkoholimääriin. Tämä tuki oletusta, että dopamiiniaiheenvaihdunnalla on merkitystä 
juomatapojen säätelijänä silloinkin, kun kyseessä ei ole alkoholismi. Alkoholismia 
tutkittaessa huolellinen diagnostiikka ja jako alatyyppeihin on keskeistä, kun kyseessä mitä 
ilmeisemmin näidenkin tutkimusten valossa on heterogeeninen, epäyhtenäinen joukko 
sairastuneita. Samanaikaiset psyykkiset häiriöt tulisi diagnosoida ja seuloa alkoholismin 
alatyyppien tunnistamiseksi (mm. tyyppi-2-alkoholismiin liittyvä antisosiaalinen 
persoonallisuushäiriö). Tämä on olennaista sekä tutkimuksen että yksilöllisen hoidon 
suunnittelun kannalta. 
 
 
Yleinen suomalainen asiasanasto: aineenvaihdunta; alkoholismi; dopamiini; juomatavat; 
perinnöllisyys; serotoniini; välittäjäaineet
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is dedicated to all those wondering
whether addiction is a disease or not,
and to those who are not sure if they have been affected or not. 
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1 INTRODUCTION 
In 2006, 88 % of the adult population in Finland reported using alcohol. The 
number of heavy consumers is estimated to be 6–12 % of the adult population, 
as many as 500 000 individuals. This 10% of drinkers with the highest 
consumption account for almost half of the alcohol (for over 40%) consumed in 
Finland. Most young people start to experiment with drinking between the ages 
of 12 and 16 years, and only one-fifth of 16-year-olds were not using alcohol at 
all in 2006. The latest rapid increase in consumption and adverse effects of the 
increase were seen after the lowering of taxes on alcoholic beverages in the 
beginning of 2004. In 2006, the average adult total alcohol consumption in 
Finland was 10.6 litres of 100% alcohol. The total consumption has more than 
doubled over the past three decades. This has brought Finland to the medium 
level of alcohol consumption among European countries. Compared with them, 
binge drinking (heavy intoxication) still continues to be more common in Finland 
(Mäkelä, 2003; Nylander et al., 2007). 
 The number of alcohol-related deaths was estimated as 3050 in 2006, and 
there was an increase of over 20% in the seven years since 1999, and an 
especially rapid growth since 2004. The increase was exclusively due to 
alcohol-related diseases or alcohol poisonings, since the number of fatal 
accidents or violence with alcohol involved had not changed. Alcohol-related 
causes were the most common cause of death among working-age (15–64 
years) males and females in Finland in 2006. In recent years, some 80% of the 
fatal violent offences and 70% of assaults have been committed under the 
influence of alcohol. It was estimated that in 2005 Finnish society paid almost 
one million euros in direct costs, and between three and six billion euros in 
indirect costs, as a result of alcohol use (Nylander et al., 2007). 
 The clinical outcome of alcoholism after a standard detoxification treatment is 
known to be poor, even if psychosocial therapy is implemented, up to 70% of 
alcoholics resuming drinking within one year. However, the results of the 
research in the past 30 years suggest that individuals who had obtained 
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treatment for their drinking problem still had a slightly better outcome than those 
who did not (Johnson, 2008). Even so, the data from long-term follow-up 
studies suggest a very low effectiveness of the treatments available. In addition, 
several large studies have shown that the traditional Twelve Step Facilitation of 
Alcoholics Anonymous continues to be as effective as the more modern and 
costly cognitive and behavioural therapies (Room et al., 2005). The medications 
tried so far have shown only a modest additive effect, and the efficacy is usually 
seen only in limited subpopulations of the treated alcoholics. Molecular genetic 
studies are expected to help in targeting the existing pharmacological 
treatments at different types of alcoholics for a better response, and to develop 
completely new treatments by detecting the differences in neurobiology of the 
various forms of alcoholism (Room et al., 2005; Johnson, 2008). 
 The individual vulnerability to alcohol use disorders can be both inherited and 
environmental. Family studies have shown this to be true, and twin pair studies 
have suggested that genetic and environmental factors are equally important in 
determining the risk for alcoholism (50-50%). Numerous adoption studies have 
also provided strong support for the action of genetic factors (Goldman et al., 
2005a). Based on the strong familial aggregation of alcohol abuse and twin 
studies in Sweden and in the USA, C.R. Cloninger proposed the dichotomy of 
two subtypes in alcoholism: late-onset, socially dependent, cautious type 1, and 
early-onset, antisocial, impulsive violent type 2. Cloninger originally proposed a 
dichotomy of dopaminergic and serotonergic deficits in neurotransmission 
between these subtypes (Cloninger, 1987; Cloninger, 1995). Later studies on 
the neurobiology of alcoholism and violence have supported Cloninger’s ideas 
(Bowirrat and Oscar-Berman, 2005). In the field of molecular genetics, most of 
the candidate genes implicated in alcoholism have been related to 
neurotransmission (or alcohol metabolism). The model of inheritance in 
vulnerability to alcoholism is believed to be complex and polygenic, different 
subtypes of the disorder probably having different genetic aetiologies, with a 
varying environmental impact on the development (Bevilacqua and Goldman, 
2009). 
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 Considering the heterogeneity of alcohol use disorders, the affected study 
subjects in genetic studies should be classified into subtypes on the basis of 
available research evidence. However, only a few of the studies on candidate 
genes and alcoholism have been conducted this way, whereas the molecular 
genetic linkage studies among large family samples have yielded intermediate 
phenotypes. These phenotypes are more homogenous clinical subgroups of 
alcoholic individuals, believed to have shared neurobiology and vulnerability to 
the disorder. This classification of subgroups has been applied in studies to 
increase the power of association (Enoch et al., 2003; Schuckit et al., 2004; 
Goldman and Ducci, 2007; Bevilacqua and Goldman, 2009). Some of the 
results have also supported the existence of Cloninger’s dichotomy among 
alcoholics, and this neurogenetic model still offers a simple way to categorize 
the index subjects in a clinical interview (Dick et al., 2002; Fu et al., 2002). The 
combined results of studies on serotonergic and dopaminergic genes in 
alcoholism have been equivocal. The suggested reasons for this inconsistency 
have included studying polymorphisms with an unknown functional impact, 
ethnically different study populations (even different from the controls in the 
same study), and studying all alcoholics as one group suffering from a 
homogenous disorder (Comings and Blum, 2000; Trikalinos et al., 2004). 
 In our studies we tried to avoid the weaknesses in the previous candidate 
gene studies on alcoholism. The alcoholic index subjects were classified as type 
1 or 2, as Cloninger has proposed. We were studying the functional 
polymorphisms COMT and 5-HTTLPR, shown to affect dopamine and serotonin 
transmission. We also investigated whether the dopaminergic polymorphisms 
COMT or TaqI A, believed to affect dopamine transmission as well, had any 
impact on alcohol consumption among a large population sample of socially 
drinking males. These men, and all of the affected index subjects and controls, 
were white males of Finnish origin representing an ethnically homogenous 
group. 
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2 REVIEW OF THE LITERATURE 
 
2.1 Social drinking, abuse and dependence of alcohol 
What is a sensible or a "healthy" amount of alcohol to drink? Where is the limit 
between social drinking and abuse? Who is an alcoholic? The answers to the 
last two questions can be found in the diagnostic manuals. They do not list the 
amounts of alcohol consumed, however, only the ways alcohol has taken over 
the life of an affected individual. The debate about the healthy amount to drink 
is based on the findings of a decreased risk of cardiovascular diseases among 
subjects drinking small to moderate amounts of alcohol, compared with the risk 
of abstainers. Another reason fuelling this debate is probably the popularity of 
alcohol as a legal recreational substance. With respect to total mortality, the risk 
is illustrated as a J shaped curve, with alcohol consumed on the x axis and 
mortality on the y axis. When the amount consumed increases from the bottom 
of the J, the health hazards and total mortality significantly and rapidly increase 
as well. It means that drinking too much is eventually worse than drinking 
nothing at all. Low levels of alcohol intake (1-2 drinks per day for women and 2-
4 drinks per day for men) are inversely associated with total mortality in both 
men and women. This was stated in a meta-analysis by Di Castelnuovo et al. 
(2006). Another more recent review questioned this generally accepted finding, 
suggesting a systematic error in prospective epidemiological studies reporting 
that moderate regular use of alcohol is protective against coronary heart 
disease. Fillmore et al. (2007) claimed that the abstainer category in most of the 
studies has been contaminated by former drinkers who quit because of ill 
health. The few studies without this error showed abstainers and moderate 
drinkers to be at equal risk for all-cause and coronary heart disease mortality, 
i.e. low levels of alcohol were not protective at all (Fillmore et al.,2007). 
 The limits for the safe use of alcohol, based on the available evidence, were 
set by Royal Colleges of Physicians, Psychiatrists and General Practitioners in 
Great Britain in 1995: 168 grams of ethanol weekly for a male, and 112 grams 
for a female, 21 units and 14 units of drink, respectively. Daily limits of not more 
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than three drinks for a male and two for a female have also been 
recommended, to avoid favouring binge drinking at weekends (Jackson and 
Beaglehole, 1995; Gaziano and Hennekens, 1995). The same limits have been 
adopted in Finland to identify excessive alcohol use. The nationally 
recommended limits for hazardous drinking, between social drinking and abuse, 
are 24 drinks weekly for a male and 16 for a female (Halme et al., 2008). 
 In Finland, binge drinking at weekends is a very common feature of alcohol 
use. The risk limits for this heavy drinking aiming at intoxication are five units for 
a female and seven units for a male, on one day, every weekend (Seppä, 
2003). In a sense, drinking more than these recommendations is considered 
heavy drinking, and beyond the scale of social alcohol consumption. Inevitably 
there are individual differences and great variation in the risks and harms 
experienced by a single person in this heavy, or hazardous, drinking group; not 
everybody becomes an alcohol-dependent alcoholic. Still, this is a high-risk 
group and there is only a thin line marking the shift from heavy use to alcohol 
abuse. Abuse, on the other hand, has a considerable overlap with true alcohol 
dependence. There is no conclusive evidence of the prognosis from heavy 
drinking to dependence, neither are there any longitudinal studies showing the 
lack of that prognosis, or indicating individual protective factors (Halme et al., 
2008). 
 The life of an alcoholic individual has been described as a cycle of 1) 
anticipation, 2) intoxication, and 3) withdrawal with a negative affect. The 
essential features of alcohol addiction/dependence are preoccupation with the 
next drink, loss of control over consumption, and seemingly compulsory 
continuation with the vicious circle despite knowledge of negative long- and 
short-term consequences (Koob, 2003). The aetiology of alcohol dependence is 
far from known, and the variation between the affected subjects is considerable, 
reflecting the heterogenous nature of addictive states in general. Elucidating the 
interactive environmental and hereditary factors that contribute to the 
development of alcohol dependence will permit a better comprehension of the 
reasons why some people are unable to control their alcohol use. It is hoped 
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that understanding the genetic predisposition to alcohol use disorders will 
enable a better understanding of the biological mechanisms involved. This in 
turn would provide us with a framework for the development of treatment and 
relapse prevention approaches. In addition, the classifications developed for 
genetic studies of alcoholic subjects may even help to target the treatments 
better than today. Of course, that would be the ideal outcome of the genetic 
studies as well, targeting the treatment according to the genotype of the patient 
(Ball and Collier, 2002). 
 The essential nature of substance dependence makes these disorders 
frustrating to treat and leads to repetitive disappointments, not just to the 
dependent individual and his/her near ones, but also to professionals trying to 
help the affected. The core symptom of dependence/addiction is relapse and 
the continuous risk of relapse. The risk seems to decrease during very long 
periods of abstinence, but apparently it never disappears. Even among medical 
professionals, not to mention public opinion, there is often discomfort and 
reluctance to apply the label of illness to substance use disorders such as 
alcohol abuse. They are often viewed as arising from poor self-control, 
character weakness, or lack of moral fibre, and are generally considered to be 
self-acquired states. These views are in contradiction with the scientific 
evidence on the nature and development of addictive states, recognizing 
addiction as a brain disease (Melis et al., 2005). Some of these data, the earlier 
dating back to the 1970’s, are presented in this review below. Consistently with 
the disease concept, substance use disorders including alcoholism have been 
constantly listed and described in the international classifications of diseases for 
several decades. The latest versions of these classifications are reviewed next. 
 
2.1.1 Diagnosis of alcoholism 
Clinical addictions are generally diagnosed using the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-III-R, 1987; DSM-IV, 1994) issued by the 
American Psychiatric Association (APA), or the International Classification of 
Disease (ICD) of the World Health Organization (WHO). These classifications 
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are generally used for research purposes, too. Both manuals recognize two 
categories of addictive/dependant behaviours: the less serious form of abuse, 
and the more serious form of dependence. Clinically, abuse is often observed to 
precede and predict actual dependence (American Psychiatric Association, 
1987; American Psychiatric Association, 1994; WHO, 1993; Stakes, 1997). 
 The DSM-IV criteria for alcohol abuse are: 1) recurrent use resulting in a 
failure to fulfil the main obligations at work, school or home; 2) recurrent use in 
physically hazardous situations; 3) recurrent alcohol-related legal problems; and 
4) continued use despite persistent or recurrent social or interpersonal problems 
caused or exacerbated by the use. At least one of the four during the previous 
12 months is required, and the subject must not have fulfilled the criteria for 
alcohol-dependence ever. The criteria for alcohol dependence are: 1) observed 
tolerance to alcohol; 2) withdrawal symptoms or the need to use alcohol to 
avoid symptoms; 3) alcohol used in larger amounts or over longer periods than 
intended; 4) unsuccessful efforts to cut down the use; 5) excessive time related 
to obtaining alcohol or recovering from drinking; 6) impaired social, recreational 
or work activities because of drinking; and 7) continued use despite knowledge 
of the physical or psychological consequences. The diagnosis requires at least 
three of these seven criteria during the previous 12 months. 
 The former version of DSM-III-R included the same symptoms of alcohol 
dependence grouped differently in nine criteria, of which three were required for 
a diagnosis. There were fewer criteria for abuse and they were less strict than in 
the later DSM-IV, but essentially the same core symptoms of abuse were listed 
in both versions (APA 1987; APA 1994). The ICD-10 criteria for the harmful use 
of alcohol (synonymous with abuse) include clear evidence of physical or 
psychological harm which may harm interpersonal relationships. At least one 
month of constant use or repetitive use during the previous 12 months is 
required, and the symptoms must not fulfil the criteria for alcohol dependence. 
The criteria for dependence are: 1) an irresistible urge to drink; 2) drinking more 
or over a longer period than intended, or unsuccessful attempts to cut down on 
drinking; 3) withdrawal symptoms or use of alcohol to avoid these symptoms; 
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drinking alcohol or recovering after drinking; and 6) continued use despite 
knowledge of the physical or psychological consequences. At least three of 
these criteria are required during the whole of the previous month or repeatedly 
during the previous 12 months (WHO, 1993; Stakes, 1997). 
 The criteria of the DSM or ICD classification for alcohol dependence do not 
essentially differ, ICD-10 having been the official classification in Finland since 
the end of the 1990s. The diagnostic criteria used in this thesis, when 
appropriate, are based on the more precisely defined DSM (versions III-R and 
IV). Regarding genetic studies, the problem with these relatively strict 
classifications is that they are based on the outcome. They do not reflect 
aetiologies of vulnerability to alcohol abuse or dependence, but just define the 
endpoint of the disease process, the endpoint being a heterogeneous group of 
alcoholics with different aetiological backgrounds (Ducci and Goldman, 2008). 
The strategies to discover the genetic effects in diseases with complex 
aetiologies (as alcoholism has proven to be) include reclassification of the 
disorder into less heterogeneous subtypes, such as using Cloninger’s typology 
or defining intermediate phenotypes. These methods are discussed below in the 
relevant sections. In this dissertation "alcohol abuse" and "alcohol dependence" 
are included in "alcohol use disorders". Abuse and dependence are commonly 
used as synonyms in clinical contexts and records, but dependence actually is a 
more advanced and a more precisely defined state of abuse. In a diagnostic 
context there is a clinical overlap even when using DSM criteria. "Substance 
use disorders" here includes all substances of abuse, also alcohol. "Alcohol 
dependence" and "alcoholism" and "alcohol addiction" are used as synonyms. 
An "alcoholic" is an "alcohol dependent" individual. 
 The Michigan Alcoholism Screening Test (MAST) was originally developed 
and validated as a structured interview instrument to rapidly detect alcoholism 
with 25 simple "yes" or "no" questions. It has been reliably used as a self-
administered aid for a clinical interview, as was done to screen the type 1 
alcoholic subjects in this study. Even the validation study found the number of 
4) observed tolerance to alcohol; 5) excessive time related to obtaining and 
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false positives to be very low; MAST does not often identify a non-alcoholic as 
an alcoholic (Selzer, 1971). Alcohol consumption of the socially drinking 
subjects in these studies was assessed with a structured quantity and 
frequency method from the Nordic alcohol consumption inventory and its 
modification (Hauge and Irgens-Jensen, 1981; Kauhanen et al., 1992). 
 
2.1.2 Diagnosis of antisocial personality disorder 
To classify the alcoholic subjects in this study (type 1 versus type 2 alcoholism), 
they were screened for antisocial personality disorder (ASPD) according to the 
DSM-IV criteria, as well as for alcohol dependence. The criteria for antisocial 
personality disorder describe a pervasive pattern of disregard for and violation 
of the rights of others occurring since the age of 15 years: 1) failure to conform 
to social norms with respect to lawful behaviours (arrested repeatedly); 2) 
deceitfulness (indicated by repeated lying, or conning others); 3) impulsivity or 
failure to plan ahead; 4) irritability and aggressiveness (repeated physical fights 
or assaults); 5) reckless disregard for the safety of self or others; 6) consistent 
irresponsibility (failure to sustain consistent work behaviour or fulfil financial 
obligations); and 7) lack of remorse (indifferent or rationalizing behaviour after 
having mistreated or stolen from others). At least three of these criteria must be 
present. The individual has to be at least 18 years of age when diagnosed, and 
there has to be evidence of conduct disorder before the age of 15. Conduct 
disorder is defined as a repetitive and persistent pattern of behaviour in which 
either the basic rights of others or major age-appropriate social norms or rules 
are violated (including different forms of aggression to people or animals, 
destruction of property, deceitfulness or theft, and serious violations of rules) 
(American Psychiatric Association, 1994). 
 Given the similar pattern of symptoms, it is not difficult to see that conduct 
disorder in a subject less than 15 years of age predicts antisocial personality 
disorder in the adult. The antisocial personality disorder shares many of its traits 
with Cloninger’s type 2 alcoholism described in a section below. 
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2.1.3 Epidemiology and co-morbidity of alcoholism 
The lifetime prevalence of alcohol dependence or abuse in the USA in 1990 
was estimated to be 13.5% in a large epidemiological catchment area (ECA) 
study, in which over 20 000 persons were interviewed. Almost 40% of those 
suffering from alcohol disorder also suffered from another mental disorder, the 
highest rates of specific disorders being affective, anxiety or antisocial 
personality disorder. Among those with a mental disorder, the lifetime 
prevalence of alcohol disorder was 22% (Regier et al., 1990). In another study 
among 928 male alcoholic patients in treatment, over 60% of the subjects 
fulfilled lifetime criteria for at least one other additional mental disorder. Affective 
and anxiety disorders as well as antisocial personality and drug abuse were the 
most frequently identified (Penick et al., 1994). 
 Kessler et al. (1994) published another ECA study in the National Co-
morbidity Survey (USA), where over 8000 participants were interviewed. Nearly 
50% reported at least one lifetime DSM-III-R disorder, the most common being 
major depressive disorder, alcohol dependence, and social or simple phobias. 
The lifetime prevalence of alcohol dependence for both sexes was 14% and 
that of abuse almost 10% (together over 23%). More than half of all the lifetime 
disorders were concentrated in one-sixth (14%) of the study population with 
three or more co-morbid disorders. The lifetime prevalence of antisocial 
personality disorder among males was 5.8% (Kessler et al., 1994). (The co-
morbidity of antisocial personality disorder with alcohol dependence has a 
crucial impact in the development of type 2 alcoholism, as discussed below in 
the section on Cloninger’s neurogenetic model). The same group of researchers 
replicated the survey in 2001–2003 in the same area in Michigan, USA, 
interviewing over 9000 participants. The most prevalent lifetime disorders again 
were major depressive disorder (16.6%) and alcohol abuse. Almost one-fifth of 
the study population (18.6%) suffered from alcohol abuse (13.2%) or 
dependence (5.4%), and about 50% had at least one lifetime disorder (Kessler 
et al., 2005). The estimates of the prevalence of substance abuse, including 
alcohol, were consistent with those reported elsewhere in the world in 2000–
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2004 (Demyttenaere et al., 2004). The estimates for alcohol disorders were 
lower in this later survey than in the earlier one (just under 20% versus a little 
over 20%). The authors speculated that this was due to the more strict criteria 
for substance dependence in the DSM-IV classification used in the later study 
(Kessler et al., 2005). 
 In 2004, the World Health Organization (WHO) estimated that 2 billion people 
consume alcohol, 1.3 billion use tobacco, and 185 million use illicit drugs 
worldwide. The number of subjects with alcohol use disorder was estimated to 
be almost 80 million (Bevilacqua and Goldman, 2009), It has been estimated on 
a population basis that alcohol alone subtracts an average of 4 disability-
adjusted life years per person (the years of life lost due to premature death or 
disability), the same as tobacco, whereas illicit drugs subtract less than one 
year. For comparison, insulin-dependent (type 1) diabetes subtracts only 0.1 
years. The addiction disease burden has a higher impact in the industrialized 
Western world than in the developing countries, where life expectancies are 
shorter (Merikangas and Risch, 2003). 
 
2.1.4 Alcohol consumption, alcohol disorders and public health in Finland 
In 2006, 88% of the adult population in Finland reported using alcohol. Of these, 
the number of heavy consumers is estimated to be even 500 000 (6–12% of the 
adult population). This 10% of drinkers with the highest consumption account 
for almost half of the alcohol (over 40%) consumed in Finland. The percentage 
of alcohol consumers is greatest among young adults and middle-aged people. 
About 10% of adults of both sexes are abstainers. Men tend to use alcohol 
more often and to consume more drinks on one occasion than women. Most 
young people start to experiment with drinking between the ages of 12 and 16 
years, with only one-fifth of 16-year-olds not using alcohol at all (Nylander et al., 
2007). 
 In Finland, alcohol consumption was well below the mean in other European 
countries up to the 1960s. After new alcohol legislation in 1969, allowing among 
other things the sale of medium strong beer (class III) in grocery stores, 
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consumption in Finland more than doubled in ten years. Thereafter there was a 
more or less steady increase during the upswing in the economy in the1980s, 
and this has continued since the end of 1990s after a temporary decrease. The 
latest rapid increase in consumption and adverse effects of the increase were 
seen after the lowering of taxes on alcoholic beverages at the beginning of 
2004. Connected to this, the quotas on tax-free imports of alcohol from other 
EU countries to Finland were abolished, and nearby Estonia with very low retail 
prices on alcohol joined the EU, enabling cheap and rather unrestricted 
importing of alcohol. In 2006 the real retail prices (adjusted for inflation) in 
Finland were still 20% lower than in 2003 (Nylander et al., 2007). 
 In 2006 the total alcohol consumption of an average adult was 10.6 litres of 
100% alcohol. Again, the total consumption has more than doubled over the 
past three decades, since the first boom in the 1970s. This has brought Finland 
to the medium level of alcohol consumption among other European countries. 
Compared with them, binge drinking (heavy intoxication) continues to be more 
common in Finland. One man in four reported drinking at least six units of 
alcohol on one occasion weekly, and one woman in eight at least four units on 
one occasion weekly. One man in six, but only one woman in twenty, reported 
being heavily intoxicated at least once a month during the previous year 
(Mäkelä, 2003; Nylander et al., 2007). The prevalence of hazardous, heavy 
drinking possibly preceding abuse or dependence at least in some cases was 
5.8% in a Finnish study, being more prevalent among middle-aged, divorced, 
and unemployed males (Halme et al., 2008). The authors thought that this very 
probably is an underestimation. 
 In an annual postal survey follow-up carried out by the National Public Health 
Institute (KTL) between 1978 and 2006 among working-age citizens in Finland, 
the trends in chronic disease-related health behaviours were mainly positive 
concerning smoking, food habits and leisure time activities (Helakorpi et al., 
2007). However, overweight had become more prevalent, and the consumption 
of alcohol had steadily increased. The difference in consumption between 
educational groups had disappeared among men, but highly-educated women 
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were drinking slightly more than those with a lower educational level (Helakorpi 
et al., 2007). 
 Mortality rates among heavy drinkers and alcoholics are claimed to have 
increased at least two-fold, or even up to eight-fold compared with the general 
population. On the other hand, the number of deaths related to alcohol has 
generally been underestimated in the statistics (Saarnio and Mäkelä, 1997). 
The number of alcohol-related deaths was estimated to be 3050 in 2006, and 
there has been an increase of over 20% in the seven years since 1999, and an 
especially rapid growth since 2004. The increase was exclusively due to 
alcohol-related diseases or alcohol poisonings, since the number of fatal 
accidents, or violence with alcohol involved, had not changed. Alcohol-related 
causes were the most common cause of death among working-age (15–64 
years) males and females in Finland in 2006. In addition, using a broader 
definition alcohol was a contributory cause of death in 1600 more cases 
(Nylander et al., 2007). 
 Inpatient wards registered over 36 000 periods of care with an alcohol-related 
disease as a primary or secondary diagnosis in 2006. Traditionally, a strong link 
has existed between alcohol use and violent offences in Finland. In recent 
years, 70–80% of the fatal violent offences and assaults have been committed 
under the influence of alcohol. In 2006 over 31 000 violent offices were 
recorded by the police in Finland. Almost 26 000 cases of drunk driving were 
detected by the police, and alcohol was involved in one in four fatal road traffic 
accidents (Nylander et al., 2007). 
 It was estimated that in 2005 Finnish society paid almost one million euros in 
direct costs, and between three and six billion in indirect costs as a result of 
alcohol use. A third of the direct costs were caused by public disturbances. 
Health care accounted for a quarter, and social services for a one-fifth of the 
direct costs (Nylander et al., 2007). Reducing the level of alcohol consumption 
and preventing related harms has been the main objective of Finnish alcohol 
policy also in recent years. This seems reasonable considering the costs and 
the diverse negative effects of alcohol on the health of the Finnish population, 
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specifically of the heaviest drinkers. Still, less than half of the municipalities 
have an alcohol and drug strategy of detoxification or other treatments. Only 
half of the municipalities in Finland can offer immediate access to a 
detoxification program, and in one in ten municipalities there is no available 
detoxification treatment at all (Nylander et al., 2007). 
 
2.1.5 Treatment of alcoholism 
The clinical outcome of alcoholism after a standard detoxification treatment is 
known to be poor, even if psychosocial therapy is implemented, with up to 70% 
of patients resuming drinking within one year (Johnson, 2008). Based on 30 
years of research, it can be concluded that individuals obtaining treatment for 
their drinking problem have a slightly better outcome than those who are not. 
However, the results of follow-up studies over a period longer than one year 
suggest very low long-term effectiveness of the treatments available. There 
seems to be a little if any difference in the effect between the types of therapies 
offered, longer and shorter duration of treatment, or between medical in-patient 
and non-medical out-patient treatment. In addition, several large studies have 
shown the traditional Twelve Step Facilitation of Alcoholics Anonymous to still 
be as effective as the more modern and costly cognitive and behavioural 
therapies (Room et al., 2005). 
 There has been growing interest, even occasional enthusiasm, in developing 
pharmacological therapies to improve the treatment effects of alcohol 
dependence, as an adjunct to psychosocial therapies. The medications tried so 
far have shown only a modest additive effect, however, and the efficacy usually 
is seen only in limited subpopulations of the treated alcoholics. The tested 
medicines include disulfiram, naltrexone and its depot formulations, 
acamprosate, topiramate, SSRIs (selective serotonin re-uptake inhibitors), 
ondansetron, and quetiapine. As an example, acamprosate is considered to 
hold a substantial value for an extra treatment effect with a 13% overall 
improvement in twelve months abstinence rates. (This would generally be 
judged as modest pharmacological efficacy of treatment.) Molecular genetic 
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studies are expected to help in targeting the existing pharmacological 
treatments at different types of alcoholics for better response, and to develop 
completely new treatments by detecting the differences in the neurobiology of 
the various forms of alcoholism (Goldman et al., 2005b; Room et al., 2005; 
Johnson, 2008). 
 
2.2 Cloninger’s neurogenetic model of alcoholism (types 1 and 2), 
antisocial personality disorder (ASP) and impulsive violent behaviour 
One of the pioneers of alcohol research, Jellinek (1960), distinguished different 
subgroups of alcoholism, such as the individuals who had an "inability to abstain 
entirely", or those who could abstain even for longer periods but were unable to 
stop drinking binges once they started, and thus suffered from "loss of control". 
In spite of this, many clinical and developmental studies of alcoholism generally, 
even until recently, have used heterogenous samples of subjects without 
subgroups. This has made the findings difficult to interpret and replicate. On the 
other hand, alcohol abuse has a strong familial aggregation, alcoholism being 
three to five times as frequent in parents, siblings and children of alcoholics as 
in the general population. Based on this and further studies of Swedish 
adoptees and families in the United States, Cloninger proposed the dichotomy 
of alcoholism in two subtypes based on their clinical features and patterns of 
inheritance (Cloninger, 1987; Cloninger, 1995). 
 The two subgroups (type 1 and 2) can be distinguished in terms of a tri-
dimensional combination of heritable personality traits: novelty seeking, harm 
avoidance and reward dependence. Cloninger noted that the subtypes should 
not be considered as discrete disease entities, and an individual alcoholic may 
have features of both types. There are polar extremities of both subtypes 
among alcoholics, but generally the features of the three personality traits form 
a continuum. Type 1 alcoholics most typically are high in harm avoidance and 
reward dependence, but low in novelty seeking. True type 2 subjects exhibit the 
opposite traits: high in novelty seeking, but low in harm avoidance or reward 
dependence. The findings of the adoptee studies indicated that the risk for type 1 
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alcoholism was increased only if there was both a genetic (inherited) 
predisposition and a familial, environmental exposure to heavy drinking. 
Because it requires both kinds of predisposition before the risk is increased 
(more than doubled in both sexes of the adoptees), type 1 alcoholism has been 
described as "milieu-limited". In contrast, the adopted-away sons of fathers with 
early-onset spontaneous alcohol-seeking behaviour (type 2 alcoholic fathers) 
did not need environmental provocation to develop similar addictive behaviour 
early in life. The risk for alcoholism in these sons was nine-fold that in the sons 
of other fathers. Because the daughters of type 2 fathers were at higher risk 
only for somatic anxiety but not for alcoholism, type 2 alcoholism has been 
called "male-limited" ("from father to son") (Cloninger, 1987; Cloninger, 1995). It 
has been estimated that 80% of alcoholics in general fall into the type 1 
category (both males and females) and the remaining 20% into the type 2 
category (almost exclusively only males) (Tupala and Tiihonen, 2004). 
 The two types were further characterized by opposite definitions and 
descriptions: type 1 has an adult onset after 25 years of age, but a rapid 
development of dependence on the anti-anxiety effects of alcohol. This leads to 
alternating drinking binges (loss of control and guilt feelings) and periods of 
abstinence, without prominent antisocial or impulsive violent behaviour. Type 2 
has a teenage onset, at the latest before 25 years of age, no guilt feelings for 
the drinking or no desire to quit. Type 2 alcoholics also have a propensity to 
abuse different kinds of drugs for their euphoriant effects, not just alcohol. They 
are also prone to recurrent crime and impulsive violent outbursts from a young 
age, especially under the influence of alcohol. Type 2 males are risk-taking 
adventurers seeking for occasional euphoria in a selfish manner, optimistic but 
antisocial and even vengeful in nature. They are also described as aloof, 
lacking compassion and empathy, and non-sensitive to reward or punishment 
starting from childhood (conduct disorder). At the opposite pole, type 1 
alcoholics are anxiety-prone, deliberate, cautious, reward-dependent and 
friendly. They are socially dependent and empathic, but also worried, fearful 
and pessimistic (Cloninger, 1987; Cloninger, 1995). The two types are often 
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described and compared by a pair of words: a worrier and a warrior, type 1 vs 
type 2 (Goldman et al., 2005a). 
 In a study of 171 primary alcoholic males, Irwin et al. (1990) confirmed the 
clinical importance of age at onset of symptoms of alcohol abuse. In their study, 
younger age at onset was significantly associated with more severe alcohol-
related life problems later on, abuse of other drugs and childhood criminality. 
These same high-risk subjects also more often met the criteria for adult ASP, 
though subjects with a primary diagnosis of ASP were originally excluded from 
the analysis. Thereafter, the comparison between Cloninger’s subtypes 1 and 2 
did not reach significance. The authors concluded that differentiation between 
type 2 alcoholism and ASP may not be meaningful, but these two disorders may 
share the same aetiology: type 2 alcoholics actually suffer from ASP, while 
alcohol-related problems such as impulsive violence are only one part of the 
syndrome (Irwin et al., 1990). Cadoret et al. (1995) found evidence of two 
genetic pathways to drug abuse/dependency in their study among 95 male 
adoptees. One pathway went directly from a biological parent’s alcoholism to 
the adoptee’s drug abuse/dependency. The second path was circuitous, starting 
from the antisocial personality disorder in the biological parent, proceeding 
through adoptee aggressivity, conduct disorder, antisocial personality disorder, 
and eventually ending up in drug abuse or dependency. The results suggested 
the existence of two inheritable forms of alcoholism, resembling Cloninger’s 
types 1 and 2 (Cadoret et al., 1995). 
 In the National Longitudinal Alcohol Epidemiologic Survey in 1992 in the 
USA, almost 43 000 participants were interviewed for drug and alcohol use 
disorders. The study found the age at first drug use/drink to be a powerful 
predictor of lifetime abuse problems among both sexes: the odds of lifetime 
abuse or dependence among the sample of lifetime users was reduced 4–5% 
for each additional year that drug use onset was delayed. The reason for this 
was not clear. Either there was a combination of risk factors mediating the 
protective effect of the delay, or the early start was an indicator of the inevitable 
development difficult to modify (Grant and Dawson, 1998). Other researchers 
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have also suggested that the early start of alcohol use is not necessarily the 
reason for developmental problems in a child and it might be just one of the 
manifestations of general maladaptive behaviour (Prescott and Kendler, 1999). 
 Cloninger originally proposed in his typology that a dopaminergic deficit 
would be related to type 1 and serotonergic deficit to type 2 alcoholism 
(Cloninger, 1987; Cloninger, 1995). Offenders with ASP are found to have low 
mean concentrations of 5-hydroxyindolacetic acid (5-HIAA, the main metabolite 
of serotonin) in their cerebrospinal fluid (CSF), indicating lower than normal 
serotonin turnover in the brain (Linnoila et al., 1983; Virkkunen et al., 1989; 
Virkkunen et al.,1996a). The primary behavioral traits correlating with low CSF 
5-HIAA have been found to be increased irritability, impaired impulse control 
and stimulus (novelty) seeking, along with disturbed diurnal activity rhythms 
(Virkkunen et al., 1996b). Possibly, as a compensatory mechanism to the low 
brain serotonin turnover (the low CSF 5-HIAA), entry of the amino acid 
tryptophan (precursor of serotonin) into the brain increases. This may result 
from the increased plasma insulin levels (Virkkunen and Narvanen, 1987; 
Tiihonen et al., 2001; Virkkunen et al., 2009). 
 Brain imaging studies also implicate deficits in serotonergic 
neurotransmission in type 2 alcoholic subjects (Tiihonen et al., 1997). On the 
other hand, brain imaging studies have found a dysfunction in dopaminergic 
neurotransmission among type 1 alcoholics, mostly indicating decreased 
transmission (Hietala et al., 1994; Volkow et al., 1996; Tiihonen et al., 1998). 
Tiihonen et al. (1995) found alterations in striatal dopaminergic function 
(transporter densities) among both types of alcoholics but in opposite directions: 
markedly lower dopamine turnover in type 1, and slightly higher in type 2, 
compared with healthy controls. 
 Impulsivity is generally considered deleterious to normative, adaptive 
functioning and social interactions. Gerald and Higley (2002) studied nonhuman 
primates (rhesus monkeys) and speculated that the benefits derived from 
impulsivity may have maintained the genotypes and phenotypic expression of 
low 5-HT turnover. In primate societies low 5-HT activity has been linked to 
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impulsive, risk-taking and dangerous behaviour, including high rates of alcohol 
consumption if available. The researchers observed that males with low CSF 5-
HIAA leave their natal group at a younger age to seek sexual opportunities. The 
more inhibited primate males staying in the group are less likely to reproduce 
("nothing ventured, nothing gained"). The quick-tempered aggressiveness may 
also serve as a life-saving behavioural trait for a solitary male, and also as an 
aid in fighting over females. In primate societies the males with low brain 5-HT 
levels reproduce younger than their mates with higher levels of CSF 5-HIAA. 
They may "live fast, die young". (This is a clinical picture observed in antisocial, 
impulsive aggressive human males as well.) Natural selection can maintain 
such genotypes leading to earlier fertility at the expense of later survival, 
because the individual may have already reproduced at the time when the 
genes exert their damage (premature death) (Gerald and Higley, 2002). 
 Since Cloninger’s first published version of his typology, several researchers 
have formulated new ones with two to four subclasses of alcoholism, based on 
different theoretical backgrounds. Those with two subtypes have a close 
resemblance to Cloninger’s dichotomy, even though identified in different 
samples and within different ethnic groups (Babor et al., 1992; Schuckit et al., 
1995). Those including more than two categories (most often a chronic/severe 
type, a depressed/anxious type, a mildly affective type and an antisocial type) 
also try to cover the alcoholic individuals who would not fit in the strict polar 
extremities of a pure dichotomy. Unfortunately few of the typologies have been 
examined longitudinally to test their clinical value and predictive utility 
(Hesselbrock and Hesselbrock, 2006). However, Babor’s classification of type A 
and B alcoholism, as a broader concept of alcoholism than Cloninger’s 
dichotomy, is a common tool in alcohol research these days (Roache et al., 
2008). 
 Cloninger’s dichotomic classification was supported by the Collaborative 
Study on the Genetics of Alcoholism (GOGA), which found a significant 
replicated linkage to chromosome 1 for a quantitative phenotype related to 
aspects of alcohol use (resembling that of Cloninger’s type 1 subjects) and 
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anxiety. In the same study, two of the symptom clusters (factors) identified and 
related to the diagnosis of alcohol dependence corresponded to Cloninger’s 
type 1 and type 2 alcoholism, accounting for 14% and 41% of the variance, 
respectively (Dick et al., 2002). In a twin study by Fu et al. (2002) using the 
Vietnam Era Twin Registry, 3360 military veteran male twin pairs (of which 
almost 2000 were monozygotic and 1500 dizygotic) were interviewed to screen 
for lifetime DSM-III-R diagnosis of antisocial personality disorder (ASPD), 
alcohol dependence (AD), marijuana dependence (MJD), and major depression 
(MD). The results indicated that a substantial proportion of the genetic variance 
in the risk of AD and of the total variance (genetic and shared environmental) in 
the risk of MJD were accounted for by the genetic effects associated with 
ASPD, which appeared to be the major determinant of risk of substance 
dependence. The researchers suggested that the temporal ordering of the 
disorders started from ASPD, MD and substance dependence (AD, MJD) being 
secondary to ASPD. There was a strong comorbidity between ASPD and MD as 
well (Fu et al., 2002). 
 
2.3 Neurobiology of alcoholism 
The effects of alcohol in the brain are considered non-specific, and in animal 
studies acute alcohol administration has been found to increase the action of 
the neurotransmitters GABA (gamma-aminobutyric acid), glutamate, dopamine, 
serotonin and opioid peptides. Of these, dopamine has been most strongly 
associated with the reward pathway, and is considered crucial for the 
reinforcing effects of alcohol, leading to repetitive recreational use, abuse or 
sometimes compulsory use of alcohol, called dependence or alcoholism. 
Stress-associated hormonal changes also may contribute to the development 
and maintenance of dependence, especially the hypothalamus-pituitary-adrenal 
cortex axis (HPA axis), and corticotropin releasing factor (CRF) and its binding 
protein (CRH-BP) (Enoch et al., 2008a). The involvement of multiple 
neurotransmitters, not just dopamine, in reward mechanisms is very probable. 
The actions and co-actions of different transmitters have been hypothetically 
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described as a reward cascade, where the release of dopamine still is 
considered a crucial point (Koob and LeMoal, 2001; Bowirrat and Oscar-
Berman, 2005). Regarding the effects of alcohol, the brain dopamine, serotonin 
and glutamate turnover and function have been the object of extensive 
research. They are discussed in the next sections, and the functions of other 
transmitters listed above more briefly in the relevant sections related to 
candidate gene association studies below. 
 
2.3.1 Brain dopamine function, reward mechanisms and alcoholism 
The crucial role of the catecholamine neurotransmitter dopamine (DA) in the 
brain reward mechanisms is well established. Natural reward feedback is 
essential for the survival of the individual and the species. The individual tends 
to return and repeat the rewarding and reinforcing action, even with some 
trouble, once having learned it. Natural sources of reward include food, sexual 
interaction, positive social interactions and brain stimulation by humour or other 
pleasure. Dopamine also mediates the rewarding feelings from unnatural 
sources such as addictive drugs including heroin and other opiates, cocaine, 
amphetamine, nicotine and alcohol. Dopamine has been called the brain’s 
"pleasure chemical". However, dopamine may not be the only transmitter 
mediating reward, though dopaminergic pathways are often referred to as the 
"brain’s reward circuit" (Koob, 2003; Melis et al., 2005). 
 DA is synthesized in the neuron and once released into the extraneuronal 
synaptic cleft it binds to the post- and presynaptic receptors, evoking biological 
events which can result in the rewarding psychological experiences described 
above. DA receptors are divided into two subtypes, or families: D1-like (D1 and 
D5) and D2-like (D2, D3, and D4). The D2-like, predominantly D2, is found at 
high levels in typical DA-rich brain areas, such as the striatum and nucleus 
accumbens (NAC). In cortical regions, D1 receptors are the more prominent 
receptor subtype. DA reuptake carrier or dopamine transporter (DAT) is a 
protein that terminates the action of released DA and regulates its concentration 
by collecting and eliminating DA from the synaptic cleft. In the presynaptic 
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neuron, DA is inactivated by the enzyme catechol-O-methyltransferase (COMT, 
see the relevant section below) (Tupala and Tiihonen, 2004). 
 Drugs abused by humans stimulate dopamine release from the NAC in the 
brain’s mesolimbic system, and this is postulated to be the main neural network 
mediating the reinforcing effects of drugs and alcohol. The NAC is speculated to 
act as a filter, or gate, between the brain regions controlling moods or drives 
and action (Tupala and Tiihonen, 2004). Numerous animal studies have shown 
ethanol (alcohol) to cause a dose-dependent release of DA in the rat brain 
NAC, and withdrawal from ethanol decreases the release. The animals will 
reinstate the rewarding DA release on the prewithdrawal level by self-
administering alcohol, if possible. It has also been demonstrated that just the 
anticipation or the expectancy of alcohol elicits reward-related DA activity in the 
NAC of the rat. This possibly is an indication of a more or less permanent 
change caused by neurochemical reinforcement after repeated alcohol 
administration (Koob and LeMoal, 2001). In human studies the subjective 
perception of pleasure induced by the cocaine-like psychostimulant drug 
methylphenidate has correlated positively with the levels of DA released, 
measured with positron emission tomography (PET) using radioligand (Volkow 
et al., 1999). 
 The animal studies after experimental brain lesions seem to suggest that 
lower levels of DA activity are associated with higher levels of consumed 
alcohol, possibly to restore the artificial dopaminergic deficit - the disturbed 
"reward balance". The studies with inbred ethanol-preferring and non-preferring 
rat strains mostly indicate that the density of D2 receptors in limbic areas might 
be lower in ethanol-preferring animals (Tupala and Tiihonen, 2004). (The 
preferring strains act as a model of alcoholism in humans.) Phillips et al. (1998) 
showed a markedly decreased alcohol preference in mice knock-outs totally 
lacking functional D2 receptors, which also underlined the importance of intact 
DA signalling and D2 receptors concerning ethanol-related behaviours. 
 In human studies the growth hormone response to the DA agonists 
apomorphine or bromocriptine has been lower in alcoholic subjects, supporting 
41
the theory of an association between decreased DA transmission and 
alcoholism. DAT binding is considered to be a marker of DA neuron terminals, 
and the whole hemisphere autoradiography (WHA) studies have revealed lower 
DAT densities among type 1 alcoholics. Also, the density of D2 receptors in 
WHA studies seems to be lower among type 1 alcoholics. These findings might 
explain why some humans (the type 1 alcoholics), because they experience 
natural reinforcing and rewarding mechanisms as insufficient, are more 
vulnerable to more frequent consumption and higher doses of alcohol than the 
non-addicted general population (Tupala and Tiihonen, 2004). 
 
2.3.2 Brain serotonin (5-HT) function, alcoholism and violent behaviour 
Monoamine neurotransmitter serotonin and its receptors are found both in the 
central nervous system and peripherally in the human body. Within the brain, 
the raphe nuclei contain the cell bodies of 5-HT neurons with projections to 
various regions in the brain. 5-HT is synthesized in the neuron from amino acid 
tryptophan, the enzyme tryptophan hydroxylase catalyzing the rate-limiting step 
in the conversion. The gene coding for the tryptophan hydroxylase responsible 
for this reaction in the human brain is called TPH2 (Walther and Bader, 2003). 
Once released extracellularly from the presynaptic vesicles, 5-HT binds to 
postsynaptic receptors transmitting a signal. 5-HT also binds to presynaptic 5-
HT1A and 5-HT1B/D autoreceptors, which modulate the further release of 5-HT. 
The serotonin transporter protein (5-HTT) is responsible for the reuptake of 5-
HT out of the synapse and for the termination of the synaptic transmitter action 
of 5-HT. In the presynaptic neuron, monoamine oxidase-A (MAO-A) inactivates 
intracellular 5-HT, thus regulating its levels. The 5-HT receptor family consists 
of 7 known subtypes of 5-HT1-7, some with subtypes of their own, such as 5-
HT1A-F (Veenstra-VanderWeele et al., 2000). 
 In animal studies including alcohol-preferring or non-selected rat strains, a 
sizeable number of studies support the notion that facilitating serotonergic 
transmission decreases ethanol intake. Also, the blockade of 5-HT-3 or 5-HT-2 
receptors with antagonists results in decrease of intake. It remains unclear 
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whether decreasing transmission would actually increase ethanol intake in 
animals. Acute ethanol intake most probably transiently increases the brain’s 5-
HT levels, and possibly transmission as well. As a consequence, this would 
activate the mesolimbic dopaminergic reward system, too (LeMarquand et al., 
1994). The acute effect of ethanol might be biphasic, though, with the increase 
followed by a decrease in 5-HT transmission leading to behavioural disinhibiton 
in animals. In a case of chronic intake, the serotonergic system more likely 
adapts with successive doses of alcohol, and the net effect in transmission 
remains minimal or negative (LeMarquand et al., 1994). In contrast, after 
withdrawal of chronic ethanol administration, a decrease in brain serotonin 
transmission occurs. In animals, this increases the sensitivity of the neural 
system to perturbation by exogenous stimuli, disturbing the ability to maintain 
self-organization, and leading to impulsive non-inhibited behavioural reactions 
(LeMarquand et al., 1994). An almost consistent finding, however, is that the 
levels of CSF serotonin and dopamine metabolites are positively correlated with 
one another, and serotonergic stimulation facilitates dopamine release, at least 
when basal activity is low (Jibson et al., 1990). 
 The serotonergic projections from raphe nuclei to the forebrain are 
considered crucial in human behavioural inhibition and impulse control. 
Serotonin often modulates dopaminergic activity, too. The hypothalamic area 
with projections from the suprachiasmatic nucleus is supposed to control 
individual carbohydrate intake, and the suprachiasmatic nucleus is thought to 
act as the major circadian pacemaker ("the intrinsic clockwork"). This nucleus 
receives a serotonergic input from the raphe nulei in the brain stem, so there 
might be an anatomical and serotonergic link between the regulation of the 
sleep-wake cycle, regulation of blood glucose metabolism and impulse control. 
Disruptions of these functions, along with disturbances in brain serotonin 
functions, are common among persons with antisocial personality disorder 
(ASP) and habitual impulsive violent behaviour. The same subjects most often 
also suffer from alcoholism, referred to as type 2 (Virkkunen et al., 1994a; 
Virkkunen et al., 1994b). 
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 2.3.3 Brain glutamate (Glu) function, NMDA receptors, and alcoholism 
Approximately half of the synapses in the brain are excitatory synapses that use 
glutamate as their neurotransmitter. The glutamergic neurons are most 
abundant in the cerebral cortex and limbic regions. The postsynaptic glutamate 
receptors are divided into ionotropic receptors, including NMDA (N-methyl-D-
aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) 
and kainate, and into metabotropic receptors. Synaptic concentration of 
glutamate is partly regulated by glutamate aspartate transporter (GLAST). 
Glutamate activity at NMDA receptors is believed to mediate associative 
learning (Enoch, 2003; Schumann et al., 2008). 
 Glutamate receptors are primary targets of alcohol action, and acute 
intoxication inhibits the NMDA receptor complex, by reducing the effect of 
glutamate and thus impairing learning and memory. This impairment is evident 
even at the low blood alcohol levels associated with social drinking. This also 
logically explains blackouts associated with acute intoxication. Reduced 
glutamate activity in the hippocampus area leads to temporal impairment of 
spatial memory. On the other hand, there have been observations of acute low 
doses increasing extracellular glutamate temporarily. This makes the effects of 
alcohol on glutamate transmission paradoxical and ambiguous (Gass and Olive, 
2008). Chronic abuse of alcohol causes sensitisation (upregulation) of NMDA 
receptor subunits, mainly the units NR1, NR2 and NR2B. These changes in 
neurotransmission may contribute to the hyperexcitatory symptoms observed 
during withdrawal (e.g. seizures), and hyperexcitability after chronic use may 
contribute to craving and relapse behaviour as well. Consequently, the effects 
of alcohol on glutamate NMDA receptors are associated with every phase of the 
alcohol disorder: intoxication, withdrawal, tolerance, dependence, craving, and 
relapse (Gass and Olive, 2008). 
 
44
2.3.4 Long-term effects of alcohol on neurotransmission and reward  
thresholds: tolerance, dependence, withdrawal, craving and relapse 
A considerable amount of data has been gathered on the acute reinforcing 
effects of alcohol. The data are not conclusive, but even less is known about the 
long-term mechanisms involved in the development of dependence and 
tolerance. In particular, there has been a lack of data regarding relapse after 
periods of variable length of abstinence. Moreover, the choices of medical 
treatments for effective relapse prevention are few. The long-term effects of 
alcohol ingestion on neurotransmission are probably different from the acute 
effects. In animal studies the changes during long-term intocixation have been 
even reverse to ones observed during acute ingestion. This would actually 
mean a decrease in the function of neurotransmitters such as dopamine, 
serotonin, GABA and glutamate, associated with chronic use of alcohol. This 
leads to an elevation in brain reward thresholds, a possible explanation for 
tolerance and for the need to increase the dose observed in dependent states. 
The animals try to compensate for this shift in reward balance by self-
administering ethanol, if they are allowed to do so (Koob and LeMoal, 2001; 
Koob, 2003). 
 Koob and LeMoal (2001) have proposed a model for the brain changes 
occurring during the development of addiction that explains the persistent 
vulnerability to relapse long after the compulsory abuse has ceased. At the 
beginning of the abuse, drug seeking is driven by positive reinforcement of the 
actual use and the anticipation of use, resembling a classical impulse control 
disorder. When the drug taking (or drinking) continues, the negative affects 
become more prominent over time. The addiction becomes driven by this 
negative inforcement instead of the positive one felt at the beginning. The 
addiction also takes on characteristics of a compulsive disorder, presumably 
recruiting the same neural circuits associated with such a disorder (cortico-
striatal-thalamic loop). An addicted person, like one suffering from compulsive 
disorder, performs repetitive behaviours to reduce anxiety and distress, not to 
provide pleasure or to gain a reward. This leads to activation of the brain stress 
45
system while the reward system is in a constant under-activated state (Koob 
and LeMoal, 2001). 
 One of the direct mediators of stress is corticotrophin-releasing factor (CRF). 
Increased levels of circulating glucocorticoids apparently have a minor impact. 
The shift from normal homeostasis to a less rewarding, more stressful state was 
termed a shift to allostasis by Koob and LeMoal (2001): achieving stability 
through change, but leading to chronic deviation of the normal reward 
thresholds. According to the hypothesis, the reward or stress systems never 
return to the original states, even if some normalisation occurs during protracted 
abstinence periods. The activated brain stress system mediated by CRF and 
the negative affective state observed in dependence and during acute 
withdrawal remain as more or less permanent changes. Consequently, once-
addicted subjects are constantly more vulnerable to relapse than they were 
before they started the abuse in the first place. This is reflected as a symptom 
of craving even after long periods of abstinence (Koob and LeMoal, 2001). In 
animal studies it has been shown that even the environmental stimuli predicting 
reward and not just the reward itself (e.g. the taste of alcohol) can activate 
mesolimbic dopaminergic transmission. Indications of similar changes have 
been found in the brain imaging studies of alcoholic human subjects, too (Weiss 
and Porrino, 2002). These findings of course have direct implications for the 
increased risk of relapse in different contexts and environments. 
 
2.4 Genetics of alcoholism 
The individual vulnerability or resilience to alcohol use disorders can be both 
genetic and environmental, such as availability of alcohol, positive parental or 
peer support or lack of it. Genetic vulnerability factors for alcoholism have been 
divided into three categories: 1) heritable personality traits may predispose the 
individual to seek out and consume alcohol, increasing the chances of 
becoming addicted (traits such as anxiety or impulsivity); 2) an inherited 
differential response to alcohol affects one’s vulnerability, e.g. low response to 
the sedating effects of alcohol facilitates drinking large quantities and increases 
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the risk for alcoholism; 3) genetic variation in neurobiological pathways 
(transmission) may render some individuals more vulnerable to the loss of 
control, such as defects in the natural reward mechanisms of the brain. For 
each individual the balance between environmental and genetic risk factors and 
their constant interplay is different and even varies between different phases of 
life (Enoch, 2003). 
 
2.4.1 Family, twin, and adoption studies and transmission of addiction 
Alcohol dependence has been traditionally known to cluster in families. Plutarch 
(as early as AD 45–125) stated "ebrii gignunt ebrios" ("drunks beget 
drunkards"). Much later it was shown in a more empirical fashion that among 
6250 alcoholics and 4100 non-alcoholics, an alcoholic was six times more likely 
to report parental alcoholism (Cotton, 1979) or that the rates of alcoholism were 
doubled in relatives of alcoholics compared with that in controls (Guze et al., 
1986). Dawson et al. (1992) calculated the risks from a study of over 23 000 
drinkers: the increase was 170% for an individual with both a first- and second-
degree alcoholic relative, almost 100% with a only first-degree alcoholic relative, 
and still almost 50% for an individual with only second or third degree relative 
affected. However, family studies do not distinguish between genetic and 
shared environmental effects (Goldman et al., 2005a). 
 The basic presumption behind twin studies is that monozygotic twins, sharing 
all of their genes in common, are more similar in phenotype than dizygotic 
twins, who on average have only 50% of their genes in common. The studies 
among di- and monozygotic twins between 1960 and 1997 gave typically figures 
of 0.5 for males and 0.25 for females as an estimate of heritability in alcoholism. 
Goldman et al. (2005a) also calculated the heritability as 0.5, derived from a 
data of almost 10 000 twin pairs. This would mean that the genetic and 
environmental factors are equally important in determining the risk for 
alcoholism (50–50%) (Ball and Collier, 2002; Goldman et al., 2005a). 
 Adoption studies provide a different view of the interaction between 
environmental and genetic factors, looking at individuals reared by unrelated 
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parents. (Some aspects of this were discussed above in the section on 
Cloninger’s neurogenetic model of alcoholism.) Adoption studies in 1945–1987 
provided strong evidence for the action of genetic factors, especially among 
males. There seemed to be no correlation between the drinking behaviour in the 
adoptees and alcoholism in the foster family, nor any protective effect of being 
raised away from the biological parent (Ball and Collier, 2002). It has also been 
suggested that women with the same degree of genetic risk are less likely than 
males to become alcoholics. Perhaps there has to be more interplay between 
genes and environment for women to reach a risk threshold to develop 
alcoholism (Quickfall and el-Guebaly, 2006). On the other hand, it has been 
claimed that alcoholism is just as heritable in women as in men, and that the 
detection of genetic influences in women may have been limited, especially in 
the earlier studies, due to the smaller number of female alcoholic subjects in 
general (Dick and Bierut, 2006). The greater tendency for assortative mating 
among female than male substance abusers (and alcoholics) may actually 
cause greater familial loading (familial aggregation of drug disorders) among 
women (Merikangas et al., 1998). 
 In twin studies, addictions appear to be among the most heritable psychiatric 
disorders, based on correlations, which is not always the result of pure genetic 
influence, but may be due to gene-environment interactions and measurement 
errors (Goldman et al., 2005a). Drugs also differ in their addiction liability, which 
should correlate with heritability if the neurobiological basis of the addiction 
process was inherited. It seems that when using estimated risk rankings, the 
addiction liability predicts heritability, so cocaine and opiates, the most addictive 
substances, are among the most heritable. Cannabis, hallucinogens and 
caffeine are among the less addictive and less heritable. Alcohol has a medium 
risk of addiction development and also a medium degree of heritability 
(Goldman et al., 2005a; Bevilacqua and Goldman, 2009). 
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2.4.2 Molecular genetics studies 
It is generally accepted that the risk for alcoholism is coded by multiple genes 
and polymorphisms in those genes, rather than a single "alcoholism gene". This 
is called polygenic inheritance, each gene (and its different allelic forms) 
exerting a small effect to reach a threshold of liability if combined with 
unfavourable environmental effects. On the other hand, genes may also be 
associated with protection from risk. There are two complementary methods in 
molecular approaches to identifying chromosomal regions and specific 
candidate genes: linkage and association. They both rely on the availability of 
polymorphic genetic markers throughout the genome. The polymorphic 
mutations in DNA may vary greatly in size, but the more common shorter 
mutations, involving only one or up to tens of bases, are the most useful as 
genetic markers for mapping the entire genome for research purposes. The two 
kinds of polymorphisms commonly used and listed in databases are variable 
number tandem repeats (VNTRs or microsatellites) containing multiple tandem 
repeats of two to five bases (the number of tandem repeats defining the allele), 
and single-nucleotide polymorphisms (SNPs), which are single-base 
substitutions at a particular position in a DNA sequence (most usually consisting 
of only two alleles at a locus). Several genetic marker sets that cover the entire 
human genome are commercially available (Dick and Foroud, 2002; Ball and 
Collier, 2002). 
 As a method, linkage can cover long genetic distances, but has low power to 
detect genes of small effect: it is usually able to identify only regions of interest 
on a particular chromosome. Conversely, association can detect genetic loci of 
minor effect, but is limited to short genetic distances. Systematic linkage 
analysis of the human genome has been feasible since the 1990s. The 
completion of the Human Genome Project and identification of a large number 
of single nucleotide polymorphisms (SNPs) spaced throughout the genome has 
made genome-wide association studies possible, rather than having to focus on 
chromosomal regions identified by traditional linkage method (Dick and Foroud, 
2002; Ball and Collier, 2002; Quickfall and el-Guebaly, 2006). 
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2.4.2.1 Linkage to a chromosomal region 
Linkage studies involve the comparison of affected and non-affected individuals 
within families or other large groups, with the intention of looking for genetic 
markers occurring with a higher rate than random distribution would allow. In 
other words, in family-based samples the purpose is to identify chromosome 
regions that are shared more often among phenotypically similar relatives 
(Sham and McGuffin, 2002). 
 One of the largest linkage studies on alcoholism is the Collaborative Study on 
the Genetics of Alcoholism (COGA), which collected detailed phenotypic data 
on individuals in families with multiple alcoholic members, starting in the middle 
of the 1990s. Initially a genome screen was completed in 105 multiplex alcohol-
dependent families, and subsequently a replication sample of 157 similar 
independent alcoholic families. The control group included over 1200 individuals 
from different families (Reich et al., 1998; Quickfall and el-Guebaly, 2006). 
 The phenotype "alcohol dependence" (the clinical diagnosis) was linked to 
several chromosomes: 1, 2, 3, 4, 7, and 8. In addition, many other intermediate 
phenotypes (see below) created during the study were linked to chromosomes 
4, 5, 6, 9, 13, 15, 16, 17 and 21. The phenotypes included some highly heritable 
electrophysiological measures reflecting central nervous disinhibition: 
abnormalities in EEG, evoked EEG rhythms and event-related potentials (such 
as increased betapower in resting EEG, reduced theta and delta oscillations, 
and a reduced P300 amplitude). As in complex diseases, the linkage regions 
were broad, encompassing hundreds of genes (Dick et al., 2006; Edenberg and 
Foroud, 2006). 
 After extensive genotyping and analysing, one of the most promising areas in 
the COGA sample seemed to be on chromosome 4p containing GABA receptor 
genes (GABRA2) (Edenberg et al., 2004). Several research groups replicated 
this finding (Lappalainen et al., 2005; Enoch et al., 2006b; Soyka et al., 2008). 
The adjacent gene GABRG1 has also been associated with alcohol disorders, 
and is suggested to contribute to the risk independently from GABRA2, in an 
additive manner (Covault et al., 2008; Enoch et al., 2009a; Ray and Hutchison, 
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2009). Thus these findings on both GABA receptor genes have already been 
replicated in several different population samples, including the F-N, GOGA, 
and some other cohorts. There were positive signals also on chromosome 4q 
containing alcohol dehydrogenase (ADH) gene cluster, and on chromosome 7q 
containing gene CHRM2 encoding muscarinic asetylcholine receptor subtype 2 
(Edenberg and Foroud, 2006). A linkage signal was also derived from GABRA6 
gene on chromosome 5 in the F-N cohort (Radel et al., 2005). However, these 
findings on chromosome 5 could not be replicated in the COGA cohort (Dick et 
al., 2005). 
 The COGA researchers stated that the major impact of the entire study was 
the finding that the linkage signals provided by the endophenotypes were more 
sharp (located directly over the gene subsequently found to be associated with 
the overlapping region of an endophenotype and clinical diagnosis of 
alcoholism). The clinical diagnosis alone did not necessarily yield a peak at the 
precise location (Dick et al., 2006). 
 One of the major limitations of the COGA was that even though the enrolled 
families were primarily of European descent, there was a considerable amount 
of heterogeneity. This was a potential confounder when searching for multiple 
genetic markers/genes with small effects (Quickfall and el-Guebaly, 2006). A 
second linkage study, also financed by the National Institute on Alcohol Abuse 
and Alcoholism (NIAAA) like the COGA, was done in a much more 
homogenous population, a Southwest American Indian tribe. The study found 
one marker on chromosome 11 close to the D4 dopamine receptor gene and 
tyrosine hydroxylase genes, and on chromosome 4 close to GABA receptor 
genes (as in the COGA) (Long et al., 1998). Other large linkage study projects 
have been the Irish Affected Sibling Pair study (the Roscommon study), the 
Mission Indians (Native Americans) study, the study in a sample of multiplex 
families in the Pittsburgh area, and the studies in the Finnish F-N cohort 
(Prescott et al., 2005; Ehlers et al., 2004; Hill et al., 2004, Lappalainen et al., 
1998). The advantage of isolated populations, and large families within them, is 
the reduced genetic heterogeneity. (In the model of heterogeneity, different 
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alleles lead to the same phenotype, but an individual allele can suffice to 
produce the phenotype.) 
 
2.4.2.2 Association with an Identified Genetic Polymorphism 
The frequency of linkage disequilibrium (LD) leads to indirect associations and 
false assumptions of causality, because the observed association may actually 
be at neighbouring allelic polymorphisms in LD with the studied allele. Another 
common reason for bias, population stratification, is caused by subgroups of the 
population in the study and the variance of the suspected allele frequencies and 
the disease frequencies between these subpopulations. One result of this is that 
we observe an association, either a false positive or a false negative, between 
an allele and a disorder in a subpopulation, without any actual causality (Sham 
and McGuffin, 2002). 
 The Hardy-Weinberg equilibrium or distribution (H-W) is used to define a 
pure random and independent transmission of alleles, which is violated if the 
genes are not picked freely from the pool. Assortative mating, most commonly 
inbreeding, biases the Hardy-Weinberg distribution. Population stratification is a 
form of hidden inbreeding (Gardno and McGuffin, 2002). Therefore, the more 
the allele frequencies differ from H-W equilibrium, the more likely the sample 
(and the results) are to be biased because of population stratification. 
 The simplest way to study association is by comparing individuals with the 
disorder/trait (cases) and unaffected subjects from the same population 
(controls) for differences in allele or genotype frequencies. There is an analogy 
to epidemiology, exposure here meaning the presence of an allele/genotype. In 
the most straightforward way, no family data of the subjects are required. If the 
real existing association is with a haplotype rather than a single gene, parental 
or even grandparental data are needed for a statistical procedure called 
haplotype relative risk calculation (HHRR) (Terwilliger and Ott, 1992). Briefly, a 
haplotype is a set of alleles at two or more adjacent loci, which are inherited 
together tightly linked on a segment of an ancestral chromosome generation 
after generation. HHRR compares the frequency of the two alleles passed from 
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the parents to the affected child with the frequency of the remaining two alleles. 
To avoid errors caused by population stratification, close relatives instead of 
unrelated controls are sometimes used (parents or sometimes unaffected 
siblings). In these family-based association tests, case-parent triads (the index 
subject with both parents, plus even siblings) may be used to compare the 
transmitted and non-transmitted alleles using the transmission/disequilibrium 
test (TDT) (Spielman et al., 1993). The transmitted alleles represent the case 
and the non-transmitted the control: the data are collected from a group of 
families. These two methods (HHRR and TDT) usually give similar results (Dick 
and Foroud, 2002; Sham and McGuffin, 2002). 
 
2.4.2.3 Case-Control association studies on candidate genes – general 
issues and limitations 
The development of molecular genetics led to the discovery of numerous 
polymorphisms, many of which were tested for an association with psychiatric 
disorders, especially from the beginning of the 1990s. Enthusiastic testing in 
different populations with samples of variable sizes led to conflicting results; the 
published association were usually soon followed by negative findings showing 
a lack of the suggested association between the polymorphism and alcoholism, 
for example. The negative linkage studies concerning candidate genes showing 
an association in case-control settings caused disbelief and confusion. The 
situation raised a lot of concern in the literature, even demands for a total 
discontinuation of case-control studies in genetics (Paterson, 1997). 
 Comings (1998) emphasized that each of the tested genes or polymorphisms 
could have explained only from 1% to 5% of the variance in alcoholism. In a 
polygenic disorder, at least 25 different genes, approximately, would be 
involved, and they can be very common in population. Consequently, polygenic 
disorders in different forms and degrees of severity are common, too. Negative 
linkage studies as well as negative HHRR and family-based association results 
should be expected concerning polygenic inheritance. They lose power in these 
situations, and exceptionally high numbers of subjects/families would be 
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needed. Comings also pointed out the importance of careful screening of the 
matched controls (matched for ethnicity as well, because the allele frequencies 
vary between these groups). The control group in a case-control study should 
be matched at least for age, sex, and ethnic and social background (as many 
environmental variables as possible), and above all else, for alcohol intake 
(Comings, 1998; Comings and Blum, 2000). 
 Trikalinos et al. (2004) scrutinized 55 cumulative meta-analyses of genetic 
associations (579 studies). Their purpose was to assess whether a statistical 
significance in early studies had any predictive ability for the outcome: 
established or refuted association after replications. The authors concluded that 
the magnitude of the effect in early studies could not adequately predict the true 
association. Conversely, many genuine associations would have been missed if 
the research had been abandoned as futile since the early underpowered 
studies showed negative results. The authors also reminded that biological 
plausibility supporting the association in the first observations, often 
emphasized in the literature, is not always straightforward and will not 
guarantee the future of the associations in the following replications. Biological 
reasoning can also be misleading if evoked post hoc to support the 
epidemiological findings (Trikalinos et al., 2004). 
2.4.2.4 Intermediate phenotypes 
The polygenic inheritance in behavioural traits (such as alcohol use) or in 
complex diseases (such as alcoholism) usually makes the impact and effect 
size of a single gene very small. If the whole diagnostic group of patients with 
complex disease/disorder is to be studied, extraordinarily large sample sizes 
are needed to detect the genetic loci with relevant but small effects on the 
phenotype. One promising approach to increase the power of association 
studies is to deconstruct the complex phenotype into disease risk mediating 
subunits, which are likely to be influenced by variation at fewer genes. These 
subunits can identify more homogenous clinical subgroups with common 
neurobiology and in some cases common genetic vulnerability, sometimes very 
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small subsets of the whole population of patients with a complex disease. 
These intermediate phenotypes are defined as mechanism-related 
manifestations of complex phenotypes. Sometimes they are almost 
synonymously referred to as endophenotypes. Strictly speaking though, an 
endophenotype is genetically inherited, and is an even smaller subset of the 
whole phenotype group than the intermediate phenotype including the risk 
mechanism of vulnerability. Intermediate phenotypes can be used to redefine 
the complex disease (Enoch et al., 2003; Schuckit et al., 2004; Goldman and 
Ducci, 2007). Gottesman and Gould (2003) descriptively define an intermediate 
phenotype as a "measurable component unseen by the unaided eye along the 
pathway between disease and distal genotype". 
 Heritability for alcoholism may be as high as 0.65 (Goldman et al., 2005a), so 
there is a need to identify more homogenous subpopulations sharing the 
mechanism of vulnerability among alcoholics, to direct attention to the particular 
genes responsible for aetiology. There already are intermediate phenotypes for 
alcoholism with respective genetic loci and polymorphisms. The involvement of 
these particular genetic polymorphisms was predicted on the basis of the known 
functional significance of the different alleles of these genes. Among these 
intermediate phenotypes and polymorphisms are: 1) attention/dyscontrol in 
cognitive performance tests and COMT Val158Met gene (with moderate 
heritability) and MAOA gene; 2) reward and DRD2 and OPRM1 genes; 3) 
stress/resiliency in performance tasks and questionnaires (such as TPQ) and 5-
HTTLPR polymorphism in SLC6A4 gene (La, S, Lg alleles) and COMT 
Val158Met gene (with unknown degree of heritability); and 4) brain 
volume/structure assessed by MRI and several polymorphisms including 5-
HTTLPR and COMT again (with heritability depending on the brain region) 
(Goldman and Ducci, 2007; Bevilacqua and Goldman, 2009). The level of 
response to alcohol (LR) is listed, too, with an estimated high heritability of 0.4–
0.6. The genetic loci are not known, though, but some studies suggest an 
association between LR and 5-HTTLPR and some other gene polymorphisms, 
as discussed later in the section on this polymorphism and personality traits 
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(Enoch et al., 2003; Schuckit et al., 2004). Other intermediate phenotypes that 
have been suggested include deviations or abnormalities in EEG or event 
related potentials (ERP), lifetime history of depression, staying unaffected 
though living in an alcoholic environment, and maximum number of drinks ever 
consumed during a drinking session (Enoch et al., 2003). 
2.4.2.5 Genome-wide scans and whole genome association 
Genome-wide scans (GWS) include whole genome linkage, which was 
discussed above, and whole genome association (WGA) studies. Both allow a 
hypothesis-free mapping of suspicious loci within the genome. Linkage analysis 
is powerful for detecting the effects of uncommon alleles, whereas whole 
genome association detects the effects of relatively common alleles (present in 
over 5% of the study subjects) and gives a more refined localization in smaller 
chromosome regions. WGA analyses with dense panels containing more than 
500 000 polymorphisms have been run in the search for associations in 
complex diseases, but the median odds ratios for one genotype have remained 
below 2. The typical effect size of genetic variations in complex diseases is 
small, and consequently the sample sizes required for a WGA study to reach 
the level of significance (0.05) has been estimated to be as high as 15 000 
subjects. WGAs in large case-control data sets have not been reported for 
alcoholism (Ducci and Goldman, 2008). 
 WGAs lack the power to detect uncommon alleles, so they inevitably give 
false negative findings. But there is also a problem with false positive findings 
due to the high number of markers analysed, and multiple testing. Furthermore, 
current test panels are composed of SNPs only, while other types of 
polymorphisms, such as copy number variations (CNVs), should be interrogated 
to perform a genome-wide evaluation of suspicious disease loci (Ducci and 
Goldman, 2008). So far, 3 million SNPs have been listed, and they are 
estimated to cover 25–30% of all the relatively common SNPs in humans, with 
frequencies of over 0.05 in population. The number of loci involved in complex 
traits and diseases could be hundreds for many of them. The disease loci can 
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also have interactions with multiple linked genes, and each gene is is likely to 
contain multiple functional variants. Also, non-additive interactions can be 
present at all levels. Genetic complexity is present on multiple levels, and might 
be fruitfully thought of as fractal. Most probably there is a need to replace some 
current phenotypic and disease classifications with ones that better correspond 
to underlying genetic causes, by combining genotypic and phenotypic 
information (Kruglyak L, 2008). 
 
2.4.3 Candidate genes showing association with alcohol use 
Using complementary strategies of linkage and the candidate gene approach, 
several polymorphisms have been associated with alcohol use disorders. Most 
of the genes implicated have been related to neurotransmission, via 
neurotransmitter receptors or neuropeptides, or to alcohol metabolism, i.e. 
pharmacokinetics (Bevilacqua and Goldman, 2009). The most promising 
candidates according to the recent literature are briefly reviewed below. The 
biological hypothesis or support for the role of the particular gene or 
polymorphism in vulnerability to alcoholism is discussed. The studies on 
candidate genes of special interest in this study (COMT, 5-HTTLPR, TaqI A1) 
are reviewed last and more extensively. This is not meant to be – indeed, could 
not possibly be – a complete up-to-date list of the polymorphisms affecting the 
vulnerability to alcohol use disorders. On the other hand, the polymorphisms 
that may be involved in vulnerability to develop antisocial impulsive-violent type 
2 alcoholism are discussed in a comprehensive way. 
 
2.4.3.1 ADH and ALDH genes 
Isoenzymes in the alcohol dehydrogenase (ADH) class play a major role in 
ethanol metabolism, converting alcohol to acetaldehyde. Polymorphisms in 
genes ADH1, ADH2 and ADH4 on chromosome 4 coding enzyme classes I, II 
and possibly IV are thought to be involved in individual differences in ethanol 
elimination. Acetaldehyde accumulation is responsible for the flushing and other 
aversive symptoms (nausea, headache, increased heart and respiratory rate). 
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(These actually are the effects of the relapse-preventing drug disulfiram.) The 
lower number of alleles ADH1B*2 and ADH1C*1 coding for more active enzyme 
forms have been associated with alcoholism, and these more active forms of 
enzymes leading to faster aversion are thought to be protective against 
alcoholism. The activities of the enzymes are different in vitro and in vivo, which 
has made the results of the association studies sometimes difficult to interpret. 
Different alleles of ADH1B gene seem to affect the risk and may protect from 
alcoholism, though the protective effect seems to vary across environments, so 
the impact is more or less inconsistent. The ADH4 gene has also been reported 
to be associated with alcoholism, but the role of allelic variants in the ADH2 
gene remains uncertain (Oroszi and Goldman, 2004; Goldman et al., 2005a; 
Dick and Bierut, 2006; Quickfall and el-Guebaly, 2006; Higuchi et al., 2006). 
 After the conversion of ethanol to acetaldehyde, the next step is the 
conversion of acetaldehyde to acetate by aldehyde dehydrogenase (ALDH), 
primarily by ALDH2. The polymorphic gene coding for this isoenzyme goes by 
the same name and is located on chromosome 12. The enzyme produced by 
the ALDH2*2 allele is inactive, leading to aversive symptoms after alcohol 
ingestion, the impact being very strong among homozygous carriers. The allele 
is very common in Asians: a lower frequency of this allele was found among 
Japanese alcoholics as early as 1982. ALDH*2 most certainly plays a protective 
role by reducing the risk for alcoholism 10-fold, giving stronger protection than 
either ADH1B or ADH1C alleles. The effects of genes coding for high-activity 
ADH (faster production of acetaldehyde) and low-activity ALDH (slower 
elimination of acetaldehyde) are additive in producing protection against 
alcoholism. In general, the genes coding for alcohol-metabolising enzymes ADH 
and ALDH have been most consistently associated with alcohol dependence or 
protection against alcoholism (Goldman et al., 2005a; Dick and Bierut, 2006; 
Higuchi et al., 2006). 
 
58
2.4.3.2 GABA receptor genes 
GABAA receptors (i.e. type A) are the major inhibitory class of neurotransmitter 
receptors in the mammalian brain. (The other two types of GABA receptor 
superfamily are B and C.) They are activated by GABA, which is also the major 
inhibitory transmitter in the adult CNS. These receptors are also a target for 
benzodiazepines, barbiturates, anesthetics, neurosteroids and alcohol. They 
have been implicated in acute and chronic effects of alcohol, including 
tolerance, dependence and withdrawal (Krystal et al., 2006; Enoch et al., 
2008b). GABAergic interneurons in the ventral tegmental area (VTA, which is 
part of the reward pathways in the human brain) act as inhibitory regulators of 
DA (dopamine) neurons. A subset of GABAA receptors in the VTA may be 
implicated in the switch from heavy drinking to dependence. GABAA receptors 
modulate anxiety and stress responses, the target symptoms of alcohol and 
benzodiazepine use, and benzodiazepines are commonly used to ameliorate 
alcohol withdrawal symptoms. In studies on knock-out mice lacking GABAA 
receptors, the most pervasive finding has been the decrease in alcohol 
consumption. GABAA receptors are composed of five heterogenous subunits (at 
least 21 subunits belonging to eight classes have been identified so far), 
allowing for tremendous diversity and multiple subtypes. These individual 
subunits of GABAA receptors have not yet been definitely linked with specific 
behavioural actions or effects of alcohol (Lobo and Harris, 2008; Enoch, 2008b). 
 Judging from the data on GABAA receptors and alcohol reviewed above, it is 
reasonable to search for genetic associations between these receptors and 
alcohol use disorders. Most of the genes coding for different types of GABAA 
receptors are organized into clusters on chromosomes 4, 5 and 15 (4p, 5q, 
15q). The region containing GABAA receptor genes on chromosome 4 
especially has consistently emerged in genome-wide linkage scans, with just 
the diagnosis of alcohol dependence, or even stronger when analysed together 
with electrophysiological (EEG) endophenotypes (Edenberg et al., 2004). A 
significant association was found with GABRA2 gene in that region. This finding 
was replicated later in case-control studies in different ethnic samples 
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(Lappalainen et al., 2005; Enoch et al., 2006b; Soyka et al., 2008). No 
functional polymorphisms affecting receptor function have been identified so far, 
so the evident and possibly even fundamental association lacks biological 
support. There have also been negative findings showing a lack of association 
between GABRA2 and alcoholism. On the other hand, there are results 
indicating that the association is with a haplotype rather than the single gene. It 
is difficult to draw definite conclusions after the finding that the two most 
abundant haplotypes in white study populations are both associated with 
alcoholism (Enoch et al., 2008b). 
 Recently, GABRG1, an adjacent gene to GABRA2, has been strongly 
suggested to predispose to alcohol use disorders. The effect is probably 
independent, but may be additive to the effect of GABRA2. The preliminary 
finding on this association (Enoch et al., 2009a) has already been replicated 
(Covault et al., 2008; Ray and Hutchison, 2009), which reflects the present 
interest in the association between GABA receptor genes and alcohol use 
disorders, and suggests that they might be important in future studies. There is 
also premilinary evidence of an association between GABA receptor genes 
(GABRA2) and externalising behaviour in childhood and adolescence, the 
suspected genetic effect being modified by environmental factors such as 
parental monitoring. In the innovative study by Dick et al. (2009) the gene-
environment interaction (GxE) was represented, as intensified parental 
monitoring prevented the genetically predisposed vulnerable children from 
developing impulsive antisocial behaviours. 
 
2.4.3.3 NPY, Galanin and GALR3 genes 
Neuropeptide Y (NPY) is a neurotransmitter or a modulator consisting of 36 
amino acids. It is believed to be involved in diverse biological functions: control 
of food intake, neuronal development, seizure activity, and emotional 
responses. In recent years NPY has been associated with neurobiological 
responses to ethanol and ethanol consumption or preference in general. Brain 
NPY levels have been shown to be inversely related to alcohol preference in 
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rodents. NPY-deficient knock-out mice drink more than wild-type mice, and 
transgenic mice over-expressing NPY drink less, and are also more sensitive to 
sedative/hypnotic effects of alcohol. The lower level of NPY in alcohol-preferring 
(P) rats compared with non-preferring (NP) rats has been explained by a 
functional polymorphism in the promoter region of the NPY gene on 
chromosome 7 (Oroszi and Goldman, 2004; Higuchi et al., 2006). 
 In humans, the expression of the Pro7 allele of the NPY gene might yield 
higher concentrations of blood NPY. This is uncertain, since the functional 
impact of the Leu(7) to Pro(7) polymorphism in humans is not known. The Pro7 
allele has been linked to serious health risks: higher serum cholesterol levels in 
obese subjects, enhanced atherosclerosis, and higher blood pressure. It was 
also associated with a 34% higher ethanol consumption among middle-aged 
men in Eastern Finland, and with alcoholism among European Americans 
(Kauhanen et al., 2000). These findings could not be replicated in subsequent 
studies in Scandinavian populations. The later results even showed conflicting 
protective effects of the Pro 7 allele against alcoholism (Zhu et al., 2003). Again, 
a novel SNP of the NPY gene has shown an association with alcohol 
dependence, but this finding has not been replicated yet (Mottagui-Tabar et al., 
2005). The data above show no definite role of the NPY gene in the 
development of human alcohol use disorders, though the studies in rodents 
were promising (Higuchi et al., 2006). 
 Galanine is a neuropeptide consisting of 30 amino acids, generated from 
preprogalanin, which in turn is encoded by the galanin gene (GAL) on 
chromosome 11q. Galanin is believed to regulate emotionality and anxiety in 
the limbic regions of the human brain. Animal studies have implicated galanin in 
alcohol abuse and anxiety. A study by Belfer et al. (2006) found a highly 
significant haplotype association, as well as a SNP association, between 
alcoholism and GAL among 514 Finns from the F-N cohort and 135 Plains 
American Indians (both samples included alcoholic and non-alcoholic males). 
The results suggest that a polymorphism in the GAL gene might contribute to 
vulnerability to alcoholism, possibly mediated by anxiety. The same research 
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group later reported an association between galanin receptor gene 3 (GALR3) 
and alcoholism. However, no functional polymorphism in galanin genes has 
been found yet (Belfer et al., 2006; Belfer et al., 2007). 
 
2.4.3.4 OPRM1 gene 
Opioidergic neurotransmission has been implicated in the reinforcing effects of 
several drugs of abuse, including alcohol and nicotine. Both ethanol and 
nicotine increase the level of the endogenous opioid -endorphin (beta-) in a 
dose-dependent manner. The opioid receptor 1 (OPRM1) is the primary site of 
action of -endorphin (and the opioid receptor antagonist naltrexone). The 
effects of opioids in general are suggested to be mediated via at least three 
types of receptors, , , and  (mu, kappa and delta). OPMR1s are widely 
distributed in the brain, the highest levels being found in the thalamus 
(mediating pain and stress responses), and in components of the limbic system, 
such as the amygdala, nucleus accumbens and gingulate cortex (mediating 
reward and emotions). -endorphin release by alcohol mediates part of the 
rewarding effects of the drug either by stimulating OPRM1 or indirectly by 
releasing dopamine (in the reward pathways) (Oroszi and Goldman, 2004; Dick 
and Bierut, 2006). OPRM1 is encoded by the OPRM1 gene on chromosome 6 
(6q), and it shows several polymorphisms. One is a common functional 
polymorphism Asn40Asp, first detected in the F-N cohort by Bergen et al. 
(1997; Anton et al., 2008). The less common Asp40 allele leads up to threefold 
higher binding affinity of -endorphin at the receptor than the wildtype Asn40. 
The observed frequencies of the Asn40Asp alleles in humans have varied 
between 0.80-0.90 and 0.20-0.10. There were no differences in allele 
frequencies between violent alcoholic offenders and controls in the F-N cohort 
(Bergen et al., 1997). 
 Laboratory studies have suggested that the OPRM1 Asp40 allele might be 
associated with increased sensitivity to the effects of alcohol in humans, 
including feelings of euphoria (Higuchi et al., 2006). The drugs naltrexone and 
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nalmefene are associated with favourable but variable treatment outcomes in 
alcoholism. One or two copies of the Asp40 allele predicted lower relapse rates 
in a study by Anton et al. (2008), but there have also been contradictory findings 
(Arias et al., 2008). The influence of the OPRM1 gene on the development of 
alcohol dependence alone has remained obscure (Oroszi and Goldman, 2004; 
Dick and Bierut, 2006; Higuchi et al., 2006). 
 
2.4.3.5 CHRM2 gene 
A region on chromosome 7q was linked to the phenotype of alcohol 
dependence in the COGA study, and also to comorbid or independent diagnosis 
of depression, and to some electrophysiologic endophenotypes defined in the 
study. One of the identified genes in the region was CHRM2 coding for the 
muscarinic asetylcholine receptor subtype 2, which is involved in multiple brain 
functions. The finding was replicated in another study and sample. However, 
the case-control studies with SNPs of the gene have not shown any 
associations, nor have any functional polymorphisms been identified yet 
(Edenberg and Foroud, 2006; Higuchi et al., 2006; Dick and Bierut, 2006). 
 
2.4.3.6 HTR1B, 5-HTR3, and MAO A genes 
Serotonin (5-HT) and especially serotonin 1B receptor has been implicated in 
aggression in animal and human studies, as discussed above. Knock-out mice 
lacking the 5-HT 1B receptor gene (on chromosome 6q in humans) are more 
aggressive and have a preference for alcohol. This gene was linked to 
antisocial (type 2) alcoholism in the F-N cohort and in a southwestern Native 
American sample (Lappalainen et al., 1998). However, the replications have 
been variable, and no functional polymorphism has been identified (Goldman et 
al., 2005a). 
 The effect of serotonin at the 5-HT 3 receptor, consisting of subunits A and 
B, is directly potentiated by ethanol, and chronic alcohol intake sensitises the 
receptor (Enoch, 2003; Goldman et al., 2005b). Ondansetron, a 5-HT3 agonist, 
is used as an antiemetic. This drug has shown favourable treatment effects in 
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early-onset alcoholism, but a worsening of abuse problems in late-onset cases 
(Johnson et al., 2008). Ducci et al. (2009) discovered an association between a 
5-HTR3B gene polymorphism (HTR3B AAG Ins/Del with estimated allele 
frequencies of 0.90 and 0.10), and also a haplotype involving that gene, and 
alcohol dependence combined with antisocial personality disorder in the F-N 
cohort. Enoch et al. (2009b) recently reported findings in the same F-N cohort 
suggesting that both 5-HT3A and 5-HT3B receptor genes might influence 
vulnerability to alcoholism, and a finding of a possible functional polymorphism, 
as well. 
 Monoamine oxidase A (MAO A) catabolizes serotonin, noradrenalin and 
dopamine. It is located on the X chromosome, which naturally causes the 
inherited single polymorphic allele effective in XY males. A common 
polymorphism in the MAO A gene’s transcriptional control region ("MAOA-LPR") 
affects transcriptional activity, resulting in high and low activity alleleles. The 
impact of this polymorphism on serotonin metabolism is unclear, but it is 
presumed, on the basis of inconsistent data, that high activity of the MAO A 
enzyme leads to decreased transmission (Saito et al., 2002; Tikkanen et al., 
2009). A prospective study by Caspi et al. (2002) with a large number of male 
children showed that negative childhood experiences and maltreatment 
together with low activity MAO A (possibly leading to higher than normal 
serotonin levels in the brain) predicted childhood conduct disorder and adult 
antisocial behavior. However, conflicting results of different studies have shown 
that both the high and low activity genotypes are associated with aggression 
and violence (Tikkanen et al., 2009). Tikkanen et al. (2009) showed that heavy 
drinking combined with MAO A high-activity genotype predicted recidivistic 
violence among 174 antisocial impulsive violent Finnish male offenders 
suffering from alcohol dependence or abuse, in other words from type 2 
alcoholism. This was concluded to indirectly confirm the previous findings of the 
association between low CNS serotonin transmission and the risk of impulsive 
violence and type 2 alcoholism (Tikkanen et al., 2009). The role of the MAO A 
genotype in determining vulnerability to alcoholism alone has remained very 
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unclear judging from the inconsistent results of different studies (Caspi, 2002; 
Saito et al., 2002; Tikkanen et al., 2009). 
 
2.4.3.7 Glutamatergic neurotransmission genes 
The data concerning acute and long-term effects of alcohol on glutamate 
transmission, specifically on glutamate NMDA receptors, imply that genetic 
polymorphisms encoding glutamatergic neurotransmission might be involved in 
the development of alcohol dependence (Enoch, 2003; Schumann et al., 2008). 
Schumann et al. (2008) conducted the largest study on glutamatergic 
neurotransmission genes this far in southern Germany. Their samples consisted 
of 544 and 793 alcoholic subjects and 553 and 1002 controls, respectively in 
the first and second samples. The third sample consisted of 144 trios of 15-
year-old adolescents and their parents, who were analysed for early risky 
drinking behaviour. 
 Based on the previous reports on the associations between glutamergic 
genes and alcoholism Schumann et al. (2008) chose 10 polymorphisms for a 
systematic analysis of alcohol dependence. The polymorphisms in genes NR2A 
and MGLUR5 (coding for NMDA receptor subunit 2A and metabotropic 
glutamate receptor 5) were shown to predict alcohol dependence in the first 
sample. In the second sample, they tried to independently replicate the finding, 
but only the NR2A polymorphism yielded a significant result. In the TDT test 
among 144 trios, overtransmission of the C allele of the NR2A polymorphism 
was observed, related to heavy drinking behaviour. The finding confirmed the 
impact of NR2A polymorphism, and possibly of NMDA receptors as well, in 
vulnerability to alcoholism, because early-adolescent alcohol abuse predicts 
alcohol related problems in adulthood (Schumann et al., 2008). 
 
2.4.3.8 Other polymorphisms: HNMT, NTRK2 and CRH-BP genes 
Histamine as a neurotransmitter has been studied far less than aminergic 
neurotransmitters, even though histamine is expressed in cortical and limbic 
areas of the human brain, which are involved in emotion and cognition. 
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neurotransmitter action of histamine. A C314T transition in exon 4 of the HNMT 
gene, which is a common functional polymorphism, results in a Thr105Ile 
substitution in the enzyme protein. The Thr105 allele has two-fold higher 
activity, probably predicting diminished histamine levels in the brain, and 
consequently may be involved in the individual differences affecting cognition 
and experienced anxiety or sedation. The allele frequencies of Thr105Ile are 
estimated to be 0.90/0.10 (Oroszi et al., 2005). In a large study of 857 subjects 
carried out among the Finnish F-N cohort and Plains American Indians, Oroszi 
et al. (2005) found the Thr105 allele to be more frequent among alcoholic 
individuals. The low levels of brain histamine in these subjects might be 
associated with higher levels of anxiety and might lead to self-medication with 
alcohol. On the other hand, varying levels of histamine may explain why some 
subjects are more resistant to the sedating effect of alcohol and are able to 
drink more than others. However, this finding of Oroszi et al. (2005) was not 
confirmed in a smaller sample of German alcoholics and controls (Reuter et al., 
2007). 
 The role of brain-derived neurotrophic factor (BDNF) in the mechanisms of 
alcohol dependence has been demonstrated in animal studies. In humans, 
linkage scans of alcoholism have revealed chromosomal regions containing 
genes coding for BDNF and its cognate receptor, neurotrophic tyrosine kinase 
receptor B (NTRK2 gene). In a study among 500 Finnish antisocial alcoholics 
and controls (the F-N cohort), the entire NTRK2 region was covered with SNPs, 
three of which were associated with this subtype of alcoholism (Xu et al., 2007). 
This finding concerning brain growth factors is of interest considering the results 
of a brain imaging study showing increased white matter in the brains of violent 
antisocial alcoholic subjects. However, this quite unexpected observation by 
Tiihonen et al. (2008) has not yet been replicated. 
 The resting EEG is a dynamic index of cortical activation, cognition and 
consciousness and has been suggested to be heritable. Enoch et al. (2008a) 
used resting EEG frequency bands (alpha, theta and beta) as intermediate 
The action of histamine-N-methyltransferase (HNMT) is crucial in terminating the 
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phenotypes in a dense whole genome linkage scan among 300 Plains Indians 
and 200 white Americans. They found a connection between the resting EEG 
power, anxiety, alcohol use disorders and the CRH-BP gene coding for high 
affinity binding protein for corticotrophin releasing hormone (CRH). The binding 
protein modulates the action of CRH, a primary mediator of the mammalian 
neuroendocrine and behavioural responses to stress, which makes CRH-BP a 
relevant candidate gene for anxiety and addiction (Enoch et al., 2008a). 
 
2.4.4 Association studies on COMT gene polymorphism 
2.4.4.1 COMT enzyme and COMT polymorphism 
Catechol-O-methyltransferase enzyme inactivates catechol hormones, drugs 
containing catechol (e.g. L-dopa for Parkinson’s disease) and catecholamines, 
including those acting as neurotransmitters such as dopamine. COMT enzyme 
occurs in mammals as two distinct forms: a cytoplasm-soluble protein (S-
COMT) and a membrane-bound protein (MB-COMT). S-COMT activity is the 
most prevalent in all tissues except the human brain, where most of the enzyme 
activity (70%) comes from MB-COMT (Tenhunen et al., 1994; Syvänen et al., 
1997). The level of COMT activity in humans has been shown to vary between 
individuals in trimodal distribution of low, intermediate and high levels, and was 
known to be genetically polymorphic already in the 1970s (Lachman et al., 
1996). 
 Both forms of COMT enzyme are coded by a single gene, which is expressed 
in all tissues and located on chromosome 22q11. No brain specific variants 
have been detected (Syvänen et al., 1997; Lachman et al., 1996). A common 
polymorphism at codon 108/158 (S-COMT / MB-COMT) of the COMT gene, 
resulting from a nucleotide transition (G to A) and causing a valine to 
methionine substitution in the enzyme, was found to be functional. 
Homozygosity for the valine (G) allele was associated with three- to four-fold 
enzyme activity compared with the homozygous methionine (A) genotype (and 
thus possibly leading to less sustained dopamine effect in the brain). The 
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heterozygous genotype had an intermediate level of enzyme activity. At least 
some of the variation in activity may be caused by the thermolability of the 
COMT-methionine form. These results obtained from human liver tissue or red 
blood cells will very probably be expressed in brain tissue as well (Lachman et 
al., 1996). The frequency of the valine/methionine alleles in white population is 
found to be 0.51/0.49 (Bevilacqua and Goldman, 2009). The COMT valine and 
methionine alleles (val and met) are later also referred to as H (for high activity) 
and L (for low activity) alleles, respectively. 
 The sex- and brain-region-specific contribution of COMT enzyme activity (of 
genetic origin) in the maintenance of dopamine levels and in the regulation of 
dopamine neurotransmission and consequent changes in behaviour was shown 
in a study on COMT knock-out mice (Gogos et al., 1998). COMT-deficient 
homozygous male mice showed a 2- to 3-fold higher level of dopamine in the 
frontal cortex, but no changes of dopamine content in either the striatum or 
hypothalamus were noted, nor were there any locomotor deficits present. 
COMT-deficient homozygous female mice showed higher anxiety. Aggressive 
behaviour was markedly higher in heterozygous COMT-deficient male mice. 
The authors speculated that the COMT activity of a heterozygous COMT-
deficient mouse is comparable with that in a human subject homozygous for the 
L allele, although in general experimental results on knock-out mice cannot 
readily be used as a model for complex human behaviours. 
 It has been detected that COMT valine and methionine alleles reside on 
haplotypes (i.e. in patterns of alleles at nearby linked loci, transmitted and 
inherited together rather than segregated by meiotic recombination), and these 
haplotypes are common to different populations. These aspects reflect an 
ancient origin of both alleles in the human genome, and a potential role of 
selection in their maintenance (Oroszi and Goldman, 2004; Goldman et al., 
2005a). 
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2.4.4.2 COMT polymorphism and cognitive function, and personality traits 
The abundant literature concerning COMT polymorphism and major mental 
disorders such as schizophrenia or bipolar disorder is not discussed here 
because it is irrelevant. The effect of COMT polymorphism on personality and 
cognition is closely related to alcohol use disorders, and it is therefore briefly 
discussed below. 
 The inherited differences in COMT activity are likely to predict variation in 
dopaminergic neurotransmission in the frontal cortex of the brain (prefrontal 
area), where the levels of another crucial regulator, dopamine transporters, are 
low. This was shown in the study on COMT knock-out male mice described 
above (Gogos et al., 1998). Solid data indicate that dopamine enhances 
prefrontal neuronal function during working memory tasks and thus also 
enhances cognitive performance (Egan et al., 2001; Goldman et al., 2005a). 
 A highly sophisticated study among 175 patients with schizophrenia, their 
219 unaffected siblings and 55 healthy controls showed that low activity L allele 
of COMT polymorphism predicted better cognitive performance during 
neuropsychological testing of executive functions. When the normal subjects 
were assessed with functional magnetic resonance imaging (fMRI) during a 
working memory task, the L allele again predicted a more efficient physiological 
response in the prefrontal cortex. The effect was allele dose dependent: the 
individuals homozygous for L allele showed the most efficient results, and 
heterozygotes were intermediate when compared with the least efficient group 
of subjects homozygous for high activity H allele (with faster dopamine 
inactivation and less sustained transmission). In a family-based analysis there 
was also a significant hereditary transmission of the H allele to schizophrenic 
offspring. This indicates that the COMT H allele might also be if not an actual 
risk factor for then a modulator of the prognosis in schizophrenia, because it 
impairs prefrontal function (Egan et al., 2001). The COMT H allele and its 
haplotypes have been linked to prefrontal lobe function in other studies, as well 
(Malhotra et al., 2002). 
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 On the other hand, the low activity L allele has also been linked to higher 
levels of anxiety and a lower pain threshold. A study among two community 
samples of 149 white and 252 Plains American Indians subjects (predominantly 
females, without lifetime psychiatric diagnosis) found an association between 
COMT L/L homozygous genotype and higher anxiety levels measured by the 
Tridimensional Personality Questionnaire (TPQ, Cloninger et al., 1991) and low-
voltage alpha resting EEG among the female subjects (Enoch et al., 2006a). 
These EEG findings had previously been shown to be associated with anxiety 
and alcoholism by the authors, potentially reflecting intermediate mechanisms 
(Enoch et al., 1999). A lower pain threshold, stronger affective response to pain, 
and inability to activate the endogenous brain opioid system following pain was 
associated with the L allele in a brain imaging study by Zubieta et al. (2003). 
Lower pain threshold was associated with L allele haplotypes in a study of a 
large cohort of women by Diatchenko et al. (2005), as well. 
 Women generally are considered to be more prone to anxiety than men. 
However, the findings above might indicate that the carriers of the low activity L 
allele tend to "worry" or suffer from anxiety because of the lower resiliency to 
stress and pain, but they also gain better cognitive functions in change (with 
more sustained frontal dopamine transmission). This balance of advantages 
forms the basis for the "Warrior/Worrier" model (Goldman et al., 2005a): the 
warrior has better stress resiliency, and a higher pain threshold with a more 
functional endogenous opioid system, but also less effective executive cognitive 
performance (which probably reduces stress before the “battle”). This 
dichotomy of advantages/losses may be responsible for the selection to 
conserve both of these alleles (or haplotypes containing the alleles) in the 
human genome across populations. 
 There are also differences in COMT activity based on sex. At least in vitro 
estrogen can inhibit COMT gene transcription, and women have been shown to 
have significantly lower COMT activity than men (Enoch et al., 2006a). This is 
consistent with the data mentioned above on the association between anxiety 
and low COMT activity and, on the other hand, between female sex and 
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predisposition to anxiety. Sexually dimorphic behavioural changes in mice 
associated with low COMT activity are described above (Gogos et al., 1998). 
Altogether, this indicates that sex may modify genetically determined behaviour, 
the same genotype resulting in different behavioural consequences in males 
and females. 
 It has also been suggested that the COMT genotype and associated variation 
in prefrontal cognitive function act as a modifier against a background of other 
aetiological factors to affect behaviour. In a recent study among almost 500 
children from three cohorts, Caspi et al. (2008) showed a conditional 
association between antisocial conduct disorder and the COMT H/H (Val/Val) 
genotype, presumably with less effective prefrontal cognitive processing. The 
association was observed only in children with ADHD, not in those without. It is 
generally accepted that about 50% of the children and adolescents with ADHD 
show antisocial tendencies (Caspi et al., 2008). 
 
2.4.4.3 COMT polymorphism and alcoholism or substance abuse 
Dopamine release in the human brain has been suggested to play a major role 
in euphoria induced by substances of abuse and thus possibly in the 
development of alcoholism. Consequently, it would be logical to search for an 
association between the functional COMT L/H polymorphism and alcoholism or 
other substance abuse. A study among 175 Japanese alcoholics (the majority 
males) and 350 age and gender matched controls found no difference in COMT 
allele frequencies or genotypes between subjects and controls. No association 
between genotypes and age of onset of alcoholism or antisocial behaviour were 
detected, either (Ishiguro et al., 1999a). Vandenbergh et al. (1997) found that 
the COMT H allele was significantly more common among 200 white 
polysubstance abusers than 100 controls. The association was explained 
through impulsivity or dyscontrol, not by liability to excessive anxiety. 
Altogether, association studies on the COMT genotype and alcoholism were 
rare in the 1990s. 
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2.4.5 Association studies on serotonin transporter gene polymorphisms 
 
2.4.5.1 Serotonin transporter (5-HTT) and 5-HTT gene polymorphisms 
Serotonin transporter (5-HTT) is a functional protein that regulates the amount 
of serotonin (5-HT) in a synaptic gap by taking up 5-HT back to a presynaptic 
neuron and hence finishing transmission. It is therefore crucial in fine-tuning 
brain serotonergic neurotransmission controlling the magnitude and duration of 
5-HT responses (Lesch et al., 1994; Lesch et al., 1996). 5-HT and its 
transporter are abundant in the central and peripheral nervous system, and are 
also found in platelets, placental and pulmonary plasma membranes. 
 The human 5-HTT is encoded by a single gene (termed SLC6A4) on 
chromosome 17 (more precisely 17q11.1-17q12) (Lesch et al., 1994; Lesch et 
al., 1996). A variable number tandem repeat polymorphism (VNTR) is found in 
the second intron of the gene, with at least four different alleles identified as 
containing 9–12 repeats (Lesch et al., 1994). The functional impact of the VNTR 
polymorphism remains unknown. 
 Another well-known polymorphism is located 1 kb (kilobases) upstream from 
the transcription site in the promoter region of the 5-HT gene (in the 5´- flanking 
region) and is known as 5-HTTLPR (5-HTT gene linked polymorphic region) or 
the SERT gene (Lesch et al., 1994; Lesch et al., 1996). The polymorphism 
consists of 44-base pair insertion- or deletion-involving repeat elements. The 
alleles are called L (long) and S (short) depending on the number of repeats. 
The polymorphism appears to influence gene function by changing transcription 
efficiency. The basal activity of the L variant is more than twice that of the S 
form. That means that 5-HT uptake in cells homozygous for L allele is twice that 
in cells carrying one or two S alleles. It also suggests a dominant-recessive 
nature of the polymorphism with possible dominance of the S allele (Lesch et 
al., 1996), but this has subsequently been questioned, and a co-dominant 
action of the alleles has been proposed (Hu et al., 2004). A study using 5-
HTTLPR knock-out mice to reduce transporter expression demonstrated a 
marked dose-dependent increase in extraneuronal 5-HT in the striatum and 
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frontal cortex, associated with a decreased expression of the gene (Mathews et 
al., 2004). 
 Later, 14 new variants were found among Japanese and white subjects, both 
for S type and for L type, with proposed but not observed functional differences 
between them (Nakamura et al., 2000). Hu et al. (2006) showed the functionally 
triallelic nature of 5-HTTLPR polymorphism: a common single-base substitution 
(A to G) in the L allele creates La and Lg alleles. In lymphoblastoid cell lines (in 
vitro) the transcriptional activity of the Lg is reduced to the same level as the S 
allele (Hu et al., 2006). Hu et al. (2006) speculated that the main result of not 
paying attention to the triallelic nature of 5-HTTLPR, i.e. not scoring the low 
function Lg allele, is probably to obscure the effect of the highest expressing 
LaLa genotype. The effect is perhaps less crucial for phenotypes previously 
associated with the low activity S allele. The authors listed the frequencies of 
these three alleles, and the six new functional genotypes in different 
populations. In a group of 770 Finns the frequencies were: Lg allele 0.09, SLg 
genotype 0.08, LgLg genotype 0.1. (Consequently, the net effect would be a 
frequency of +0.09 added to the SS genotype group mainly from the former SL 
group.) The Lg allele frequencies varied considerably between populations, 
being highest among 600 African Americans (0.24) and lowest among American 
Indians (0.01) (Hu et al., 2006). However, other researchers have not been able 
to replicate the results of Hu et al. (2006) regarding the association between Lg 
allele and lower 5-HTT expression (Martin et al., 2007). 
 The studies on 5-HTTLPR polymorphism reviewed below, despite the 
confusing data by Hu et al. (2006), are based on the findings by Lesch et al. 
(1996) of the biallelic polymorphism and the functional difference in 
transcriptional activity between L and S type alleles. The frequency of the L and 
S alleles among white subjects is 0.60/0.40 respectively. If the low activity Lg 
allele is included, the allele frequencies L/S/Lg are 0.50/0.40/0.10. Even after 
the report by Hu et al. (2006) it is generally claimed that the 5-HTTLPR gene 
has only two common functional alleles: L and S. The in vivo transcriptional 
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effects of the single-nucleotide polymorphisms described by Hu et al. (2006) are 
not known (Uher and McGuffin, 2008). 
 
2.4.5.2 5-HTTLPR and personality related traits 
The abundant literature concerning 5-HTTLPR polymorphism and bipolar 
disorder, especially depression and the suggested GxE interactions, is not 
discussed here. It is not relevant, whereas the effect of the 5-HTTLPR 
polymorphism on personality is closely related to alcohol use disorders, and is 
briefly discussed below. 
 In addition to testing possible associations between actual psychiatric 
disorders and known polymorphisms, a substantial body of studies has 
examined the relationship of candidate genes to personality dimensions. 
However, the results have been inconsistent. The polymorphisms most often 
studied are presumed to be involved in the regulation of the serotonin- or 
dopamine-mediated neurotransmission. A meta-analysis by Munafò et al. 
(2003) listed 46 studies reporting data on associations between candidate 
genes and human personality traits, screened by different personality scales, 
most often with NEO inventories (Costa and McCrae, 1997) or TCI/TPQ 
personality inventories (Cloninger et al., 1991). Studies involving subjects with 
psychiatric disorders such as substance abuse were excluded. In a fixed-effects 
model, significant associations were found related to serotonin transporter (5-
HTTLPR) and dopamine receptor (DRD2, DRD3 and DRD4) polymorphisms. 
Half of the studies reported data on 5-HTTLPR. After multivariate analysis to 
control for the significant heterogeneity between the studies, only the 
association between the 5 HTTLPR polymorphism and so-called avoidance 
traits (but not aggression or approach traits, which were also studied) remained 
significant. However, even that significance was lost after further sensitivity 
analyses (excluding studies with allele frequencies not in H-W equilibrium) 
(Munafò et al., 2003). 
 A more recent meta-analysis concentrating on 5-HTTLPR polymorphism and 
anxiety-related personality traits in adults (Sen et al., 2004) gathered data on 23 
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studies involving 5629 subjects. The first published association between 5-
HTTLPR and neuroticism, screened by the NEO inventory, was reported by 
Lesch et al. (1996). Neuroticism is characterized as "negative emotionality", 
such as anxiety, low mood, vulnerability and hostility. Roughly half of the 
studies included used NEO, measuring neuroticism, and the rest used the 
TCI/TPQ scale, measuring harm avoidance. These two traits have a correlation 
of 0.55 (De Fruyt et al., 2000), indicating significant variation in the outcome 
measures by the two scales. The meta-analysis shows a borderline significant 
association between the 5-HTTLPR S allele and increased anxiety as a trait 
(P=0.087). Eight studies of the 23 listed found a significant association. Not a 
single study found an association between the L allele and higher anxiety trait 
scores. This argues against a chance finding in an overall analysis. There was a 
significant heterogeneity among the results of the different studies also in this 
meta-analysis, but it was more limited among studies using NEO. The 
demographic variables such as gender and ethnic composition were not 
significant confounding variables (Sen et al., 2004). 
 Studies of the association between 5-HTTLPR and physical or verbal 
aggression, reflecting behavioural disinhibition as a personality trait, have been 
scarce. A Chinese study in Taiwan (Liao et al., 2004) among 135 males 
convicted for extremely violent crimes found an excess of S allele among index 
subjects compared with 111 controls, but no association between ASP or 
substance abuse. Haberstick et al. (2006) conducted family-based tests of 
association in a sample of 732 twins and their parents. They found a borderline 
significant association between S allele and aggressive behavior in middle 
childhood (at the age of 9). 
 An elegant study among a relatively small number (28) of healthy subjects 
but using a direct assay of brain function, BOLD fMRI (blood oxygen level 
dependent functional magnetic resonance imaging), studied the association 
between 5-HTTLPR polymorphism and amygdala response to fearful stimuli 
(Hariri et al., 2002). Based on the previous studies showing abnormal levels of 
anxiety among S allele carriers, and the recognized role of amygdala in 5-HT-
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mediated fear responses, the authors presumed that individuals with the S 
allele would exhibit a greater amygdala response. The genotype groups did not 
differ in overall performance, indicating a lack of non-specific effects on the 
results. Neither were there significant group differences in anxiety- or fear-
related traits screened by the standard behavioural measure TPQ 
(Tridimensional Personality Questionnaire, see above), probably because of the 
small sample size. The main results, however, confirmed the authors‘ 
hypothesis: the responses of the right amygdala were significantly greater 
among the S carriers than among subjects homozygous for the L allele. The 
heightened responses probably reflect increased excitatory action of synaptic 5-
HT due to the decreased 5-HT transporter expression in S allele carriers, but 
may also reflect partial desensitization of inhibitory 5-HT1A receptors following 
high levels of synaptic 5-HT. Finally the authors conclude that the observed 
different responses in adult subjects may be rooted in early individual 
developmental processes influenced by serotonergic neurotransmission. 
 In this context, the level of subjective response to alcohol’s desired 
(intoxicating, euphoric) or negative (e.g., nausea) effects are viewed as a 
personality trait. "Low Level of Response (low LR)" is also one of the more 
thoroughly investigated phenotypes associated with alcoholism risk (Schuckit et 
al., 2004). It is considered to be a risk-related, inherited intermediate phenotype 
possibly preceding alcoholism, as described above. One of the polymorphisms 
studied for an association is 5-HTTLPR. Schuckit et al. (1999) published a 
follow-up case-control study in 1999, and later they expanded it by adding more 
subjects, for a total of 85 males with clearly high or low LR to alcohol. The 5-
HTTLPR L allele was associated with low LR at age 20 and with the 
development of alcohol dependence or abuse during the follow-up of 10, 15 and 
20 years (Schuckit et al., 1999; Hu et al., 2005). Also, the polymorphism called 
GABA A alpha6 Pro385Ser in chromosome 5 and the uncommon 385Ser allele 
showed a non-significant trend for association to a low LR. The 5-HTTLPR L 
allele showed an allele-dosage (stepwise) association with LR and also 
alcoholism, and the effect of GABA A alpha6 Pro385Ser was additive to that 
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(Hu et al., 2005). The authors also subdivided L alleles into functional subtypes 
La and Lg, without a change in the observed association. 
 
2.4.5.3 5-HTTLPR polymorphism (S and L alleles) and alcoholism 
Central nervous serotonin activity has been shown to modulate alcohol 
consumption in animals (LeMarquand et al., 1994). This has encouraged the 
study of the 5-HTTLPR gene as a potential candidate in alcoholism. An 
association between the S allele and severe dependence was detected in a 
subset of 100 subjects drawn from a sample of 315 German alcoholics (Sander 
et al., 1997). A trend towards association between the S allele and alcoholism 
was observed in a smaller subset of 64 antisocial subjects from the same 
sample (Sander et al., 1998). Also, Hammoumi et al. (1999) detected an excess 
of the S allele among French alcoholics. Ishiguro et al. (1999b) found an 
association between the L allele and earlier onset of dependence among 166 
Japanese alcoholics and 290 controls. Negative findings were reported in two 
studies among European American subjects (Gelernter et al., 1997; Edenberg 
et al., 1998a). Jorm et al. (1998) also failed to find any association between 5-
HTTLPR genotypes and alcohol disorders in a large white Australian general 
population sample of 759 subjects. 
 
2.4.6 Association studies on dopamine receptor D2 gene polymorphisms 
 
2.4.6.1 DRD2 and DRD2 gene polymorphisms 
The dopamine receptor D2 (DRD2) belongs to a D2-like family of the human 
dopamine receptors together with the receptor subtypes D3 and D4. The other 
family includes receptor subtypes D1 and D5. The gene for D2 is isolated and 
sequenced: it is located on chromosome 11 at q22-q23 (Grandy et al., 1989). 
Several polymorphic markers have been identified in the DRD2 gene, the 
review by Pato et al. (1993) already listed 8 identified polymorphisms in this 
gene. Among them are Ser311Cys and –141C Ins/Del, the latter being a 
functional polymorphism. The allele frequencies of the –141C Ins/Del are 
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0.91/0.09 (Bevilacqua and Goldman, 2009). However, our knowledge of how 
the transcription of the human D2 receptor is regulated is limited (Pohjalainen et 
al., 1998; Parsian et al., 2000). In the literature none of the several 
polymorphisms located in the coding region of the DRD2 gene (thus more 
possibly affecting the transcription) shows a strong replicated association with 
psychiatric disorders. 
 The TaqI A polymorphism, a RFLP (restriction fragment length 
polymorphism) with two alleles called A1 and A2, was the first of the DRD2 
polymorphisms to be detected. It has been the most studied, the DRD2 gene in 
general probably being the most intensively studied gene in alcoholism during 
the 1990s (Noble 1998a). (During this decade the most studied topic was 
probably the genetics involved in GABA transmission, especially in the GABA 
receptors.) The results concerning associations between TaqI A and alcoholism 
(Blum et al., 1990; Noble et al., 1991; Noble 1998a), or the lack of associations 
have been controversial (Bolos et al., 1991; Goldman et al., 1992; Gelernter et 
al., 1993). Unfortunately the polymorphic TaqI A site is located outside the 
coding region of the DRD2 gene (10 kb downstream from the coding region). 
Consequently, it would have to be in linkage disequilibrium with another clearly 
functional polymorphism to affect D2 receptor availability, and possibly the 
development of individual personality traits or vulnerability to psychiatric 
disorders (Laruelle et al., 1998). However, there is evidence of a TaqI A SNP 
and linkage disquilibrium involving TaqI A that extends into the DRD2 gene, up 
to 25 kb away from the TaqI A itself. In other words, the possibility of LD 
between TaqI A and DRD2 is not totally excluded (Kidd et al., 1998). 
 Recently it has been recognized that the TaqI A polymorphism is actually 
located within the coding region of a kinase gene neighbouring the DRD2 gene. 
This complex, called the ankyrin repeat and kinase domain, contains the 
ANKK1 gene, and probably codes for proteins involved in signal transduction 
pathways. ANKK1 is a novel serine/threonine kinase gene, one of the "tyrosine 
kinase like genes (TKL)" (Neville et al., 2004). It is suggested that TaqI A SNP 
polymorphism actually causes an amino acid substitution within the substrate 
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binding domain of this gene, affecting binding specificity. In this way TaqI A 
polymorphism could be involved in dopaminergic transmission along with 
ANKK1, via a signal transduction pathway or other cellular responses to 
external stimuli. Genes of related functions (such as DRD2 and ANKK1) are 
sometimes found clustered together (Neville et al., 2004; Hill et al., 2008). There 
is some preliminary evidence from the COGA sample suggesting an association 
between SNPs in the DRD2/ANKK1 and severe alcohol dependence (Dick and 
Bierut, 2006). 
 Also, a recently identified SNP of the DRD2 gene, C957T, has been 
proposed as being responsible for some of the phenotypic features previously 
associated with the TaqI A polymorphism, such as D2 receptor availability in the 
striatum (Hirvonen et al., 2004). On the other hand, the TaqI A of the ANKK1 
gene is associated with increased striatal activity of aromatic L-amino acid 
decarboxylase, which is the final enzyme in the biosynthesis of dopamine 
(Laakso et al., 2005). C957T and TaqI A polymorphisms have been reported to 
be in LD with each other, and both have been suggested to have a functional 
impact in dopaminergic transmission. It is unclear which of the previously 
reported associations with TaqI A are explained by associations with ANKK1 
and which by associations with C957T (Ponce G et al., 2008). 
 TaqI B, C and D polymorphisms have also been identified. TaqI B is 
supposed to be in strong linkage disequilibrium with TaqI A, but the functional 
role of any of the TaqI polymorphisms is not clear (Ritchie and Noble, 2003). 
 
2.4.6.2 TaqI A polymorphism and DRD2 availability 
After Blum et al. (1990) discovered the association between TaqI A and 
alcoholism, Noble et al. (1991) published their finding on reduced DRD2 binding 
capacity associated with the TaqI A1 allele in a dose-dependent fashion. The 
A1 allele was also strongly associated with alcoholism in this same study. The 
brain samples of 66 alcoholic and non-alcoholic subjects were studied post-
mortem. Also, Thompson et al. (1997) found an association between the A1 
allele and reduced DRD2 receptor binding in the human striatum. They studied 
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44 healthy middle-aged to elderly subjects post-mortem by autoradiography. 
Pohjalainen et al. (1998) studied 54 healthy Finnish volunteers with positron 
emission tomography (PET), and found a statistically significant reduction in 
DRD2 availability in subjects with the A1/A2 genotype compared with the A2/A2 
group (the study group did not include any A1/A1 subjects). The existence of 
the A1 allele accounted for 12% of the variance in DRD2 availability. Jönsson et 
al. (1999) obtained similar results, an association between A1 allele and low 
DRD2 density, in their PET study on 56 healthy white subjects, but the sample 
included only a few A1/A1 subjects. In a post-mortem study, Ritchie and Noble 
(2003) found a lower number of DRD2 binding sites in the brains of A1 allele 
carrier subjects (40% fewer receptors compared with those without A1). This 
was a subset of their former 1991 study involving brain tissue from 20 alcoholic 
and 21 nonalcoholic subjects. Noble et al. (1997) also studied mean relative 
glucose metabolic rate (GMR) by PET in different brain regions of 15 healthy 
white volunteers while they were executing a continuous performance task. 
They found lower GMR in dopamine receptor-rich brain areas, closely 
associated with the prefrontal system, in subjects carrying A1 allele. 
 In some of the above studies an association between the TaqI B genotype 
and DRD2 availability was also found, which seems to be quite natural 
considering the replicated finding of a strong linkage disequilibrium between 
TaqI A and TaqI B polymorphisms. One of the so-called synonymous ("silent") 
mutations, C957T mentioned above, has been shown to explain 18% of the 
variance in striatal binding potential (BP) (Hirvonen et al., 2004). Together with 
the effect of the TaqI A1 allele, they explained 40% of the variance in DRD2 BP, 
in other words, receptor availability. 
 There are also conflicting findings. Laruelle et al. (1998) studied 47 healthy 
controls and 23 subjects with schizophrenia (and with previous exposure to 
dopaminergic antipsychotic drugs) by PET. The study group, none of the 
subjects with a history of alcohol or other substance abuse, included a few 
subjects with the A1/A1 genotype. They could not find any association between 
DRD2 binding potential and TaqI A or B genotypes. Commenting on the 
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conflicting findings, Hitzemann (1998) pointed out that in previous studies the 
frequency of the A1 allele had varied considerably in subjects from different 
ethnic groups, which explained some of the variance in the results. Moreover, 
the age of the study subjects had not been controlled for, and aging seems to 
cause a marked receptor loss in animals with high youthful receptor density. 
Previous studies had strongly indicated that DRD2 density/availability is 
regulated by multiple genes, not just the DRD2 gene, which would likely have 
only a moderate effect size, other genes controlling most of the variance. There 
is also a wide natural variation in DRD2 density among normal controls without 
any neurological or psychiatric pathology (Hitzemann, 1998). Gelernter et al. 
(1993) had already emphasized  the importance of controlling for the ethnic 
origin of the study samples when they were criticizing the first over-optimistic 
observations on the association between TaqI A polymorphism and alcoholism. 
 To clarify the subtype of the dopamine receptors involved in alcohol self-
administration, Phillips et al. (1998) studied DRD2 knock-out mice. These mice 
showed an aversion to alcohol and were less sensitive to movement disorders 
caused by alcohol than wild-type mice. Homozygous D2 -/- mice lacking D2 
receptors consumed only half the amount of alcohol that the wild-type mice 
consumed, and heterozygous mice had an intermediate level of alcohol 
consumption. Referring to the debate about the association between alcoholism 
and DRD2 polymorphism, the authors stated that their study neither supported 
nor refuted the influence of allelic variation at the human DRD2 locus in 
modulating ethanol consumption. "Whether naturally occurring DRD2 allelic 
variation could account for large differences in ethanol preference drinking and 
sensitivity in mice, similar to those induced by deletion of the DRD2 gene, 
remains to be established", the authors concluded. 
 
2.4.6.3 TaqI A polymorphism and personality traits 
The aetiology of alcoholism has been associated with several behavioral 
markers in children of alcoholics, such as cognitive deficits in visuospatial 
abiIity. Connected with this, alterations in brain electrical potentials have been 
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observed in these children, such as reduced amplitude and prolonged latency of 
the P300 event-related potential (ERP). Many studies have shown that children 
raised by alcoholic parents experience significantly more stressors than usual, 
and this probably makes them more vulnerable to alcohol use disorders. Based 
on these findings, in a partial replication of their earlier study, Berman et al. 
(2003) studied 146 healthy high-risk sons and daughters of alcoholic parents. 
The somewhat confounding results indicated that both sex and TaqI A genotype 
modified the association between negative affect and other risk markers. 
Among the TaqI A1 allele carrier boys, experienced family stress was 
associated with reduced visuospatial ability and reduced P300 amplitude. 
 Madrid et al. (2001) tested the predictive power of the TaqI A genotype in the 
development of alcoholism in a sample of 309 males of Mayan descent in 
Honduras. The participants were interviewed and then more systematically 
studied for alcoholism and stress and for TaqI A genotypes. (The authors 
remarked that 20% of the working population in Honduras suffers from 
alcoholism.) Three explanatory models for alcoholism were tested: 1) 
demographic variables alone; 2) stress and TaqI A genotype separately; 3) 
interaction between stress and genotype. Neither alcoholism nor experienced 
stress alone was associated with genotypes. However, stress and the Taq A1 
allele together significantly predicted the degree of alcoholism (model 3). Stress 
had no effect on the development of alcoholism in the A2/A2 genotype group 
and only a modest effect among heterozygous A1/A2 subjects. The authors 
suggested that this was further evidence of gene-environment interaction, and 
also that this could explain the variance in the results of previous studies on 
alcoholism and TaqI A genotypes, since they had not accounted for 
experienced stress (Madrid et al., 2001). 
 In a study by Ponce et al. (2003) among 103 alcohol-dependent Spanish 
males, subjects with the TaqI A1 allele had a higher prevalence of antisocial 
personality disorder and more often had a family history of alcoholism. A study 
by Limosin et al. (2003) among 92 French alcoholics (both sexes) showed that 
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the A1/A1 genotype was associated with lower impulsiveness assessed by 
Barrat’s Impulsiveness Scale. 
 A systematic review and meta-analysis of genetic polymorphisms and 
personality in healthy adults by Munafo et al. (2003) of 46 studies on different 
candidate genes found six studies on TaqI A polymorphism and personality 
traits (involving 600 study subjects). There was evidence of a significant 
association between the TaqI A genotype and so-called “avoidance traits", but 
the significance was lost when the heterogeneity between the studies was 
controlled for in a random effects model. In other words, there was no 
consistent association between TaqI A polymorphism and adult personality 
traits on a meta-analysis level. 
 
2.4.6.4 TaqI A polymorphism and smoking 
Alcoholism and smoking are highly comorbid, with 80–90% of alcohol-
dependent subjects smoking (three times more than in the general population). 
There is evidence of shared as well as for specific addiction vulnerability 
between these behaviours (cross-inheritance and independent heritance). 
There also seems to be a considerable genetic overlap between these 
addictions particularly in the group of heavy drinkers/heavy smokers. The 
nicotine in tobacco smoke is known to be a dopaminergic drug affecting the 
reward pathways (Enoch, 2003). Consequently, the DRD2 gene and TaqI A 
polymorphism have also been studied among smokers. Comings et al. (1996) 
studied 312 white heavy smokers from a cessation clinic and 700 controls, 
finding a significant association between the A1 allele and smoking, young age 
of onset of smoking and unsuccessful attempts to quit smoking. Spitz et al. 
(1998) studied 157 lung cancer patients and 126 controls but could not find any 
associations between TaqI A genotypes and smoking. Instead, the TaqI B1 
allele was associated with smoking, and the prevalence of the rare A1 allele 
seemed to predict the presence of the equally rare B1 allele (linkage 
disequilibrium). These few studies attempting to detect an association between 
smoking and TaqI A genotype did not yield any conclusive results. 
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2.4.6.5 TaqI A polymorphism and alcoholism  
Blum et al. (1990) published the first report of an association between 
alcoholism and the TaqI A1 allele among 35 alcoholics and 35 nonalcoholic 
controls. Numerous attempts to replicate the finding soon followed. The first 
meta-analysis three years later found eight case-control studies of TaqI A and 
alcoholism, with altogether 430 alcoholics and 490 controls, meaning that the 
number of subjects in each study was generally quite small (Pato et al., 1993). 
Four of these studies were positive on association, and the other four failed to 
find any. The authors explained the variance in results by between-study 
heterogeneity (different forms of alcoholism in different studies) and by within-
study heterogeneity (different forms of alcoholism in the same study sample). 
According to this meta-analysis, as the severity of alcohol dependence 
decreases, the rate of phenocopies (not genetically determined forms) 
increases. Also, it was known that the TaqI A1 allele frequency varied 
significantly between populations, from 9 to 75% (Barr and Kidd, 1993). So the 
population heterogeneity between the groups of cases and control subjects 
could significantly mask the real effect or demonstrate a false association. 
However, there was a statistical support for an association between the A1 
allele and alcoholism. When the results of all these studies were put together, 
the calculated RR was 2.14 (Pato et al., 1993). 
 The comprehensive review of the association between TaqI A and alcoholism 
by Noble (1998a) covered 15 US and European studies among white subjects. 
Over 1000 alcoholics (from severe to less severe forms) and 900 controls 
(including subjects assessed or not assessed for alcoholism) were involved. 
The study samples still were quite small, with a lot of heterogeneity between 
them. The prevalence of the A1 allele varied from 25 to 65% among alcoholics 
and from 12 to 35% among controls. The homozygous A1/A1 genotype was 
very rare, about 3% in both groups. Taking only those studies where the 
severity of alcoholism was defined, the author found a statistically significant 
difference in the prevalence of the A1 allele between the severe and less 
severe forms (47.7%, n=285 vs 31.6%, n=351, including genotypes A1/A1 and 
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A1/A2). Also, there was a significant difference in the prevalence of the A1 
allele between control groups not assessed for substance abuse and those from 
which alcoholics and drug abusers were excluded (31.1%, n=399 vs 15.7%, 
n=236). 
 As the findings of the review by Noble (1998a) were taken together, the more 
severe alcoholic subjects had an A1 allele prevalence three times higher that 
that of the assessed non-dependent controls. This difference was statistically 
highly significant. Even the less severe alcoholics had an A1 allele prevalence 
twice as high as that of the assessed "clean" controls. However, the A1 allele 
prevalence was almost identical among the less severe alcoholics and the non-
assessed controls. The author emphasized two critical factors: the type of 
alcoholics, and the nature of the controls. Noble (1998a) claimed that population 
stratification bias was excluded since the analysis consisted of a large number 
of white subjects from different geographic regions. He concluded that DRD2 
TaqI A polymorphism is an important gene in alcoholism, and also in other 
substance use disorders (Noble, 1998a; Noble, 1998b). 
 Later studies on TaqI A and alcoholism not listed in the reviews above have 
also shown confounding results. Hietala et al. (1997) in Finland found a 
significantly higher A1 allele frequency among 70 alcoholics compared with 50 
controls, but no association with the severity of alcoholism. Edenberg et al. 
(1998b) studied a large family-based sample, genotyping almost 1000 mainly 
white individuals from 100 families, a sample collected in the COGA study. The 
TDT and the Affected Family-Based Controls tests were applied, but failed to 
find either linkage or association between the DRD2 gene locus or TaqI A 
polymorphism and alcoholism. Konishi and colleagues first studied 130 Mexican 
American alcoholic men and controls for several polymorphisms, but failed to 
find any association between TaqI A and alcoholism. Later they expanded the 
alcoholic study group up to 200, and found an association between both the 
TaqI A1 allele and TaqI B1 allele and very early onset alcoholism, indicating a 
severe form of alcoholism (Konishi et al., 2004). In a study among 140 white 
PTSD (post traumatic stress disorder) patients and controls, the A1 allele 
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frequency was significantly higher in the heavy drinking half of the patients 
(Young et al., 2002). In this modest sample of 40 heavy drinking patients, the 
A1 allele was associated with alcohol abuse, but only if the subject also had 
PTSD (anxiety symptoms). Berggren et al. (2006) studied 357 male alcoholic 
inpatients and 800 controls in Sweden, and found an excess of the A1 allele 
among alcoholics. However, the OR for alcoholism with the A1 allele in their 
study was low, only 1.34. 
 
2.5 Summary of the literature review 
Alcohol abuse and dependence seem to be among the most strongly familial 
and inherited psychiatric disorders. The lifetime prevalence of these disorders 
combined is probably as high as 20%. Also, there is a frequent comorbidity with 
other psychiatric disorders and dependence of other drugs of abuse. Alcoholism 
is also a heterogenous condition, different forms of this brain disease having 
different courses. So the model of inheritance must be complex, different 
subtypes probably having different genetic aetiologies, and the relationship 
between genetic and environmental impact varying depending on the subtype. 
Some forms of the disorder may be more strongly genetically determined than 
others. The observed common comorbidity of alcoholism with other psychiatric 
disorders increases the heterogeneity, and also suggests the polygenic 
inheritance of alcoholism. Each of the suspicious alleles adds a piece to the 
burden of vulnerability, increasing the probability of one or more disorders being 
expressed. 
 To obtain reliable results, the study subjects affected with alcoholism should 
be classified into subtypes modelled on the basis of research evidence. 
Intermediate phenotypes, more homogenous clinical subgroups with common 
neurobiology, and in some cases common genetic vulnerability, have been 
developed for molecular genetics studies to increase the power of association 
studies. Cloninger’s neurogenetic model developed on even earlier research 
evidence offers a simple way to classify alcoholics into subgroups (type 1 and 
2) in clinical interview sessions. 
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 The effects of acute alcohol intoxication on neurotransmission in the animal 
and human brain indicate involvement of several neurotransmitters. Dopamine 
and serotonin still appear to be among the most crucial ones. So far, most of 
the studies of an association between alcoholism and candidate genes have 
been about genes involved in neurotransmission. The genes involved in 
serotonin and dopamine neurotransmission have been extensively studied, but 
the findings have been equivocal. The importance of biological support for the 
study hypothesis has been emphasized: the use of functional polymorphisms 
with known effects on brain protein synthesis may yield results easier to 
interpret. 
 Concerning the polymorphisms listed above, which are suspected to 
predispose to alcohol use disorders, it should be noted that only a few are 
functional mutations. The functional exceptions include alcohol 
metabolic/pharmacokinetic polymorphisms ADH1B (His47Arg, allele 
frequencies 0.65/0.35, Southeast Asia) and ALDH2 (Glu487Lys, 0.65/0.35, 
Southeast Asia), histaminergic HNMT (Thr105Ile, 0.90/0.10), and possibly 5-
HT3B encoding for a serotonergic receptor. Also, dopaminergic COMT 
(Val158Met, 0.51/0.49) and serotonergic 5-HTTLPR (L/S, 0.60/0.40), the crucial 
polymorphisms in our studies, are distinctively functional, but at the same time 
very common, as can be seen from the observed allele frequencies (Bevilacqua 
and Goldman, 2009). On the other hand, there is considerable research interest 
and activity in GABA receptor genetics, but no functional mutations have been 
detected yet. Along with new data, this situation can, of course, change very 
rapidly in the near future. 
 Alcohol consumption habits in human populations form a continuum, starting 
from total abstinence and continuing through social drinking, heavy drinking, 
and abuse to the endpoint of severe dependence and disability. Considering the 
polygenic nature of vulnerability to alcoholism, it can be suggested that the 
genetic factors influencing the vulnerability might be expressed, to some extent, 
among the socially drinking population as well, related to the amounts of alcohol 
consumed. This indicates a need for studies of suspicious candidate gene 
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effects among social drinkers, as well, if population samples large enough are 
available. The ultimate purpose of candidate gene studies, of course, is to find 
out the differences in the neurobiology of the different forms of alcoholism. This 
would help in the development and targeting of medical treatments for this 
disorder. 
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3 AIMS OF THE STUDY 
 
This study investigated whether there are associations between alcohol 
consumption in humans and the polymorphisms of selected candidate genes. 
Alcoholic subjects were classified as type 1 or type 2, as Cloninger (1987; 1995) 
has suggested. COMT and 5-HTTLPR genotypes were compared between 
these groups and healthy controls (and the general population) in studies I–III. 
COMT and DRD2 TaqI A genotypes were studied among a large sample of 
non-alcoholic socially drinking males in studies IV and V. 
 
The specific aims: 
 
1. To study the functional polymorphism (Val158Met) in the COMT gene 
(encoding cerebral dopamine inactivation) among alcoholics and controls. I–II 
 
2. To study the functional polymorphism 5-HTTLPR (L/S) in the serotonin 
transporter gene (coding transporter synthesis) among alcoholics and controls. 
III 
 
3. To study the functional COMT (Val158Met) polymorphism in a large 
representative sample of socially drinking males. IV 
 
4. To study the DRD2 gene TaqI A polymorphism (A1/A2) (possibly affecting 
DRD2 receptor availability in the human brain) in a large representative sample 
of socially drinking males. V 
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4 MATERIAL AND METHODS 
 
4.1 Study subjects and diagnostics 
The study protocols were approved by the Research Ethics Committees of 
Kuopio University/Kuopio University Hospital and Turku University/Turku 
University Hospital (studies I–III), or the Research Ethics Committee of Kuopio 
University/Kuopio University Hospital (studies IV–V). All participants gave 
written informed consent to participate in the studies. The diagnoses of the 
index subjects were made according to DSM-III-R or DSM-IV (American 
Psychiatric Association, 1987, or 1994). All index and control subjects were 
white males of Finnish origin. The exact numbers of the index subjects from the 
same samples in studies I–III or IV–V show a slight variation between the 
studies, depending on whether the particular genotype studied was obtained in 
the genotype analysis. 
 
4.1.1 Type 1 alcoholic subjects 
The type 1 alcoholic population (total n=123 in studies I–II, and n=114 in study 
III) consisted of two independent Finnish samples of male alcoholics from the 
regions of Turku (n=67–65) and Kuopio (n=56–49). The sample in Turku 
consisted of alcoholics entering a detoxification program in that area, and 
patients in Kuopio were recruited with the help of a local rehabilitation center for 
alcoholics, where they had obtained treatment for their alcoholism. The mean 
age (±SD) of these subjects was 44.1±8.8 years (studies I–II) or 43.8±8.8 (study 
III). Inclusion criteria were serious alcohol-related problems (alcohol abuse or 
dependence resulting in a failure to fulfil obligations at work or in recurrent 
social problems) starting after the age of 25 years. The onset of alcohol-related 
problems was determined by interviewing the subjects. 
 All these type 1 patients fulfilled the Diagnostic and Statistical Manual of 
Mental Disorders’ (third edition, revised, DSM-III-R; American Psychiatric 
Association, 1987) criteria for alcohol abuse or dependence, and underwent a 
clinical examination and a self-administered Michigan Alcoholism Screening 
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Test (MAST, Selzer, 1971). Exclusion criteria were major mental disorders such 
as schizophrenia, schizophreniform and schizoaffective disorders, mood 
disorders with psychotic features, organic mental syndromes and disorders, and 
paranoid and other psychoses (screened with the Hopkins Symptoms Checklist 
90 and a clinical interview by a physician). Subjects with a history of violence or 
severe antisocial behavior, or severe physical illness, were also excluded. The 
crucial differential diagnostic factors for the alcoholic subject to be included in 
the type 1 alcoholic group were the onset of drinking problems after the age of 
25 years and the lack of a violent antisocial history, according to Cloninger’s 
model. 
 
4.1.2 Type 2 alcoholic subjects 
The type 2 alcoholics (n=62 in study II, and n=51 in study III) were committed 
for forensic psychiatric examination in a state mental hospital (Niuvanniemi 
Hospital, Kuopio) after committing an impulsive violent offense (homicide, 
attempted homicide, aggravated violent assault, assault, sexual offense, or 
arson). In Finland, most persons charged with serious violent offenses are 
committed for forensic psychiatric evaluation: 70% of all homicide offenders, for 
example, are evaluated (Eronen et al., 1996), and most of the offenders who 
are considered very violent or dangerous are evaluated in Niuvanniemi Hospital 
regardless of their residence. Therefore, the offenders included in this study 
were representative of habitually violent offenders in the Finnish male 
population. Based on the data gathered, all were recidivist offenders, although 
just under 10% of them had not been convicted in court before the evaluation. 
Forty percent of the subjects had committed at least one homicide or an 
attempted homicide and aggravated violent assaults, and 25% had committed 
at least 2 homicides or attempted homicides. The mean age (±SD) of these 
subjects was 30.4± 8.2 years in study II and 30.1±8.4 years in study III. 
 All type 2 alcoholics were subjected to an extensive forensic psychiatric 
examination including a psychiatric evaluation, standardized psychological 
tests, evaluation of physical condition with laboratory tests, 
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electroencephalography (EEG), magnetic resonance imaging (MRI), and staff 
observation in a security ward for 4–8 weeks. Inclusion criteria were serious 
alcohol-related problems before the age of 25 years and the co-morbid 
diagnosis of ASP disorder fulfilling DSM-IV (American Psychiatric Association, 
1994) criteria. Abuse or dependence had resulted in recurrent social problems 
and recurrent substance-related legal problems, fulfilling DSM-III-R criteria for 
alcohol abuse or dependence (American Psychiatric Association, 1987). The 
onset of alcohol-related problems was determined within a 1-year accuracy on 
the basis of data gathered from various sources during the forensic psychiatric 
evaluation. Exclusion criteria were major mental disorders such as 
schizophrenia, schizophreniform, and schizoaffective disorders, mood disorders 
with psychotic features, organic mental syndromes and disorders, and paranoid 
and other psychoses or severe physical illness. 
 
4.1.3 Controls (studies I–III) 
Previously published data on COMT genotypes of 3140 blood donors (Syvänen 
et al., 1997) were used as a model of the Finnish general population. There 
were also 267 unrelated controls (mean age±SD=54.6±6.92 years) from the 
Kuopio Ischemic Heart Disease Risk Factor Study (KIHD) (Salonen, 1988) 
reporting low or moderate alcohol use (self-reported avarage alcohol intake = 
1–7 drinks/week and MCV<101 FI, GGT<80 u/l). (For more details about the 
KIHD subjects, see below.) The controls in study III were 54 unrelated healthy 
males from the Turku and Kuopio regions in Finland (mean age±SD=44.1±7.9 
years). 
 
4.1.4. The representative sample of socially drinking males (studies IV–V) 
The Kuopio Ischemic Heart Disease Risk Factor Study (KIHD) is a population- 
based epidemiological study launched in the 1980s to investigate previously 
unestablished risk factors for myocardial infarction, progression of 
atherosclerosis, and other major health outcomes in middle-aged men 
(Salonen, 1988; Lakka et al., 1994; Lynch et al., 1994). The total sample of the 
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KIHD study consists of 2,682 men who were recruited in two cohorts. The 
present study is based on the second cohort, an age-stratified sample of 42-, 
48-, 54-, and 60-year-old men (n=1516, participation rate 82.6%) enrolled in the 
study between 1984 and 1989. Men who had reported no use of alcohol for at 
least 12 months were defined as abstainers (n=123, 11% in study IV; and 
n=100, 10% in study V). Since abstainers are a fairly heterogenous group 
consisting of lifetime non-drinkers as well as those who have quit because of 
health problems or other reasons, they were excluded from final analyses. The 
proportion of abstainers in this sample is similar to the 10% oserved in the 
general population in Finland (Nylander et al., 2007). From the remaining 
subjects, both sociodemographic and genotype data (COMT in study IV and 
DRD2 in study V) were available for 896 subjects and 884 subjects, 
respectively. 
 The study population was a random sample of men living in the city of 
Kuopio, or neighboring rural areas. The mean age (±SD) of the volunteers was 
51.9 (±6.73) years in study IV, and 56.1 (±6.7) years in study V. A variety of 
sociodemographic, behavioral and medical assessments were done according 
to the KIHD protocol as described earlier (Lakka et al., 1994; Lynch et al., 
1994). Age, place of residence (urban/rural), marital status, educational level 
(represented by a 7-point scale from less than elementary=1 to academic 
degree=7), current income, history of smoking in cigarette-years, and history of 
physician-diagnosed chronic diseases (ischemic heart disease, diabetes, 
stroke, cancer, diseases of the liver or pancreas, mental disorder) and severe 
trauma were recorded in the questionnaire and double-checked by the research 
staff in the interview. 
 A self-report quantity-frequency questionnaire derived from the Scandinavian 
Drinking Survey (Hauge and Irgens-Jensen, 1981) was used to record the level 
of alcohol use. The average weekly consumption of alcohol in pure ethanol 
(g/week) was calculated based on the known alcoholic content of each 
beverage type and the reported doses and frequencies of drinking sessions 
(Kauhanen et al., 1997). Serum gamma-glutamyltranspeptidase (GGT) and 
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mean corpuscular volume (MCV) was determined from baseline blood samples 
as biomarkers of excessive alcohol use. These biochemical measures were 
checked to validate the self-report data. The correlation of self-reported alcohol 
consumption with the GGT and MCV measures separately at various levels of 
alcohol consumption has been examined earlier. There was no indication of 
differential misclassification due to erroneous reporting (Kauhanen et al., 1992). 
 
4.2 Genotype analysis 
 
4.2.1 COMT 
COMT genotypes were determined by two different methods. In studies I–II 
genotypes were determined by restriction fragment length polymorphism 
(RFLP) analysis from DNA extracted from the subjects’ peripheral blood by an 
investigator unaware of phenotype, as described earlier in Lachman et al. 
(1996). Briefly, the polymorphism is generated by the presence of a G or an A 
encoding a valine or methionine at codon 158. A 210 base pair 32P-
radiolabeled PCR product was generated using the primers 5’-CTCATCAC-
CATCGAGATCAA and 5’-GATGACCCTGGTGATAGTGG (nucleotides 1881–
1900 and 2071–2090 in GenBank accession number z26491) (Tenhunen et al., 
1994). The PCR product (10 l) was treated with 5 units of Nla III for 3 hr at 
37°C and then separated by electrophoresis using 8% nondenaturing 
polyacrylamide gels (Lachman et al., 1996). The allele sizes for the COMT 
polymorphism are 85 nucleotides for the H allele and 67 for the L allele. There 
are two other bands that are common to both genotypes - 54 and 71 
nucleotides. 
 In study IV DNA was extracted from 10 ml of ethylenediaminetetraacetic 
acidanticoagulated venous blood using standard salting-out or phenol-
chloroform assays. COMT genotypes were determined by restriction fragment 
length polymorphism (RFLP) analysis from the DNA by an investigator unaware 
of the phenotype. The polymorphism is generated by the presence of a G or A 
encoding a valine or methionine at codon 158 and recognized by the heat-
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shock protein (hsp) 92 I1 restriction enzyme in the presence of A. A 179 base 
pair polymerase chain reaction (PCR) product was generated using the primers 
forward 5’-CTGCTGGAGCTGGGGGCCTAC-3’ and reverse 5’-AGGTCTTCAG-
GAATGC-3’. The reverse primer introduces a one-nucleotide mismatch to 
remove hsp 92 II restriction site at codon 164. The PCR product (5 l) was 
treated with two units of hsp 92 II for 16 hr at 37°C and then analyzed by 2% 
agarose gel electrophoresis. The diagnostic bands are 179 (valine) and 139 
(methionine). 
 
4.2.2 5-HTTLPR 
DNA was extracted from venous blood by an investigator unaware of the 
phenotype. The 5-HTT promoter polymorphism was detected by PCR using the 
primers TGAATGCCAGCAGCAGCACCTAACCC and TTCTGGTGCCACCT-
AGACGC. The PCR reaction was carried out in a 20-l volume containing 
approximately 100 ng of genomic DNA and Deep Vent polymerase (New 
England Biolabs, Beverly, MA, USA). After an initial denaturation step of 96°C 
for 2 min, the cycling parameters were 40 cycles consisting of 96°C for 30 s, 
61°C for 1 min, and 71°C for 1 min. The PCR fragment was radio labelled by 
including 5 mCi32 PdCTP in the reaction mix. In order to facilitate complete 
melting of this GC-rich region of the genome, 7-deazaguaine (New England 
Biolabs) to a final concentration of 0.5 mM was added. The PCR product is a 
406/450 base pair fragment that was resolved by electrophoresis through a 4% 
non-denaturing acrylamide gel and visualized by autoradiography. 
 
4.2.3 DRD2 TaqI A 
DNA was extracted from whole blood using standard procedures. Subjects were 
genotyped by an investigator unaware of the phenotype for the TaqIA RFLP 
polymorphism of the D2 receptor gene, as previously described (Grandy et al., 
1993). The polymorphism was detected by PCR using primers 5’-
CCGTCGACGGCTG-GCCAAGTTGTCTA-3’ and 5’-CCGTCGACCCTTCCT-
GAGTGTCATCA-3’. PCR was performed according to standard conditions of 
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94°C 1 min, 50°C 1 min, and 92°C 1.5 min consisting of 35 cycles. Digestion of 
10l of the PCR products was accomplished overnight with 5 units of TaqI 
enzyme under oil at 65°C. Three fragments of 310 bp, 180 bp, and 130 bp show 
the A1/A2 genotype. The A2/A2 genotype is indicated by two fragments of 180 
bp and 130 bp, and the A1/A1 genotype is revealed by the uncleaved 310 bp 
fragment. All three fragments are resolved on 1% agarose gel and can be 
visualized by staining with ethidium bromide (Grandy et al., 1993). 
 
4.3 Statistical analysis 
 
4.3.1 Studies I–III 
Genotype and allele distributions were analysed and compared using the chi-
square test. Odds ratios and 95% confidence intervals were calculated as 
described by Morris and Gardner (1998). The effect of age was studied 
(association was adjusted for age) using logistic regression analysis. In study I 
the population aetiological (attributable) fraction was calculated as described in 
Armitage and Berry (1994). 
 
4.3.2 Studies IV–V 
We compared the age-adjusted weekly alcohol consumption level in the three 
genotypes using the analysis of variance, checking whether the homogeneity of 
variance meets the assumptions for the model. Socio-demographic background 
variables, smoking and prior diseases, i.e. the confounding factors originally 
selected for the KIHD study in the 1980s (Lakka et al., 1994; Lynch et al., 
1994), were controlled for in the multivariate model. SPSS statistical software 
was used in all analyses. 
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5 RESULTS
 
5.1 COMT polymorphism among alcoholics and controls (I–II) 
The COMT genotype and allele (L=met, H=val) frequencies are shown in Table 
1. The COMT genotypic distributions were in Hardy–Weinberg equilibrium 
among all the groups of cases and controls. The L allele frequency was higher 
among the type 1 alcoholic subjects both in Turku (x2=5.21, P=0.023) and in 
Kuopio (x2=8.03, P=0.005) when compared with the general population. When 
the pooled data from all type 1 cases (n=67+56=123) were compared with the 
data from the general population (blood donors), the difference was statistically 
highly significant (x2=12.7, P=0.0004). The L allele frequency was significantly 
higher among type 1 alcoholics (pooled together) when compared with matched 
controls (x2=6.78, P=0.009), as well. When the genotypes of all type 1 
alcoholics (n=123) were compared with the genotypes of matched controls, the 
odds ratio (OR) for alcoholism for those subjects having the LL genotype vs 
those with the HH genotype was 2.51 (95% CI 1.22–5.19, P=0.006). The age-
adjustment in the logistic regression analysis had only a small effect on the 
odds ratio (OR for LL vs HH genotype 2.79, 95% CI 1.23–6.35, P=0.015). The 
odds ratio (OR) for type 1 alcoholism for LL genotype vs LH or HH genotype 
combined was 1.55 (95% CI 0.95–2.53, x2=3.43, P=0.064) when compared with 
controls, and this OR was 1.64 when type 1 alcoholics were compared with the 
general population. 
 
 
Table 1. COMT Genotype and allele frequencies 
 Genotype Allele
TYPE 1 CASES (n=123) LL LH HH L H
Turku (n=67) 22 (0.33) 35 (0.52) 10 (0.15) 0.59 0.41 
Kuopio (n=56) 20 (0.36) 30 (0.54)   6 (0.11) 0.63 0.38 
Total (n=123) 42 (0.34) 65 (0.53) 16 (0.13) 0.61 0.39 
TYPE 2 CASES (n=62) 14 (0.22) 32 (0.52) 16 (0.26) 0.48 0.52 
CONTROLS      
Blood donors (n=3140)1 0.24 0.50 0.26 0.49 0.51 
Healthy subjects (n=267)  67 (0.25) 136 (0.51) 64 (0.24) 0.51 0.49 
 
1Data obtained from the study by Syvänen et al. (1997) 
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Since the controls were from the same area as the alcoholics (type 1) in the 
Kuopio sample, the allele and genotype frequencies were also compared 
between these two (more homogenous) populations from Eastern Finland 
(Kuopio type 1 alcoholics vs matched controls). The L allele frequency was 
higher among these alcoholics (x2=5.29, P=0.021) than controls, and the OR for 
LL vs HH genotype was 3.18 (95% CI 1.11–9.53, x2=5.83, P=0.016). The 
population aetiological (attributable) fraction for the LL genotype in alcoholism 
was 13.3% (95% CI 2.3–25.7%). This was calculated by using the OR obtained 
for LL vs LH plus HH genotypes in the comparison of alcoholics and the general 
population (OR 1.64). The respective estimate based on the OR from the 
comparison with the matched controls from the Kuopio area was 12%. The 
population attributable risk was calculated from =e (-1): [1+e (-1)], where 
e is the proportion of the population exposed, and  is the relative risk (= OR). 
 The type 2 alcoholics did not differ from the general population or controls 
when compared for allele frequencies or genotypic distribution. Adjusting for 
age using logistic regression analysis had no significant effect on the similarity 
of the genotypic distribution of type 2 alcoholics and controls. However, the L 
allele frequency was significantly higher among type 1 alcoholics (x2=4.98, 
P=0.026) when compared with type 2 cases. The LL/LH genotype was more 
common in type 1 alcoholism than in type 2 alcoholism, the OR being 2.33 
(95% CI 1.00–5.41, P=0.030). The OR for type 1 alcoholism when compared 
with type 2 cases for those subjects with the LL genotype versus the HH 
genotype was even higher (OR=3.00, 95% CI 1.09–8.37, P=0.017). 
 
5.2 5-HTTLPR polymorphism among alcoholics and controls (III) 
The 5-HTTLPR genotype and allele frequencies are shown in Table 2. The 
genotype distributions were in Hardy–Weinberg equilibrium among type 2 
alcoholics and controls, but not among type 1 alcoholics (x2=11.9, 1 d.f., 
P<0.001). The S allele frequency was higher among type 2 alcoholics when 
compared with healthy controls (x2=8.24, P=0.004) and type 1 alcoholics 
(x2=4.86, P=0.028). Since genotype distribution among type 1 alcoholics was 
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not in Hardy–Weinberg equilibrium, the difference in allele frequency between 
type 2 and type 1 alcoholics was also studied with the more conservative 
Cochran–Armitage trend test (P=0.055). The OR for being a type 2 alcoholic 
compared with controls, and having the SS genotype, as opposed to the LL 
genotype, was 3.90, 95% Cl 1.37–11.11, P=0.011. Adjustment for age in the 
logistic regression analysis only slightly attenuated the relationship (OR 3.59). 
For homozygous SS genotype vs LS and LL genotypes, the OR was 3.14, 95% 
CI 1.12–9.02, P=0.015. There were no statistically significant differences in 
genotype or allele distributions when type 1 alcoholics were compared with 
healthy controls. 
 
 
Table 2. 5-HTTLPR genotypes and allele frequencies 
 Genotype Allele
 LL LS SS L S
Type 1 (n=114) 50 (0.44)  37 (0.32) 27 (0.24) 0.60 0.40 
Type 2 (n=51) 15 (0.30)  18 (0.35) 18 (0.35) 0.47 0.53 
Healthy controls (n=54) 26 (0.48)  20 (0.37)   8 (0.15) 0.67 0.33 
 
The table shows the serotonin transporter promoter genotype and allele frequencies among type 1 
and type 2 alcoholic subjects and healthy controls (L = Long, S = short allele of 44-bp insertion-
deletion polymorphism). 
 
 
5.3 COMT polymorphism among socially drinking males (IV) 
The mean age of the 896 subjects was 51.9 years (SD 6.73), ranging from 42 to 
61 years. The COMT genotype and allele frequencies are shown in Table 3. 
The genotypic distribution in the study population was in Hardy-Weinberg 
equilibrium (x2=1.15, 1 df, P=0.28). Table 4 shows the distribution of age and 
other background factors in the three COMT genotype groups. There were no 
marked differences in any of these variables. Also, there were no significant 
differences in the biomarkers of alcohol abuse between the three genotypes. 
The means and standard deviations of GGT were 27.8 units per litre (SD 30.2) 
in the LL group, 28.1 units per litre (SD 24.8) in the LH group, and 32.8 units per 
litre (SD 36.9) in the HH group (F=1.82, 2 df, P=0.17). For MCV, the means and 
standard deviations were 91.9 fl (SD 4.52) for the LL genotype, 92.0 fl (SD 4.28) 
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for LH, and 92.1 fl (SD 4.77) for HH (F=0.08, 2 df, P=0.93). The Pearson 
correlation coefficient between alcohol consumption and GGT was 0.27 
(P<0.001) in the total sample, 0.24 (P<0.001) in the LL genotype, 0.36 
(P<0.001) in the LH genotype, and 0.23 (P< 0.01) in the HH genotype. For 
alcohol consumption and MCV, the correlations in the total sample and in the 
LL, LH, and HH genotypes were 0.22 (P<0.001), 0.25 (P<0.001), 0.18 
(P<0.001), and 0.23 (P<0.01), respectively. 
 The age-adjusted weekly ethanol consumption was higher in the LL genotype 
group (103.4 g/week, SD 168.6) than among heterozygotes (78.7 g/week, SD 
192.3) or HH homozygotes (83.1 g/week, SD 123.0) (F=3.09, 2 df, P<0.05). A 
test for homogeneity of variances (P=0.647) indicated the appropriateness of 
the analysis. The alcohol use in the LL group was 27% higher compared with 
the two other groups combined. A multivariate adjustment for age, place of 
residence, education, income, marital status, smoking in cigarette-pack-years, 
and history of ischemic heart disease, stroke, cancer, diabetes, liver disease, 
mental disorder, and severe trauma did not affect the relationship, and the 
differences in weekly drinking remained statistically significant (F=3.48, 2 df, 
P=0.031) (Table 5). Of the covariates, young age (P<0.01) and living in an 
urban area (P<0.05) were associated with higher level of drinking. Smoking 
showed the expected relationship with a high drinking level (P<0.001). None of 
the other variables in the model had any association with alcohol use. 
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Table 3. COMT Genotypes and Allele Frequencies in the Population Sample of 896 Middle-
Aged Finnish Men 
 Genotype (Total 896) Allele
 LL LH HH L H
 
269 (30.0%)
 
428 
(47.8%) 
 
199 (22.2%) 
 
0.54 
 
0.46 
 
 
Table 4. Means (Standard Deviations) and proportions of background variables in the three 
COMT genotype groups 
LL (n=269) LH (n=428) HH (n=199) Total (n=896) 
Age (yr)  52.6 (SD7.0)  51.6 (SD 6.5) 51.7 (SD 6.8) 51.9 (SD6.7)  
Living in rural area (%) 24 21 24 22 
Annual income (Finnish marks) 87,496 (SD 54,052) 91,504 (SD 56,034) 90,130 (SD 49,833) 90,000 (SD 54,265) 
Educational level (1=low, 7=high) 2.01 (SD 1.74) 2.06 (S.D 1.78) 2.10 (SD 1.75) 2.05 (SD 1.77) 
Married (%) 88  88  91  89  
Cigarette smoking (pack-years) 168.7 (SD 310.1)  170.5 (SD 322.1)  166.0(SD 300.3)  168.0 (SD 312.7)  
Ischemic heart disease (%)  24  21  22  22  
Diabetes (%)  4  4  2  3  
History of cancer (%)  1  2  3  2  
History of stroke (%)  1  2  3  2  
Liver disease (%)  1  1  2  1  
History of mental disorder (%)  4  5  5  5 
History of serious trauma ('YO)  7  12  10  10  
 
 
Table 5. Mean weekly alcohol consumption in pure ethanol among the COMT genotype 
groups
COMT genotypes 
LL LH HH p value 
Age-adjusted mean alcohol consumption (g/week) 103.4 78.7 83.1 0.046 
Mean alcohol consumption (g/week) adjusted for 
all covariates 
 
 
103.7 
 
77.7 
 
83.8 
 
0.031 
 
 
5.4 TaqI A polymorphism among socially drinking males (V) 
The TaqI A genotypes and the self-reported ethanol consumption (g/week) 
among the non-abstainer subjects (n=884) are shown in Table 6. The table also 
shows the weekly ethanol consumption adjusted for 13 covariates. The 
genotypic distribution of the study population was in Hardy-Weinberg 
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equilibrium. There was no significant difference in the overall genotype 
distribution between the 100 abstainers and the 884 non-abstainers (A1A1 2% 
vs 7%; A1A2 30% vs 35%; A2A2 68% vs 59%). Among the 884 non-abstainers, 
the alcohol consumption in the homozygous A1A1 group was about 30% lower 
than in the A1A2 group, and 40% lower than in the A2A2 group (F=3.180, d.f. 2, 
P=0.042; F=3.200, d.f. 2, P=0.041 in an adjusted multivariate model). 
 
 
Table 6. Self-reported ethanol consumption (g/week, mean	SD) among the 884 
nonabstainer
subjects, classified into three groups according to their DRD2 TaqI A genotype 
A1A1 A1A2 A2A2
 n=58 (0.07) n=306 (0.35)  n=520 (0.59)  p value 
Ethanol consumption (g/week	SD) 58	64 82	126 97	133 0.042 
Ethanol consumption adjusted for 13 
covariates 
 
55  
 
86 
 
97 
 
0.041 
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6 DISCUSSION 
6.1 COMT (I–II)
The most prominent finding was the significant difference between type 1 
alcoholics and controls or the general population, and on the other hand, 
between type 1 and type 2 alcoholics, considering the frequencies of the COMT 
L (Met) allele or LL genotype. In this regard, type 2 alcoholics were more or less 
similar to the controls. This would mean that either the effect of dopaminergic 
COMT polymorphism is insignificant in the development of type 2 alcoholism, or 
the effect of this polymorphism is different in these two types of alcoholism. On 
the other hand, previous studies of neurobiology have shown predominantly 
serotonergic defects in type 2 alcoholism. 
 A later study using a large sample drawn from the Australian general 
population (862 white subjects) found no association between COMT genotype 
and present symptoms of alcoholism (Henderson et al., 2000). Nakamura et al. 
(2001) could not detect any significant differences in COMT allele frequencies 
or genotypes between 91 male Japanese alcoholics and 114 controls, not even 
between the subgroups considering the age of onset of alcoholism or history of 
violent behaviour. Wang et al. (2001) found a preferential transmission of the L 
allele to early-onset alcoholic subjects by applying the transmission 
disequilibrium test (TDT) among 70 German parents/offspring trios. Horowitz et 
al. (2000) found a significant excess of the H (Val) allele in a group of 38 heroin-
addicted Israelis from 35 families compared with 38 controls, using family-based 
haplotype relative risk testing. However, they failed to replicate their finding 
when using a case control design among a different but larger group of 
ethnically heterogenous heroin addicts. Enoch et al. (2006a) studied ethnically 
homogenous Plains American Indians (342 females and males), and detected a 
significant excess of COMT H allele among alcoholic subjects. 
 The studies above, published after our two studies on COMT polymorphism 
and alcoholism, did not unanimously support or contradict our findings. It is still 
safe to refer to our original hypothesis made at the end of 1990s, suggesting 
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that ethanol induces longer-lasting and more effective dopamine release and 
euphoria when the inactivation rate of this catecholamine is markedly reduced, 
as is the case with LL carriers. That would favour the development of late-onset 
type 1 alcoholism. In early-onset type 2 alcoholism with antisocial and impulsive 
violent behaviour, this would probably have a minor impact. In other words, type 
2 disorder is more or less determined by serotonergic deficits starting from an 
early age, substance use disorders being only one (secondary) symptom of the 
syndrome. 
 Since our studies were published, new data have emerged concerning the 
role of COMT polymorphism and especially showing that L (Met) allele carriers 
gain better prefrontal cognitive function and also increased vulnerability to 
anxiety and lower pain threshold. H (Val) allele carriers show the opposite traits. 
So there is a balance of advantages in better cognitive function vs better stress 
resiliency - i.e. the worrier/warrior model (Oroszi and Goldman, 2004; Goldman 
et al., 2005a). As a paradox, the worrier/warrior model would actually explain 
why H allele carriers might also be vulnerable to the development of substance 
use disorders (and alcoholism) through impulsivity, being less capable of 
thorough consideration and planning before acting. The findings by Caspi et al. 
(2008) supported this showing an association between the COMT H/H genotype 
and antisocial behaviour in children with ADHD, a combination known to 
strongly predispose to adult criminality and substance use disorders. 
Consequently, both of the COMT Val158Met alleles may increase vulnerability 
to alcoholism through different effects on brain function (Ducci and Goldman, 
2008). On the other hand, there was no excess of H allele or HH genotype in 
our sample of extremely impulsive violent type 2 alcoholics compared with 
controls: the frequencies were almost identical. Therefore, these results would 
not indicate any major impact of COMT polymorphism in the development of 
type 2 alcoholism, at least not in our sample of habitually and extremely violent 
type 2 alcoholics. These samples of alcoholic subjects, of limited size, indicated 
only the effect of the COMT L (Met) allele in the predisposition to type 1 
alcoholism. 
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 The subgroup of type 1 alcoholics, representing probably the as much as 
80% of alcoholics, is not a properly defined intermediate phenotype of 
alcoholism, being too large and heterogenous. However, the association 
between the COMT genotype and alcoholism in our sample of type 1 alcoholics 
was clear. Through clever and careful patient selection, excluding antisocial 
subjects and those suffering from major mental disorders, we may have found 
an anxiety-prone subgroup of type 1 alcoholics. After all, patients seeking 
treatment in detoxification and rehabilitation clinics in Finland, such as the 
subjects in our sample, do that on their own initiative. This may reflect the fact 
that they are more inclined to anxiety, and especially feelings of guilt, than their 
peers. Thus, what we found was that COMT L allele may have increased the 
risk for the development of alcohol dependence by increasing the vulnerability 
to stress and anxiety in this subpopulation. They probably had an increased risk 
for alcohol disorders due to other genetic and environmental factors, as well. 
 
6.2 5-HTTLPR (III) 
Our results very clearly showed an excess of S allele among type 2 alcoholics 
compared with healthy controls or type 1 alcoholics. In this regard, there was no 
significant difference when type 1 alcoholics were compared with controls. 
Considering genotypes, the risk was greatest for the homogenous SS group 
versus LL carriers (OR 3.90). For the SS genotype versus LS and LL genotypes 
combined, the risk was somewhat lower (OR 3.14). Adjustment for age is 
crucial, because type 2 subjects according to the definition and to their risk-
taking lifestyles tend to be younger, and are at risk of early death, compared 
with type 1 subjects with a more social life history. However, adjustment only 
slightly attenuated the difference here, the OR for SS genotype versus LL 
remaining 3.59. 
 The published studies since the end of the 1990s have reported contradicting 
results on associations between 5-HTTLPR and alcoholism. A study involving 
almost 1000 Japanese alcoholic subjects and matched controls could not find 
any association in general, but the SS genotype was significantly more common 
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among binge drinking alcoholics (Matsushita et al., 2001). Kranzler et al. (2002) 
studied 471 mainly European-American early-onset alcoholic subjects and 
controls, and Johann et al. (2003) 534 German alcoholics (with comorbid 
ADHD) and controls. Neither of these studies could detect any association. 
Parsian and Cloninger (2001) observed an excess of the L allele among 130 
white alcoholics compared with controls. A study with 350 Korean male 
alcoholics and controls also found an association between the L allele and 
alcoholism (Kweon et al., 2005). There have also been numerous reports of an 
association between the S allele and alcoholism (total sample sizes including 
index subjects and controls in parentheses): among French alcoholics with 
suicidal behaviour (170) (Gorwood et al., 2000); among German and Hungarian 
alcoholic probands (90) and their parents (Lichtermann et al., 2000); among 
German and Hungarian alcoholic individuals with suicidal behavior (280) 
(Preuss et al., 2001); among European-American alcoholic subjects with 
depression (550) (Nellissery et al., 2003); and among Mexican-American 
alcohol-dependent subjects (451) (Konishi et al., 2004). A trend towards a 
similar association was observed in studies by Thompson et al. (2000) and by 
Stoltenberg et al. (2002). 
 A comprehensive meta-analysis (Feinn et al., 2005) gathered data 
investigating associations between 5-HTTLPR alleles and alcoholism from 17 
studies involving 3500 alcoholics and 2300 controls, most of them of European 
ancestry. Fifteen of these studies used a case-control design, and two used the 
transmission disequilibrium test (TDT). There was an overall trend towards an 
association between the S allele and alcoholism. Of the potential moderator 
variables (year of publication, sample size, sex or age, S allele frequencies 
among alcoholics or controls, non-European descent, diagnostic criteria used, 
or co-occurring clinical feature), only the co-occurring clinical feature had a 
significant effect. These included antisocial behavior, early onset, or severe 
form of dependence, suicidal behaviour, ADHD, depression, or Tourette’s 
syndrome. These co-occuring features explained the majority of the between-
study variance in a random-effects model. For all the studies combined, the OR 
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for the S allele was 1.18, indicating that the S allele increased the odds by at 
least 18% for an individual to be diagnosed with alcoholism. However, the 
studies among alcoholics with a co-occurring clinical feature yielded an even 
higher OR of 1.22. 
 Based on the data available at the end of the 1990s, 5-HTTLPR 
polymorphism in this study was genotyped as consisting of two alleles. The later 
reports of triallelic 5-HTTLPR polymorphism, where L alleles are classified into 
high-expressing La and low-activity Lg, do not agree on the functional impact of 
these two L alleles. However, La alleles would still constitute the majority of the 
L alleles, the frequency of low-acitivity Lg alleles in white populations being 
0.09, at most. Even Hu et al. (2006) speculated, after introducing the triallelic 5-
HTTLPR, that the main result of ignoring the triallelic nature of this 
polymorphism and not scoring the low function Lg allele, is to obscure the effect 
of the highest expressing LaLa genotype. Hu et al. (2006) concluded that the 
effect would be less crucial for phenotypes previously associated with the low 
activity S allele. Unfortunately, re-analysing the genotypes was not possible in 
the present study. 
 Low-activity SS genotype is suggested to lead to lower production of 
serotonin transporter (5-HTT), and theoretically to higher levels of serotonin in 
the synaptic cleft. How would this explain the reduced serotonin transmission 
observed in type 2 alcoholics? One explanation could be that the excess of 
synaptic 5-HT is probably present in early childhood already, in individuals who 
are later in danger of developing the symptoms of type 2 alcoholism. This 
constant early excess of 5-HT would induce desensitisation of various 
postsynaptic 5-HT receptors. Alternatively, or simultaneously, an increase in 
synaptic 5-HT stimulating presynaptic 5-HT autoreceptors would lead to a 
decrease in presynaptic 5-HT release. Either way, the net effect would be a 
decrease in the brain 5-HT transmission, clinically expressed as an antisocial, 
impulsive and violent lifestyle, combined with substance use disorders, including 
alcoholism. 
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 There is a considerable body of data supporting Cloninger’s neurogenetic 
model. This evidence indicates that childhood antisocial conduct disorder 
preceding adult-onset antisocial personality disorder with habitual impulsive 
violent behaviour is actually the core syndrome, with alcoholism and abuse of 
other substances being secondary, not the cause of the behavioural deviation. 
Considering this, we may have found an association between an 
endophenotype and alcoholism. In other words, the association was not 
between the 5-HTTLPR S allele and alcoholism per se, which would just have 
added another argument to the contradictory findings on this polymorphism. 
Instead, we found an association between this transporter polymorphism and an 
impulsive, habitually violent antisocial behavioural pattern with alcoholism and 
other substance abuse (in other words, type 2 alcoholism). The antisocial, 
impulsive, habitually and extremely violent alcoholics carefully screened for this 
study represent the "hard-core" of the antisocial alcoholics. Samples consisting 
of only similar index subjects, corresponding to our sample selection, have not 
been used in other studies of alcoholism. Obviously, there are great difficulties 
in collecting a sample like ours, as these offenders usually are non-compliant to 
any medical intervention. This may in part explain why true replications of this 
study have been uncommon, and our study has remained more or less unique. 
 
6.3 COMT polymorphism among socially drinking males (IV) 
In this study we replicated the finding of an association between alcohol 
consumption and COMT genotype, observed among type 1 alcoholics in studies 
I and II, among a large number of non-alcoholic socially drinking males in 
Eastern Finland. The effect of the low-activity COMT L (met) allele in increasing 
weekly alcohol consumption was not dose-dependent. Both groups of 
homozygous subjects (LL and HH genotypes) consumed more than 
heterozygous LH subjects. This does not indicate a very strong single gene 
effect or dominance of the L allele. Nevertheless, the differences between the 
LL carriers and the two other genotype groups were clear and significant, the LL 
group consuming 27% more than the other two groups combined. Even after 
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controlling for the confounding factors (multivariate adjustment), this difference 
remained significant. 
 The obvious conclusion to draw from the results would be that the COMT 
genotype has an impact on the development of alcohol consumption habits, 
among other genetic and environmental factors. Our original explanation for this 
was the same as for the association between COMT and alcoholism that we 
discovered in our first study: individuals with low activity LL genotype may 
experience a more intense and slowly fading euphoria induced by the alcohol 
releasing dopamine in the brain. This still sounds like a logical interpretation of 
this later finding as well. 
 On the other hand, as discussed above concerning studies I and II, we have 
the two-way characteristic of the COMT genotype that probably played a role in 
keeping both alleles very common in the human genome. This means the 
balance of gaining better cognitive function but worse stress and pain resiliency 
for carriers of the L allele, and slightly diminished executive cognitive 
performance but higher pain threshold and better resilience to stress for H allele 
carriers. The LL genotype would lead to excessive worrying and vulnerability to 
alleviating the stress by drinking. Again, the LL group, which consumed most 
alcohol, may have consisted of worriers, as was speculated in connection with 
the link between COMT and type 1 alcoholism. On the other hand, the 
association between the COMT L allele and better cognitive performance is 
based on the evidence of brain imaging studies in humans (Egan et al., 2001; 
Oroszi and Goldman, 2004; Goldman et al., 2005a). It was predicted that the 
COMT genotype would make a difference in available dopamine, measured 
with metabolic activity of the human frontal cortex during cognitive performance, 
because the levels of dopamine transporters are low in this brain region. The 
COMT capacity then becomes rate-limiting in dopamine turnover. From this 
point of view the hypothesis of longer-lasting dopamine induced euphoria while 
drinking alcohol is supported, too. 
 In the results of this study we can also see the effect of the H allele in 
drinking, though only as a trend, not as a statistically significant finding. 
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Homozygous HH men consumed more alcohol than heterozygous LH males. 
This has been found in some studies of alcoholism as well. It has been 
explained by the dyscontrol or impulsivity of the HH subjects, the warrior-like 
features (Goldman et al., 2005a). Altogether, the results corroborate the 
conclusions that Ducci and Goldman (2008) presented in a recent review, 
concerning the alternative ways through which the COMT polymorphism can 
affect the development of alcohol use disorders. The background information 
collected from these subjects, originally recruited for an epidemiological study 
investigating cardiovascular risk factors, was not precise enough to allow further 
conclusions about the differences in alcohol consumption between the genotype 
groups. Again, subtyping into defined intermediate phenotypes might have 
yielded more information, considering the high number of subjects genotyped. 
 
6.4 TaqI A polymorphism among socially drinking males (V) 
We found an evident significant association between TaqI A genotypes and 
weekly alcohol consumption among this large sample of ethnically 
homogenous, non-alcoholic middle-aged males. The study design was almost 
identical to that of study IV, on a different polymorphism, but still with a 
suspected impact on dopaminergic neurotransmission and reward pathways in 
the human brain. The earlier research on neurobiology and reward 
mechanisms, as well as Cloninger’s neurogenetic model of alcoholism, strongly 
suggest an association between decreased availability of DRD2 receptors and 
markedly increased amounts of consumed alcohol (in alcoholism). Also, most 
previous studies on TaqI A polymorphism seem to suggest a weak association 
between the A1 allele and alcoholism, though there have been numerous 
conflicting findings as well (a meta-analysis by Smith et al., 2008). An existing 
association would be a reasonable conclusion, because the A1 allele has been 
claimed to associate with decreased DRD2 availability in humans (Pohjalainen 
et al., 1998; Jönsson et al., 1999; Hirvonen et al., 2004). However, our results 
did not corroborate these suggestions: they indicated an opposite association of 
decreased DRD2 availability and reduced weekly alcohol consumption. 
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 Unfortunately, the functional impact of TaqI A on DRD2 availability has not 
yet been solved. It was originally suggested that this polymorphism is in a 
linkage disequilibrium with another more functional polymorphism affecting 
DRD2 availability. However, there is a serious problem in this notion, since TaqI 
A does not lie anywhere near the DRD2 gene, and could not possibly regulate 
the expression of this gene. Recently, TaqI A was located in an adjacent 
ANKK1 gene, possibly affecting dopaminergic transmission through cellular 
responses (Neville et al., 2004). It was later shown to be associated with the 
enzymatic biosynthesis of dopamine (Laakso et al., 2005). There is also a 
reported linkage disequilibrium between TaqI A and C957T polymorphisms, the 
latter located in the DRD2 gene with a suggested functional effect on the 
receptor, possibly even shared with TaqI A. Consequently, it is still possible that 
the studied TaqI A is functional and related to DRD2, either on its own, by a 
mechanism so far unknown, or through LD. After the discovery of the 
connection of TaqI A with the ANKK1 gene, possible family-based associations 
in 220 white COGA families (n=1923) were re-analysed. The results suggest 
that there are several genes clustered in the chromosomal region containing the 
DRD2 gene which may be involved in the risk for alcoholism. The involvement 
of multiple genes may also provide an explanation for the inconsistency in the 
literature surrounding the role of DRD2 in alcoholism (Dick and Bierut, 2006). 
 The latest meta-analysis by Smith et al. (2008) gathered 44 studies, with 
almost 9400 participants, investigating the association between TaqI A 
polymorphism and the risk for alcohol dependence. They found a small but 
significant association in both dominant and recessive modes of gene action 
(higher risk for A1A2 and A1A1 genotypes, respectively), with an odds ratio of 
1.38 (95% CI 1.20–1.58). Given the modest effect size of the meta-analysis, the 
authors speculated that many of the original studies included may have been 
underpowered: as more studies were published in the course of time, the 
pooled odds ratio decreased approaching one. Because of the polarity of 
opinion on the role of TaqI A, the publication bias may not have markedly 
hindered the publishing of negative findings, showing a lack of association. The 
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lack of ethnic matching, as well as inadequate blinding or screening of controls, 
may explain the heterogeneity observed between studies. The authors 
concluded that TaqI A remained one of the possible polymorphisms affecting 
the multigenetic risk for alcoholism (Smith et al., 2008). 
 Our hypothesis when planning the study among non-alcoholic subjects was 
originally developed after the report of Phillips et al. (1998) showing low ethanol 
preference and consumption in knock-out mice totally lacking DRD2 receptors. 
Also, we were dissatisfied with most of the previous studies on TaqI A, because 
they generally included very few subjects with the A1A1 genotype. The previous 
findings in small ethnically varying samples were also hard to generalize 
because the allele frequencies showed a considerable variation in different 
populations. In our study we had a large ethnically homogenous and 
representative population sample of Finnish males. Since they were not 
alcoholics, we were not looking for an association with alcoholism, and the 
genetic aetiology of social drinking habits might not be the same as that of 
alcoholism. Whatever the functional impact of TaqI A is, this impact would not 
probably be very specific for alcoholism. The aetiologies of these two lifestyles - 
alcoholic or socially drinking - are probably different, and even the effect of the 
same genes may differ in them. This last assumption seems reasonable 
considering the reviews of the subject (the latest by Smith et al., 2008) still 
showing an association between alcoholism and TaqI A1 allele. This is quite the 
reverse to our findings among non-alcoholic drinkers. 
 Our results confirmed our original hypothesis, showing that males with the 
A1A1 genotype (and presumably the lowest DRD2 density) consumed 40% less 
alcohol than A2A2 males with the highest DRD2 density, if associated with TaqI 
A polymorphism. Heterozygous subjects showed an intermediate consumption, 
indicating a dose-dependent effect of the A1 allele in these non-alcoholic 
subjects. As shown in Table 6, the standard deviation in drinking quantities was 
the smallest in the least-drinking A1A1 group, suggesting that they are 
homogenous concerning their drinking habits. Munafò et al. (2005) also had two 
large population-based cohorts of white subjects from the UK, originally 
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randomly selected to participate in a study on genetic associations with tobacco 
smoking. The final study samples consisted of 400 and 500 subjects of both 
sexes, aged 35–75 years. Abstainers were excluded, which led to quite high 
exclusion rates from the original samples (67% and 76%). Also, men consuming 
more than 50 units per week and women consuming more than 35 units per 
week were excluded to avoid the inclusion of alcoholic subjects. This last 
exclusion may still have left some heavy drinkers of both sexes in the study 
samples. A significant association was found between the TaqI A1 allele and 
reduced alcohol consumption, the effect being stronger in men (A1/A1 and 
A1/A2 genotypes combined vs A2/A2 genotype, A1/A1 being rare, n=39). The 
authors thus replicated our findings, even though in their study the number of 
subjects after exclusions was considerably smaller than in ours. 
 The observed association with alcohol consumption is most easily explained 
by the proposed association between TaqI A genotypes and DRD2 availability. 
Non-alcoholic individuals with low densities of DRD2 may not gain as much 
pleasure from drinking and the extra dopamine released, because they lack the 
postsynaptic binding sites of dopamine which mediate reward and euphoria. 
This interpretation is not in conflict with that offered in the discussion concerning 
COMT polymorphism among the same subjects. In that study we had basically 
intact dopamine release and binding sites, only the effect of dopamine was 
sustained in subjects with slower inactivation of this transmitter. We are actually 
talking about the same phenomenon in these two contexts: more euphoria with 
longer lasting dopamine effect, or less euphoria with subtle dopamine 
transmission. Considering the development of alcoholism, there very probably 
are several other genetic and environmental factors with an equal or stronger 
impact. The TaqI A genotype is just one risk factor among others, acting 
differently in subjects vulnerable to alcoholism than in non-alcoholic individuals.
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7 SUMMARY AND CONCLUSIONS 
 
1. The results of these five studies on the functional dopaminergic and 
serotonergic polymorphisms showed significant associations in different 
populations consuming different amounts of alcohol. This further confirms 
the evidence from previous research indicating crucial roles of dopamine- 
and serotonin-mediated neurotransmission in the development of alcohol 
use habits, and alcohol abuse and dependence, i.e. alcoholism. 
2.  Alcoholism is a heterogenous disorder. Type 1 alcoholism, the category 
containing the majority of alcoholics, showed an association with the 
dopaminergic COMT polymorphism, but not with the serotonergic 5-HTTLPR 
polymorphism. 
3. Type 2 alcoholism, with ASP and habitual impulsive violent behaviour, 
showed an association with the serotonergic 5-HTTLPR polymorphism, but 
not with the dopaminergic COMT polymorphism. 
4. The dichotomy of the results on COMT and 5-HTTLPR polymorphisms 
among type 1 and type 2 alcoholics is consistent with the dopaminergic and 
serotonergic deficits suggested previously concerning these subtypes of 
alcoholism. These subtypes are based on Cloninger’s neurogenetic model, 
which was originally developed in the 1980s, before the era of molecular 
genetics, but has gained support from later molecular genetics studies, 
including studies I–III here. 
5.  The dopaminergic polymorphisms COMT and TaqI A showed an association 
with alcohol consumption among socially drinking males, indicating the role 
of dopamine-mediated reward mechanisms in regulating non-alcoholic 
drinking patterns. 
6.  Careful diagnostic procedures, classification and subtyping of alcoholic 
study subjects are essential given the heterogenous nature of this disorder. 
Comorbid disorders should be screened for to support the formulation of 
clinical subtypes. 
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 An association study alone does not prove causality. In linkage, haplotype or 
candidate gene association studies there is always the possibility of missing a 
true association or finding a false one by chance. The use of complicated 
statistical analysis in genetics epidemiology has also met criticism, especially 
multiple testing. However, there was a substantial body of research data on two 
differentially inherited types of alcoholism with different behavioural traits, and 
data supporting differences in dopaminergic and serotonergic 
neurotransmission between the two types of alcoholism. Consequently, the 
results of studies I–III concerning these subtypes, and the observed dichotomy 
at the genetic level, were more or less a confirmation of previous observations. 
 Connected to the COMT studies I–II, study IV also seems to stand on sound 
reasoning, with quite reasonable results. Only study V lacks a strong theoretical 
background, because there was no clear evidence of the functional biological 
impact of the TaqI A polymorphism. New data have emerged, but the possible 
functional nature of TaqI A has not yet been clarified. However, it was one of 
the most extensively studied polymorphisms in alcoholism in the 1990s. Our 
study subjects were not alcoholics, and our results contradict previous results 
on this polymorphism in alcoholism. However, our results confirmed our original 
hypothesis, and the role of dopamine and reward mechanisms in regulating 
drinking patterns. 
 The obvious recommendation for the future would be careful diagnosing and 
the subtyping of alcoholic subjects during clinical interview sessions, whenever 
possible. The screening of comorbid mental disorders, not just major mental 
disorders, is of utmost importance. This applies not only in research but also in 
clinical treatment planning. At the moment, there are few effective medical 
treatments for alcoholism in general. This is particularly the case in antisocial 
type 2 alcoholism, but also the treatment and prevention of type 1 alcoholism 
essentially is the treatment of comorbid depression and anxiety. For type 2 
subjects at the moment, preventive methods at an early age, even before the 
childhood conduct disorder is fully developed, are probably the treatment of 
choice. Given these basic clinical facts, the importance of screening for 
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comorbid disorders is clear when the purpose is to assess the realistic choices 
of treatments for an alcoholic patient. 
 Considering the conflicting results of the previous or later research, we very 
probably would not have obtained any significant results if we had studied our 
alcoholic subjects as one group, without subgroups. The sample sizes should 
have been many times larger than we had in order to discover any association 
among unclassified alcoholics. The large sample sizes we had in studies IV–V 
are still uncommon in psychiatric genetics studies, and even here we were 
studying an epidemiological population sample which was not designed for a 
study of alcoholism and did not consist of affected individuals. Because 
collecting large samples of affected individuals in psychiatry is a vast effort, 
defining subtypes, i.e. intermediate phenotypes, is strongly recommended in 
future studies. Another recommendation would be to concentrate on functional 
rather than non-functional polymorphisms when candidate gene association 
studies are concerned. This strategy will probably yield significant findings with 
reasonable interpretations. However, genome-wide association studies in the 
near future may vastly increase the possibilities to reveal the genetic 
determinants of various diseases and health-related phenomena in general. 
 
116
8 REFERENCES
 
1. American Psychiatric Association. Diagnostic and statistical manual of 
mental disorders 3rd ed., revised. Washington, DC: APA, 1987. 
 
2. American Psychiatric Association. Diagnostic and statistical manual of 
mental disorders 4th ed. Washington, DC: APA. 1994. 
 
3. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, 
Goldman D. An Evaluation of -Opioid Receptor (OPRM1) as a 
Predictor of Naltrexone Response in the Treatment of Alchol 
Dependence: Results from the Combined Phamacotherapies and 
Behavioral Interventions for Alcohol Depence (COMBINE) Study. Arch 
Gen Psychiatry. 2008;65:135–44. 
 
4. Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, 
Koivisto T, Mäkelä R, Kranzler HR. Effects of Opioid Receptor Gene 
Variation on Targeted Malmefene Treatment in Heavy Drinkers. 
Alcohol Clin Exp Res. 2008;32:1159–66. 
 
5. Armitage P, Berry G. Statistical Methods in Medical Research, 3nd 
edn. Blackwell Publications: Oxford, 1994. 
 
6. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, 
Dolinsky ZS, Rounsaville B. Types of alcoholics, I. Evidence for an 
empirically derived typology based on indicators of vulnerability and 
severity. Arch Gen Psychiatry. 1992;49:599–608. 
 
7. Ball D, Collier D. Substance misuse. In: Psychiatric Genetics & 
Genomics (Eds. McGuffin P, Owen MJ, Gottesman II), pp 267–279. 
Oxford University Press, 2002 
117
8. Barr CL, Kidd KK. Population frequencies of the A1 allele at the 
dopamine D2 receptor locus. Biol Psychiatry. 1993;34:204–9. 
 
9. Belfer I, Hipp H, McKnight C, Evans C, Buzas B, Bollettino A, Albaugh 
B, Virkkunen M, Yuan Q, Max MB, Goldman D, Enoch MA. 
Association of galanin haplotypes with alcoholism and anxiety in two 
ethnically distinct populations. Mol Psychiatry. 2006;11:301–11. 
  
10. Belfer I, Hipp H, Bollettino A, McKnight C, Evans C, Virkkunen M, 
Albaugh B, Max MB, Goldman D, Enoch MA. Alcoholism is associated 
with GALR3 but not two other galanin receptor genes. Genes Brain 
Behav. 2007;6:473–81. 
 
11. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila 
M, Goldman D. Mu opioid receptor gene variants: lack of association 
with alcohol dependence. Mol Psychiatry. 1997;2:490–4. 
  
12. Berggren U, Fahlke C, Aronsson E, Karanti A, Eriksson M, Blennow K, 
Thelle D, Zetterberg H, Balldin J. The TaqI DRD2 A1 allele is 
associated with alcohol-dependence although its effect size is small. 
Alcohol Alcohol. 2006;41:479–85. 
 
13. Berman SM, Ozkaragoz T, Noble EP, Antolin T, Sheen C, Siddarth P, 
Conner BT, Ritchie T. Differential associations of sex and D2 
dopamine receptor (DRD2) genotype with negative affect and other 
substance abuse risk markers in children of alcoholics. Alcohol. 
2003;30:201–10. 
 
14. Bevilacqua L, Goldman D. Genes and addictions. Clin Pharmacol 
Ther. 2009;85:359–61. 
 
118
15. Blum K, Noble EP, Sheridan PJ, Montgomery A, Ritchie T, 
Jagadeeswaran P, Nogami H, Briggs AH, Cohn JB. Allelic association 
of human dopamine D2 receptor gene in alcoholism. JAMA. 
1990;263:2055–60. 
 
16. Bolos AM, Dean M, Lucas-Derse S, Ramsburg M, Brown GL, 
Goldman D. Population and pedigree studies reveal a lack of 
association between the dopamine D2 receptor gene and alcoholism. 
JAMA. 1991;265:2667–8. 
 
17. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic 
neurotransmission, alcoholism, and reward deficiency syndrome. Am J 
Med Genet B Neuropsychiatr Genet. 2005;132B:29–37. 
 
18. Cadoret RJ, Yates WR, Troughton E, Woodworth G, Stewart MA. 
Adoption study demonstrating two genetic pathways to drug abuse. 
Arch Gen Psychiatry. 1995;52:42–52. 
 
19. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, 
Poulton R. Role of genotype in the cycle of violence in maltreated 
children. Science. 2002;297:851–4. 
 
20. Caspi A, Langley K, Milne B, Moffitt TE, O’Donovan M, Owen MJ, Polo 
Tomas MP, Poulton R, Rutter M, Taylor A, Williams B, Thapar A. A 
Replicated Molecular Genetic Basis for Subtyping Antisocial Behavior 
in Children with Attention-Deficit/Hyperactivity Disorder. Arch Gen 
Psychiatry. 2008;65:203–10. 
 
21. Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. 
Science. 1987;236:410–6.  
 
119
22. Cloninger CR, Przybeck TR, Svrakic DM. The Tridimensional 
Personality Questionnaire: U.S. normative data. Psychol Rep. 
1991;69:1047–57. 
 
23. Cloninger CR. The psychobiological regulation of social cooperation. 
Nat Med 1995;1:623–5.  
 
24. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, 
Muhleman D. The dopamine D2 receptor (DRD2) gene: a genetic risk 
factor in smoking. Pharmacogenetics. 1996;6:73–9. 
 
25. Comings DE. Why different rules are required for polygenic 
inheritance: lessons from studies of the DRD2 gene. Alcohol. 
1998;16:61–70. 
 
26. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects 
of behavioral disorders. Prog Brain Res. 2000;126:325–41. 
 
27. Costa PT Jr, McCrae RR. Stability and change in personality 
assessment: the revised NEO Personality Inventory in the year 2000. 
J Pers Assess. 1997;68:86–94. 
 
28. Cotton NS. The familial incidence of alcoholism: a review. J Stud 
Alcohol. 1979;40:89–116. 
 
29. Covault J, Gelernter J, Jensen K, Anton R, Kranzler HR. Markers in 
the 5'-region of GABRG1 associate to alcohol dependence and are in 
linkage disequilibrium with markers in the adjacent GABRA2 gene. 
Neuropsychopharmacology. 2008;33:837–48. 
 
120
30. Dawson DA, Harford TC, Grant BF. Family history as a predictor of 
alcohol dependence. Alcohol Clin Exp Res. 1992;16(3):572–5. 
 
31. De Fruyt F, Van De Wiele L, Van Heeringe C. Cloninger's 
psychobiological model of temperament and character and the Five-
Factor model of personality. Personality and Individual Differences 
2000;29:441–52. 
 
32. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, 
severity, and unmet need for treatment of mental disorders in the 
World Health Organization World Mental Health Surveys. JAMA. 
2004;291:2581–90. 
 
33. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, 
Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, 
Makarov SS, Maixner W. Genetic basis for individual variations in pain 
perception and the development of a chronic pain condition. Hum Mol 
Genet. 2005;14:135–43. 
 
34. Dick DM, Nurnberger J Jr, Edenberg HJ, Goate A, Crowe R, Rice J, 
Bucholz KK, Kramer J, Schuckit MA, Smith TL, Porjesz B, Begleiter H, 
Hesselbrock V, Foroud T. Suggestive linkage on chromosome 1 for a 
quantitative alcohol-related phenotype. Alcohol Clin Exp Res. 
2002;26:1453–60. 
 
35. Dick DM, Foroud T. Genetic strategies to detect genes involved in 
alcoholism and alcohol-related traits. Alcohol Res Health. 
2002;26:172–80. 
 
121
36. Dick DM, Edenberg HJ, Xuei X, Goate A, Hesselbrock V, Schuckit M, 
Crowe R, Foroud T. No Association of the GABAA Receptor Genes on 
Chromosome 5 With Alcoholism in the Collaborative Study on the 
Genetics of Alcoholism Sample. Am J Med Genet Neuropsychiatr 
Genet. 2005;132B: 24–8. 
 
37. Dick DM, Jones K, Saccone N, Hinrichs A, Wang JC, Goate A, Bierut 
L, Almasy L, Schuckit M, Hesselbrock V, Tischfield J, Foroud T, 
Edenberg H, Porjesz B, Begleiter H. Endophenotypes successfully 
lead to gene identification: results from the collaborative study on the 
genetics of alcoholism. Behav Genet. 2006;36:112–26. 
 
38. Dick DM, Bierut LJ. The genetics of alcohol dependence. Curr 
Psychiatry Rep. 2006;8:151–7. 
 
39. Dick DM, Latendresse SJ, Lansford JE, Budde JP, Goate A, Dodge 
KA, Pettit GS, Bates JE. Role of GABRA2 in Trajectories of 
Externalizing Behavior Across Development and Evidence of 
Moderation by Parental Monitoring. Arch Gen Psychiatry. 
2009;66:649–57. 
 
40. Di Castelnuevo A, Costanzo S, Bagnardi V, Donati M B, Iacoviello L, 
de Gaetano G. Alcohol Dosing and Total Mortality in Men and Women. 
Arch Intern Med. 2006;166:2437–45. 
 
41. Ducci F, Goldman D. Genetic approaches to addiction: genes and 
alcohol. Addiction. 2008;103:1414–28. 
 
122
42. Ducci F, Enoch MA, Yuan Q, Shen PH, White KV, Hodgkinson C, 
Albaugh B, Virkkunen M, Goldman D. HTR3B is associated with 
alcoholism with antisocial behaviour and alpha EEG power – an 
intermediate phenotype and co-morbid behaviors. Alcohol. 
2009;43:73–84. 
 
43. Edenberg HJ, Reynolds J, Koller DL, Begleiter H, Bucholz KK, 
Conneally PM, Crowe R, Goate A, Hesselbrock V, Li TK, Nurnberger 
JI Jr, Porjesz B, Reich T, Rice JP, Schuckit M, Tischfield JA, Foroud 
T. A family-based analysis of whether the functional promoter alleles 
of the serotonin transporter gene HTT affect the risk for alcohol 
dependence. Alcohol Clin Exp Res. 1998a;22:1080–5. 
 
44. Edenberg HJ, Foroud T, Koller DL, Goate A, Rice J, Van Eerdewegh 
P, Reich T, Cloninger CR, Nurnberger JI Jr, Kowalczuk M, Wu B, Li 
TK, Conneally PM, Tischfield JA, Wu W, Shears S, Crowe R, 
Hesselbrock V, Schuckit M, Porjesz B, Begleiter H. A family-based 
analysis of the association of the dopamine D2 receptor (DRD2) with 
alcoholism. Alcohol Clin Exp Res 1998b;22:505–12. 
 
45. Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, Crowe 
RR, Goate A, Hesselbrock V, Jones K, Kwon J, Li T-K, Nurnberger JI 
Jr, O'Connor SJ, Reich T, Rice J, Schuckit MA, Porjesz B, Foroud T, 
Begleiter H. Variations in GABRA2, Encoding the 
2 Subunit of the 
GABAA Receptor, Are Associated with Alcohol Dependence and with 
Brain Oscillations. Am J Hum Genet. 2004;74:705–714. 
 
46. Edenberg HJ, Foroud T. The genetics of alcoholism: identifying 
specific genes through family studies. Addict Biol. 2006;11:386–96. 
 
123
47. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, 
Straub RE, Goldman D, Weinberger DR. Effect of COMT Val108/158 
Met genotype on frontal lobe function and risk for schizophrenia. Proc 
Natl Acad Sci USA. 2001;98:6917–22. 
 
48. Ehlers CL, Gilder DA, Wall TL, Phillips E, Feiler H, Wilhelmsen KC. 
Genomic screen for loci associated with alcohol dependence in 
Mission Indians. Am J Med Genet B Neuropsychiatr Genet. 
2004;129B:110–5. 
 
49. Enoch MA, White KV, Harris CR, Robin RW, Ross J, Rohrbaugh JW, 
Goldman D. Association of low-voltage alpha EEG with a subtype of 
alcohol use disorders. Alcohol Clin Exp Res. 1999;23:1312–9. 
 
50. Enoch MA. Pharmacogenomics of alcohol response and addiction. Am 
J Pharmacogenomics. 2003;3:217-32. 
 
51. Enoch MA, Schuckit MA, Johnson BA, Goldman D. Genetics of 
alcoholism using intermediate phenotypes. Alcohol Clin Exp Res. 
2003;27:169–76. 
 
52. Enoch MA, Waheed JF, Harris CR, Albaugh B, Goldman D. Sex 
differences in the influence of COMT Val158Met on alcoholism and 
smoking in plains American Indians. Alcohol Clin Exp Res. 
2006a;30:399–406. 
 
53. Enoch MA, Schwartz L, Albaugh B, Virkkunen M, Goldman D. 
Dimensional Anxiety Mediates Linkage of GABRA2 Haplotypes With 
Alcoholism. Am J Med Genet Neuropsychiatric Genetics. 
2006b;141B:599–607. 
 
124
54. Enoch MA, Shen P-H, Ducci F, Yuan Q, Liu J, White KV, Albaugh B, 
Hodgkinson CA, Goldman D. Common Genetic Origins for EEG, 
Alcoholism and Anxiety: The Role of CRH-BP. PLOsOne 2008a;3:1–
11. 
 
55. Enoch MA. The role of GABA(A) receptors in the development of 
alcoholism. Pharmacol Biochem Behav. 2008b;90:95–104. 
 
56. Enoch MA, Hodgkinson CA, Yuan Q. GABRG1 and GABRA2 as 
independent predictors for alcoholism in two populations. 
Neuropsychopharmacology. 2009a;34:1245–54. 
 
57. Enoch MA, Yuan Q, Hodgkinson CA, Ducci F, Shen P-H, Virkkunen 
M, Roy A, Goldman D. Genes Encoding 5-HT3 Reseptors Influence 
Alcoholism Vulnerability in Two Independent Populations. Meeting 
Abstract 377. Biol Psychiatry 2009b;65:113S. 
 
58. Eronen M, Hakola P, Tiihonen J. Mental disorders and homicidal 
behavior in Finland. Arch Gen Psychiatry 1996;53:497–501.  
 
59. Feinn R, Nellissery M, Kranzler HR. Meta-analysis of the association 
of a functional serotonin transporter promoter polymorphism with 
alcohol dependence. Am J Med Genet B Neuropsychiatr Genet. 
2005;133B:79–84. 
 
60. Fillmore KM, Stockwell T, Chikritzhs T, Bostrom A, Kerr W. Moderate 
alcohol use and reduced mortality risk: systematic error in prospective 
studies and new hyptheses. Ann Epiodemiol 2007;17:S16–23. 
 
125
61. Fu Q, Heath AC, Bucholz KK, Nelson E, Goldberg J, Lyons MJ, True 
WR, Jacob T, Tsuang MT, Eisen SA. Shared genetic risk of major 
depression, alcohol dependence, and marijuana dependence: 
contribution of antisocial personality disorder in men. Arch Gen 
Psychiatry. 2002;59:1125–32. 
 
62. Gardno A, McGuffin P. Quantitative Genetics In: Psychiatric Genetics 
& Genomics (Eds. McGuffin P, Owen MJ, Gottesman II) pp 3–29. 
Oxford University Press, 2002.  
 
63. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and 
alcoholism. Biochem Pharmacol. 2008;75:218–65. 
 
64. Gaziano JM, Hennekens C. Royal Colleges' advice on alcohol 
consumption: Maintaining existing limits seems justified on current 
evidence. Br Med J. 1995;311:3–4. 
 
65. Gelernter J, Goldman D, Risch N. The A1 allele at the D2 dopamine 
receptor gene and alcoholism. A reappraisal. JAMA. 1993;269:1673–
7. 
 
66. Gelernter J, Kranzler H, Cubells JF. Serotonin transporter protein 
(SLC6A4) allele and haplotype frequencies and linkage disquilibria in 
African- and European-American and Japanese populations and in 
alcohol-dependent subjects. Hum Genet. 1997;101:243–6. 
 
67. Gerald MS, Higley JD. Evolutionary underpinnings of excessive 
alcohol consumption. Addiction. 2002;97:415–25. 
 
126
68. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, 
Karayiorgou M. Catechol-O-methyltransferase-deficient mice exhibit 
sexually dimorphic changes in catecholamine levels and behavior. 
Proc Natl Acad Sci USA. 1998;95:9991–6. 
 
69. Goldman D, Dean M, Brown GL, Bolos AM, Tokola R, Virkkunen M, 
Linnoila M. D2 dopamine receptor genotype and cerebrospinal fluid 
homovanillic acid, 5-hydroxyindoleacetic acid and 3-methoxy-4-
hydroxyphenylglycol in alcoholics in Finland and the United States. 
Acta Psychiatr Scand. 1992;86:351–7. 
 
70. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering 
the genes. Nat Rev Genet. 2005a;6:521–32. 
 
71. Goldman D, Oroszi G, O'Malley S, Anton R. Combine genetics: the 
pharmacogenetics of alcoholism treatment response: genes and 
mechanisms, J J Stud Alcohol. 2005b;15S:56–64. 
 
72. Goldman D, Ducci F. Deconstruction of vulnerability to complex 
diseases: enhanced effect sizes and power of intermediate 
phenotypes. TheScientificWorldJournal. 2007;7:124–30. 
 
73. Gorwood P, Batel P, Adès J, Hamon M, Boni C. Serotonin transporter 
gene polymorphisms, alcoholism, and suicidal behavior. Biol 
Psychiatry. 2000;48:259–64. 
 
74. Gottesman II, Gould TD. The endophenotype concept in psychiatry: 
etymology and strategic intentions. Am J Psychiatry. 2003;160:636–
45. 
 
127
75. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, 
Reed L, Magenis RE, Civelli O. The human dopamine D2 receptor 
gene is located on chromosome 11 at q22-q23 and identifies a TaqI 
RFLP. Am J Hum Genet. 1989;45:778–85. 
 
76. Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at 
the DRD2 locus. Hum Mol Genet. 1993;2:2197. 
 
77. Grant BF, Dawson DA. Age of onset of drug use and its association 
with DSM-IV drug abuse and dependence: results from the National 
Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse. 
1998;10:163–73. 
 
78. Guze SB, Cloninger CR, Martin R, Clayton PJ. Alcoholism as a 
medical disorder. Compr Psychiatry. 1986;27:501–10. 
 
79. Halme JT, Seppä K, Alho H, Pirkola S, Poikolainen K, Lönnqvist J, 
Aalto M. Hazardous Drinking: Prevalence and Associations in the 
Finnish General Population. Alc Clin Exp Res 2008;32:1615–22. 
 
80. Haberstick BC, Smolen A, Hewitt JK. Family-based association test of 
the 5HTTLPR and aggressive behavior in a general population sample 
of children. Biol Psychiatry. 2006;59:836–43. 
 
81. Hammoumi S, Payen A, Favre JD, Balmes JL, Benard JY, Husson M, 
Ferrand JP, Martin JP, Daoust M. Does the short variant of the 
serotonin transporter linked polymorphic region constitute a marker of 
alcohol dependence? Alcohol. 1999;17:107–12. 
 
128
82. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, 
Egan MF, Weinberger DR. Serotonin transporter genetic variation and 
the response of the human amygdala. Science. 2002;297:400–3. 
 
83. Hauge R, Irgens-Jensen O. Scandinavian drinking survey: sampling 
operations and data collections. National Institute for Alcohol 
Research: Oslo, 1981. 
 
84. Helakorpi S, Uutela A, Puska P. Työikäisen väestön elintapojen 
muutokset. Ylipaino on yleistynyt ja alkoholin kulutus kasvanut 2007. 
Suomen Lääkärilehti 2007;62:2975–80. 
 
85. Henderson AS, Korten AE, Jorm AF, Jacomb PA, Christensen H, 
Rodgers B, Tan X, Easteal S. COMT and DRD3 polymorphisms, 
environmental exposures, and personality traits related to common 
mental disorders. Am J Med Genet. 2000;96:102–7. 
 
86. Hesselbrock VM, Hesselbrock MN. Are there empirically supported 
and clinically useful subtypes of alcohol dependence? Addiction. 
2006;101S:97–103. 
 
87. Hietala J, West C, Syvälahti E, Någren K, Lehikoinen P, Sonninen P, 
Ruotsalainen U. Striatal D2 dopamine receptor binding characteristics 
in vivo in patients with alcohol dependence. Psychopharmacology 
(Berl). 1994;116:285–90. 
 
88. Hietala J, Pohjalainen T, Heikkilä-Kallio U, West C, Salaspuro M, 
Syvälahti E. Allelic association between D2 but not D1 dopamine 
receptor gene and alcoholism in Finland. Psychiatr Genet. 1997;7:19–
25. 
129
89. Higuchi S, Matsushita S, Kashima H. New findings on the genetic 
influences on alcohol use and dependence [Addictive disorders]. 
Current Opinion in Psychiatry. 2006;19:253–65. 
 
90. Hill SY, Shen S, Zezza N, Hoffman EK, Perlin M, Allan W. A genome 
wide search for alcoholism susceptibility genes. Am J Med Genet B 
Neuropsychiatr Genet. 2004;128B:102–13. 
 
91. Hill SY, Hoffman EK, Zezza N, Thalamuthu A, Weeks DE, Matthews 
AG, Mukhopadhyay I. Dopaminergic Mutations: Within-Family 
Association and Linkage in Multiplex Alcohol Dependence Families. 
Am J Med Genet B Neuropsychiatr Genetics. 2008;147B:517–26. 
 
92. Hirvonen M, Laakso A, Någren K, Rinne JO, Pohjalainen T, Hietala J. 
C957T polymorphism of the dopamine D2 receptor (DRD2) gene 
affects striatal DRD2 availability in vivo. Mol Psychiatry. 2004;9:1060–
1. 
 
93. Hitzemann RJ. The regulation of D2 dopamine receptor expression. 
Mol Psychiatry. 1998;3:198–203. 
 
94. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, 
Ebstein RP. Confirmation of an excess of the high enzyme activity 
COMT val allele in heroin addicts in a family-based haplotype relative 
risk study. Am J Med Genet. 2000;96:599–603. 
 
95. Hu X, Zhu G, Lipsky RH, Goldman D. HTTLPR Allele Expression Is 
Codominant, Correlating with Gene Effects on fMRI and SPECT 
Imaging Intermediate Phenotypes, and Behavior. Biol Psychiatry. 
2004:55;191S. 
 
130
96. Hu X, Oroszi G, Chun J, Smith TL, Goldman D, Schuckit MA. An 
Expanded Evaluation of the Relationship of Four Alleles to the Level of 
Response to Alcohol and the Alcoholism Risk. Alcohol Clin Exp Res. 
2005;29:8–16. 
 
97. Hu X, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, 
Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D. 
Serotonin transporter promoter gain-of-function genotypes are linked 
to obsessive-compulsive disorder. Am J Hum Genet. 2006;78:815–26. 
 
98. Irwin M, Schuckit M, Smith TL. Clinical importance of age at onset in 
type 1 and type 2 primary alcoholics. Arch Gen Psychiatry. 
1990;47:320–4. 
 
99. Ishiguro H, Shibuya H, Toru M, Saito T, Arinami T. Association study 
between high and low activity polymorphism of catechol-O-
methyltransferase gene and alcoholism. Psychiatric Gen. 
1999a;9:135–8. 
 
100. Ishiguro H, Saito T, Akazawa S, Mitushio H, Tada K, Enomoto M, 
Mifune H, Toru M, Shibuya H, Arinami T. Association between 
drinking-related antisocial behavior and a polymorphism in the 
serotonin transporter gene in a Japanese population. Alcohol Clin Exp 
Res. 1999b;23:1281–4. 
 
101. Jackson R, Beaglehole R. Alcohol consumption guide Iines: Relative 
safety vs absolute risks and benefits. Lancet. 1995;346:716. 
 
102. Jellinek EM. The Disease Concept of Alcoholism. New Haven: College 
and University Press, 1960. 
 
131
103. Jibson M, Faull KF, Csernansky JG. Intercorrelations among 
monoamine metabolite concentrations in human lumbar CSF are not 
due to a shared acid transport system. Biol Psychiatry. 1990;28:595–
602. 
 
104. Johann M, Bobbe G, Putzhammer A, Wodarz N. Comorbidity of 
alcohol dependence with attention-deficit hyperactivity disorder: 
differences in phenotype with increased severity of the substance 
disorder, but not in genotype (serotonin transporter and 5-
hydroxytryptamine-2c receptor). Alcohol Clin Exp Res. 2003;27:1527–
34. 
 
105. Johnson BA. Update on neuropharmacological treatments for 
alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 
2008;75:34–56. 
 
106. Jorm AF, Henderson AS, Jacomb PA, Christensen H, Korten AE, 
Rodgers B, Tan X, Easteal S. An association study of a functional 
polymorphism of the serotonin transporter gene with personality and 
psychiatric symptoms. Mol Psychiatry. 1998;3:449–51. 
 
107. Jönsson EG, Nöthen MM, Grnhage F, Farde L, Nakashima Y, 
Propping P, Sedvall GC. Polymorphisms in the dopamine D2 receptor 
gene and their relationships to striatal dopamine receptor density of 
healthy volunteers. Mol Psychiatry. 1999;4:290–6. 
 
108. Kauhanen J, Julkunen J, Salonen JT. Coping with inner feelings and 
stress: heavy alcohol consumption in the context of alexithymia. 
Behav Med. 1992;18:121–6. 
 
132
109. Kauhanen J, Kaplan GA, Goldberg DE, Salonen JT. Beer binging and 
mortality: results from the Kuopio ischaemic heart disease risk factor 
study, a prospective population based study. BMJ. 1997;315:846–51. 
 
110. Kauhanen J, Karvonen MK, Pesonen U, Koulu M, Tuomainen TP, 
Uusitupa MI, Salonen JT. Neuropeptide Y polymorphism and alcohol 
consumption in middle-aged men. Am J Med Genet. 2000;93:117–21. 
 
111. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, 
Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month 
prevalence of DSM-III-R psychiatric disorders in the United States. 
Results from the National Comorbidity Survey. Arch Gen Psychiatry. 
1994;51:8–19. 
 
112. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters 
EE. Lifetime prevalence and age-of-onset distributions of DSM-IV 
disorders in the National Comorbidity Survey Replication. Arch Gen 
Psychiatry. 2005;62:593–602. 
 
113. Kidd KK, Morar B, Castiglione CM, Zhao H, Pakstis AJ, Speed WC, 
Bonne-Tamir B, Lu RB, Goldman D, Lee C, Nam YS, Grandy DK, 
Jenkins T, Kidd JR. A Global survey of haplotype frequencies and 
linkage disequilibrium at the DRD2 locus. Hum Genet. 1998;103:211–
27. 
 
114. Konishi T, Luo HR, Calvillo M, Mayo MS, Lin KM, Wan YJ. ADH1B*1, 
ADH1C*2, DRD2 (-141C Ins), and 5-HTTLPR are associated with 
alcoholism in Mexican American men living in Los Angeles. Alcohol 
Clin Exp Res. 2004;28:1145–52. 
115. Koob GF, LeMoal M. Drug addiction, dysregulation of reward, and 
allostasis. Neuropsychopharmacology. 2001;24:97–129. 
133
 
116. Koob GF. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res. 
2003;27:232–43. 
 
117. Kranzler H, Lappalainen J, Nellissery M, Gelernter J. Association 
study of alcoholism subtypes with a functional promoter polymorphism 
in the serotonin transporter protein gene. Alcohol Clin Exp Res. 
2002;26:1330–5. 
 
118. Kruglyak L. The road to genome-wide association studies. Nat Rev 
Genet. 2008;9:314–8. 
 
119. Krystal JH, Staley J, Mason G, Petrakis JL, Kaufman J, Harris RA, 
Gelernter J, Lappalainen J. -Aminobutyric Acid Type A Receptors and 
Alcoholism. Arch Gen Psychiatry. 2006;63:957–68. 
 
120. Kweon YS, Lee HK, Lee CT, Lee KU, Pae CU. Association of the 
serotonin transporter gene polymorphism with Korean male alcoholics. 
J Psychiatr Res. 2005;39:371–6. 
 
121. Laakso A, Pohjalainen T, Bergman J, Kajander J, Haaparanta M, Solin 
O, Syvälahti E, Hietala J. The A1 allele of the human D2 dopamine 
receptor gene is associated with increased activity of striatal L-amino 
acid decarboxylase in healty subjects. Pharmacogenet Genomics. 
2005;15:387–91. 
 
134
122. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, 
Weinshilboum RM. Human catechol-O-methyltransferase 
pharmacogenetics: description of a functional polymorphism and its 
potential application to neuropsychiatric disorders. Pharmacogenetics. 
1996;6:243–50. 
 
123. Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, 
Salonen JT. Relation of leisure-time physical activity and 
cardiorespiratory fitness to the risk of acute myocardial infarction. 
NEJM. 1994;330:1549–54. 
 
124. Lappalainen J, Long JC, Eggert M, Ozaki N, Robin RW, Brown GL, 
Naukkarinen H, Virkkunen M, Linnoila M, Goldman D. Linkage of 
antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 
populations. Arch Gen Psychiatry. 1998;55:989–94. 
 
125. Lappalainen J, Krupitsky E, Remizov M, Pchelina S, Taraskina A, 
Zvartau E, Sornberg LK, Covault J, Kranzler HR, Krystal JH, Gelernter 
J. Association Between Alcoholism and -Amino Butyric Acid 
2 
Receptor Subtype in a Russian Population. Alcohol Clin Exp Res. 
2005;29:493–8. 
 
126. Laruelle M, Gelernter J, Innis RB. D2 receptors binding potential is not 
affected by Taq1 polymorphism at the D2 receptor gene. Mol 
Psychiatry. 1998;3:261–5. 
 
127. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, 
abuse, and dependence: clinical evidence. Biol Psychiatry. 
1994;36:326–37. 
 
135
128. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, 
Riederer P. Organization of the human serotonin transporter gene. J 
Neural Transm Gen Sect. 1994;95:157–162. 
 
129. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, 
Benjamin J, Müller CR, Hamer DH, Murphy DL. Association of anxiety-
related traits with a polymorphism in the serotonin transporter gene 
regulatory region. Science. 1996;274:1527–31.  
 
130. Liao D-L,  Hong C-J, Shih H-L, Tsai S-J. Possible association between 
serotonin transporter promoter region polymorphism and extremely 
violent crime in Chinese males. Neuropsychobiology. 2004;50:284–7. 
 
131. Lichtermann D, Hranilovi D, Trixler M, Franke P, Jernej B, Delmo CD, 
Knapp M, Schwab SG, Maier W, Wildenauer DB. Support for allelic 
association of a polymorphic site in the promoter region of the 
serotonin transporter gene with risk for alcohol dependence. Am J 
Psychiatry. 2000;157:2045–7. 
 
132. Limosin F, Loze JY, Dubertret C, Gouya L, Adès J, Rouillon F, 
Gorwood P. Impulsiveness as the intermediate link between the 
dopamine receptor D2 gene and alcohol dependence. Psychiatr 
Genet. 2003;13:127–9. 
 
133. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimón R, Goodwin 
FK. Low cerebrospinal fluid 5-hydroxyindolacetic acid concentration 
differentiates impulsive from nonimpulsive violent behavior. Life Sci. 
1983;33:2609–14. 
 
134. Lobo IA, Harris RA. GABA(A) receptors and alcohol. Pharmacol 
Biochem Behav. 2008;90:90–4. 
136
 
135. Long JC. Knowler WC, Hanson RL, Robin RW, Urbanek M, Moore E, 
Bennett PH, Goldman D. Evidence for genetic linkage to alcohol 
dependence on chromosomes 4 and 11 from an autosome-wide scan 
in an American Indian population. Am J Med Genet. 1998;81:216–21. 
 
136. Lynch JW, Kaplan GA, Cohen RD, Kauhanen J, Wilson TW, Smith NL, 
Salonen JT. Childhood and adult socioeconomic status as predictors 
of mortality in Finland. Lancet. 1994;343:524–7. 
 
137. Madrid GA, MacMurray J, Lee JW, Anderson BA, Comings DE. Stress 
as a mediating factor in the association between the DRD2 TaqI 
polymorphism and alcoholism. Alcohol. 2001;23:117–22. 
 
138. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman 
D. A functional polymorphism in the COMT gene and performance on 
a test of prefrontal cognition. Am J Psychiatry. 2002;159:652–4. 
 
139. Martin J, Cleak J, Willis-Owen SA, Flint J, Shifman S. Mapping 
regulatory variants for the serotonin transporter gene based on allelic 
expression imbalance. Mol Psychiatry. 2007;12:421–2. 
 
140. Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews 
AM. Gene dose-dependent alterations in extraneuronal serotonin but 
not dopamine in mice with reduced serotonin transporter expression. J 
Neurosci Methods. 2004;140:169–81. 
 
137
141. Matsushita S, Yoshino A, Murayama M, Kimura M, Muramatsu T, 
Higuchi S. Association study of serotonin transporter gene regulatory 
region polymorphism and alcoholism. Am J Med Genet. 
2001;105:446–50. 
 
142. Melis M, Spiga S, Diana M. The dopamine hypothesis of drug 
addiction: hypodopaminergic state. Int Rev Neurobiol. 2005;63:101-
54. 
 
143. Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton 
B, Zhang H, O'Malley SS, Rounsaville BJ. Familial transmission of 
substance use disorders. Arch Gen Psychiatry. 1998;55:973–9. 
 
144. Merikangas KR, Risch N. Genomic priorities and public health. 
Science. 2003;302:599–601. 
 
145. Morris JA, Gardner MJ. Calculating confidence intervals for relative 
risks (odds ratios) and standardised ratios and rates. Br Med J. 
1988;296:1313–6. 
 
146. Mottagui-Tabar S, Prince JA, Wahlestedt C, Zhu G, Goldman D, Heilig 
M. A novel single nucleotide polymorphism of the neuropeptide Y 
(NPY) gene associated with alcohol dependence. Alcohol Clin Exp 
Res. 2005;29:702–7. 
 
147. Munafò MR, Clark TG, Moore LR, Payne E, Walton R, Flint J. Genetic 
polymorphisms and personality in healthy adults: a systematic review 
and meta-analysis. Mol Psychiatry. 2003;8:471–84. 
 
138
148. Munafò MR, Johnstone EC, Welsh KI, Walton RT. Association 
between the DRD2 gene Taq1A (C32806T) polymorphism and alcohol 
consumption in social drinkers. Pharmacogenomics J. 2005;5:96–101. 
 
149. Mäkelä Pia. Alkoholin käyttö ja haitat lisääntyvät. Duodecim. 
2003;119:2481–7. 
 
150. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin 
transporter gene linked polymorphism (5-HTTLPR) shows ten novel 
allelic variants. Mol Psychiatry. 2000;5:32–8. 
 
151. Nakamura A, Inada T, Kitao Y, Katayama Y. Association between 
catechol-O-methyltransferase (COMT) polymorphism and severe 
alcoholic withdrawal symptoms in male Japanese alcoholics. Addict 
Biol. 2001;6:233–8. 
 
152. Nellissery M, Feinn RS, Covault J, Gelernter J, Anton RF, Pettinati H, 
Moak D, Mueller T, Kranzler HR. Alleles of a functional serotonin 
transporter promoter polymorphism are associated with major 
depression in alcoholics. Alcohol Clin Exp Res. 2003;27:1402–8. 
 
153. Neville MJ, Johnstone EC, Walton RT. Identification and 
Characterization of ANKK1: A Novel Kinase Gene Closely Linked to 
DRD2 on Chromosome Band 11q23.1. Human Mutation. 
2004;23:540–5. 
 
154. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic 
association of the D2 dopamine receptor gene with receptor-binding 
characteristics in alcoholism. Arch Gen Psychiatry. 1991;48:648–54. 
 
139
155. Noble EP, Gottschalk LA, Fallon JH, Ritchie TL, Wu JC. D2 dopamine 
receptor polymorphism and brain regional glucose metabolism. Am J 
Med Genet. 1997;74:162–6. 
 
156. Noble EP. The D2 dopamine receptor gene: a review of association 
studies in alcoholism and phenotypes. Alcohol. 1998a;16:33–45. 
 
157. Noble EP. DRD2 gene and alcoholism. Science. 1998b;281:1287–88. 
 
158. Nylander O, Hauhia P, Kauppinen S, Kiuru S, Notkola IL, Ojala M, 
Rintanen H, Tuomola P, Virtanen A. Yearbook of alcohol and drug 
statistics 2007. Gummerus Kirjapaino Oy, Vaajakoski. Stakes, 2007. 
 
159. Oroszi G, Goldman D. Alcoholism: genes and mechanisms. 
Pharmacogenomics. 2004;5:1037–48. 
 
160. Oroszi G, Enoch M-A, Chun J, Virkkunen M, Goldman D. Thr105Ile, a 
Functional Polymorphism of Histamine N-Methyltransferase, Is 
Associated with Alcoholism in Two Independent Populations. Alcohol 
Clin Exp Res. 2005;29:303–9. 
 
161. Parsian A, Cloninger CR, Zhang ZH. Functional variant in the DRD2 
receptor promoter region and subtypes of alcoholism. Am J Med 
Genet. 2000;96:407–11. 
 
162. Parsian A, Cloninger CR. Serotonergic pathway genes and subtypes 
of alcoholism: association studies. Psychiatr Genet. 2001;11:89–94. 
 
163. Paterson AD. Case-control association studies in complex traits - the 
end of an era? Mol Psychiatry. 1997;2:277–8. 
140
164. Pato CN, Macciardi F, Pato MT, Verga M, Kennedy JL. Review of the 
putative association of dopamine D2 receptor and alcoholism: a meta-
analysis. Am J Med Genet. 1993;48:78–82. 
 
165. Penick EC, Powell BJ, Nickel EJ, Bingham SF, Riesenmy KR, Read 
MR, Campbell J. Co-morbidity of lifetime psychiatric disorders among 
male alcoholic patients. Alcohol Clin Exp Res. 1994;18:1289-93. 
 
166. Phillips TJ, Brown KJ, Burkhart-Kasch S, Wenger CD, Kelly MA, 
Rubinstein M, Grandy DK, Low MJ. Alcohol preference and sensitivity 
are markedly reduced in mice lacking dopamine D2 receptors. Nat 
Neurosci. 1998;1:610–5. 
 
167. Pohjalainen T, Rinne JO, Någren K, Lehikoinen P, Anttila K, Syvälahti 
EK, Hietala J. The A1 allele of the human D2 dopamine receptor gene 
predicts low D2 receptor availability in healthy volunteers. Mol 
Psychiatry. 1998;3:256–60. 
 
168. Ponce G, Jimenez-Arriero MA, Rubio G, Hoenicka J, Ampuero I, 
Ramos JA, Palomo T. The A1 allele of the DRD2 gene (TaqI A 
polymorphisms) is associated with antisocial personality in a sample of 
alcohol-dependent patients. Eur Psychiatry. 2003;18:356–60. 
 
169. Ponce G, Hoenicka J, Jiménez-Arriero MA, Rodríguez-Jiménez R, 
Aragüés M, Martín-Suñé N, Huertas E, Palomo T. DRD2 and ANKK1 
genotype in alcohol-dependent patients with psychopathic traits: 
association and interaction study. Br J Psychiatry. 2008;193:121–5. 
 
170. Prescott CA, Kendler KS. Age at first drink and risk for alcoholism: a 
noncausal association. Alcohol Clin Exp Res. 1999;23:101–7. 
 
141
171. Prescott CA, Sullivan PF, Myers JM, Patterson DG, Devitt M, 
Halberstadt LJ, Walsh D, Kendler KS. The Irish Affected Sib Pair 
Study of Alcohol Dependence: study methodology and validation of 
diagnosis by interview and family history. Alcohol Clin Exp Res. 
2005;29:417–29. 
 
172. Preuss UW, Koller G, Soyka M, Bondy B. Association between suicide 
attempts and 5-HTTLPR-S-allele in alcohol-dependent and control 
subjects: further evidence from a German alcohol-dependent inpatient 
sample. Biol Psychiatry. 2001;50:636–9. 
 
173. Quickfall J, el-Guebaly N. Genetics and alcoholism: how close are we 
to potential clinical applications? Can J Psychiatry. 2006;51:461–7. 
 
174. Radel M, Vallejo RL, Iwata N, Aragon R, Long JC, Virkkunen M, 
Goldman D. Haplotype-based localization of an alcohol dependence 
gene to the 5q34 {gamma}-aminobutyric acid type A gene cluster. 
Arch Gen Psychiatry. 2005;62:47–55. 
 
175. Ray LA, Hutchison KE. Associations among GABRG1, level of 
response to alcohol, and drinking behaviors. Alcohol Clin Exp Res. 
2009;33:1382–90. 
 
176. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, 
Goodwin FK. Comorbidity of mental disorders with alcohol and other 
drug abuse. Results from the Epidemiologic Catchment Area (ECA) 
Study. JAMA. 1990;264:2511–8. 
 
142
177. Reich T, Edenberg HJ, Goate A, Williams JT, Rice JP, Van 
Eerdewegh P, Foroud T, Hesselbrock V, Schuckit MA, Bucholz K, 
Porjesz B, Li TK, Conneally PM, Nurnberger JI Jr, Tischfield JA, 
Crowe RR, Cloninger CR, Wu W, Shears S, Carr K, Crose C, Willig C, 
Begleiter H. Genome-wide search for genes affecting the risk for 
alcohol dependence. Am J Med Genet 1998;81:207–15. 
 
178. Reuter M, Jeste N, Klein T, Hennig J, Goldman D, Enoch MA, Oroszi 
G. Association of THR105Ile, a functional polymorphism of histamine 
N-methyltransferase (HNMT), with alcoholism in German Caucasians. 
Drug Alcohol Depend. 2007;87:69–75. 
 
179. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 
dopamine receptor gene with brain receptor-binding characteristics. 
Neurochem Res. 2003;28:73–82. 
 
180. Roache JD, Wang Y, Ait-Daoud N, Johnson BA. Prediction of 
Serotonergic Treatment Efficacy Using Age of Onset and Type A/B 
Typologies of Alcoholism. Alcohol Clin Exp Res. 2008;32:1502–1512. 
 
181. Room R, Babor T, Rehm J. Alcohol and public health. Lancet. 
2005;365:519–30. 
 
182. Saarnio P, Mäkelä P. Tutkimus alkoholistien kuolleisuudesta. 
Alkoholipolitiikka. 1997;62:344–9. 
 
183. Saito T, Lachman HM, Diaz L, Hallikainen T, Kauhanen J, Salonen JT, 
Ryynänen OP, Karvonen MK, Syvälahti E, Pohjalainen T, Hietala J, 
Tiihonen J. Analysis of monoamine oxidase A (MAOA) promoter 
polymorphism in Finnish male alcoholics. Psychiatry Res. 
2002;109:113–9. 
143
184. Salonen JT. Is there a continuing need for longitudinal epidemiologic 
research? The Kuopio Ischaemic Heart Disease Risk Factor Study. 
Ann Clin Res. 1988;20:46–50. 
 
185. Sander T, Harms H, Lesch KP, Dufeu P, Kuhn S, Hoehe M, 
Rommelspacher H, Schmidt LG. Association analysis of a regulatory 
variation of the serotonin transporter gene with severe alcohol 
dependence. Alcohol Clin Exp Res. 1997;21:1356–9. 
 
186. Sander T, Harms H, Dufeu P, Kuhn S, Hoehe M, Lesch KP, 
Rommelspacher H, Schmidt LG. Serotonin transporter gene variants 
in alcohol-dependent subjects with dissocial personality disorder. Biol 
Psychiatry. 1998;43:908–12. 
 
187. Schuckit MA, Tipp JE, Smith TL, Shapiro E, Hesselbrock VM, Bucholz 
KK, Reich T, Nurnberger JI Jr. An evaluation of type A and B 
alcoholics. Addiction. 1995;90:1189–203. 
 
188. Schuckit MA, Mazzanti C, Smith TL, Ahmed U, Radel M, Iwata N, 
Goldman D. Selective genotyping for the role of 5-HT2A, 5-HT2C, and 
GABA alpha 6 receptors and the serotonin transporter in the level of 
response to alcohol: a pilot study. Biol Psychiatry. 1999;45:647–51. 
 
189. Schuckit MA, Smith TL, Kalmijn J. The search for genes contributing 
to the low level of response to alcohol: patterns of findings across 
studies. Alcohol Clin Exp Res. 2004;28:1449–58. 
 
144
190. Schumann G, Johann M, Frank J, Preuss U, Dahmen N, Laucht M, 
Rietschel M, Rujescu D, Lourdusamy A, Clarke TK, Krause K, Dyer A, 
Depner M, Wellek S, Treutlein J, Szegedi A, Giegling I, Cichon S, 
Blomeyer D, Heinz A, Heath S, Lathrop M, Wodarz N, Soyka M, 
Spanagel R, Mann K. Systematic analysis of glutamatergic 
neurotransmission genes in alcohol dependence and adolescent risky 
drinking behavior. Arch Gen Psychiatry. 2008;65:826–38. 
 
191. Selzer ML. The Michigan alcoholism screening test: the quest for a 
new diagnostic instrument. Am J Psychiatry. 1971;127:1653–8. 
 
192. Sen S, Burmeister M, Ghosh D. Meta-analysis of the association 
between a serotonin transporter promoter polymorphism (5-HTTLPR) 
and anxiety-related personality traits. Am J Med Genet B 
Neuropsychiatr Genet. 2004;127B:85–9. 
 
193. Seppä K. Alkoholiongelmainen vastaanotolla. Duodecim. 
2003;119:2508–13. 
 
194. Sham P, McGuffin P. Linkage and association In: Psychiatric Genetics 
& Genomics (Eds. McGuffin P, Owen MJ, Gottesman II) pp 55–73. 
Oxford University Press, 2002. 
 
195. Smith L, Watson M, Gates S, Ball D, Foxcroft D. Meta-analysis of the 
association of the TaqI A polymorphism with the risk of alcohol 
dependency: A HuGE gene-disease association review. Am J 
Epidemiol. 2008;167:125–38. 
 
196. Soyka M, Preuss UW, Hesselbrock V, Zill P, Koller G, Bondy B. 
GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk 
for alcohol dependence. J Psychiatr Res. 2008;42:184–91. 
145
197. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage 
disequilibrium: the insulin gene region and insulin-dependent diabetes 
mellitus (IDDM). Am J Hum Genet. 1993;52:506–16. 
 
198. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, 
Amos CI, Wan Y, Cinciripini P, Hong WK, Wu X. Case-control study of 
the D2 dopamine receptor gene and smoking status in lung cancer 
patients. J Natl Cancer Inst. 1998;90:358–63. 
 
199. Stakes. Psykiatrian luokituskäsikirja. Rauma: Kirjapaino Oy West 
Point, 1997. 
 
200. Stoltenberg SF, Twitchell GR, Hanna GL, Cook EH, Fitzgerald HE, 
Zucker RA, Little KY. Serotonin transporter promoter polymorphism, 
peripheral indexes of serotonin function, and personality measures in 
families with alcoholism. Am J Med Genet. 2002;114:230–4. 
 
201. Syvänen AC, Tilgmann C, Rinne J, Ulmanen I. Genetic polymorphism 
of catechol-O-methyltransferase (COMT): correlation of genotype with 
individual variation of S-COMT activity and comparison of the allele 
frequencies in the normal population and parkinsonian patients in 
Finland. Pharmacogenetics. 1997;7:65–71. 
 
202. Tenhunen J, Salminen M, Lundström K, Kiviluoto T, Savolainen R, 
Ulmanen I. Genomic organization of the human catechol-O-
methyltransferase gene and its expression from two distinct 
promoters. Eur J Biochem. 1994;223:1049–59. 
 
203. Terwilliger JD, Ott J. A haplotype-based 'haplotype relative risk' 
approach to detecting allelic associations. Hum Hered. 1992;42:337–
46. 
146
204. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, 
Morris CM, Perry RH, Ferrier IN, Court JA. D2 dopamine receptor 
gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor 
binding in the human striatum associated with the A1 allele. 
Pharmacogenetics. 1997;7:479–84. 
 
205. Thompson MD, Gonzalez N, Nguyen T, Comings DE, George SR, 
O'Dowd BF. Serotonin transporter gene polymorphisms in alcohol 
dependence. Alcohol. 2000;22:61–7. 
 
206. Tiihonen J, Kuikka J, Bergström K, Hakola P, Karhu J, Ryynänen OP, 
Föhr J. Altered striatal dopamine re-uptake site densities in habitually 
violent and non-violent alcoholics. Nat Med. 1995;1:654–7. 
 
207. Tiihonen J, Kuikka JT, Bergström KA, Karhu J, Viinamäki H, Lehtonen 
J, Hallikainen T, Yang J, Hakola P. Single-photon emission 
tomography imaging of monoamine transporters in impulsive violent 
behavior. Eur J Nucl Med. 1997;24:1253–60. 
 
208. Tiihonen J, Vilkman H, Räsänen P, Ryynänen OP, Hakko H, Bergman 
J, Hämäläinen T, Laakso A, Haaparanta-Solin M, Solin O, 
Kuoppamäki M, Syvälahti E, Hietala J. Striatal presynaptic dopamine 
function in type 1 alcoholics measured with positron emission 
tomography. Mol Psychiatry. 1998;3:156–161. 
 
209. Tiihonen J, Virkkunen M, Räsänen P, Pennanen S, Sainio E-L, 
Callaway J, Halonen P, Liesivuori J. Free L-tryptophan plasma levels 
in antisocial violent offenders. Psychopharmacology (Berl). 
2001;157:395–400. 
 
147
210. Tiihonen J, Rossi R, Laakso MP, Hodgins S, Testa C, Perez J, Repo-
Tiihonen E, Vaurio O, Soininen H, Aronen HJ, Könönen M, Thompson 
PM, Frisoni G. Brain anatomy of persistent violent offenders: More 
rather than less. Psychiatry Res: Neuroimaging. 2008;164:201–12. 
 
211. Tikkanen R, Sjöberg RL, Ducci F, Goldman D, Holi M, Tiihonen J, 
Virkkunen M. Effects of MAOA-Genotype, Alcohol Consumption, and 
Aging on Violent Behavior. Alcohol Clin Exp Res. 2009;33:1–7. 
 
212. Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG, Ioannidis JP. 
Establishment of genetic associations for complex diseases is 
independent of early study findings. Eur J Hum Genet. 2004;12:762–9. 
 
213. Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis 
of ethanol abuse. Prog Neuropsychopharmacol Biol Psychiatry. 
2004;28:1221–47. 
 
214. Uher R, McGuffin P. The moderation by the serotonin transporter gene 
of environmental adversity in the aetiology of mental illness: review 
and methodological analysis. Mol Psychiatry. 2008;13:131–46. 
 
215. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. 
High-activity catechol-O-methyltransferase allele is more prevalent in 
polysubstance abusers. Am J Med Genet. 1997;74:439–42. 
 
216. Veenstra-VanderWeele J, Anderson GM, Cook EH Jr. 
Pharmacogenetics and the serotonin system: initial studies and future 
directions. Eur J Pharmacol. 2000;410:165–81. 
 
148
217. Virkkunen M, Närvanen S. Plasma insulin, tryptophan and serotonin 
levels during the glucose tolerance test among habitually violent and 
impulsive offenders. Neuropsychobiology. 1987;17:19–23. 
 
218. Virkkunen M, De Jong J, Bartko J, Goodwin FK, Linnoila M. 
Relationship of psychobiological variables to recidivism in violent 
offenders and impulsive fire setters. A follow-up study. Arch Gen 
Psychiatry. 1989;46:600–3. 
 
219. Virkkunen M, Kallio E, Rawlings R, Tokola R, Poland RE, Guidotti A, 
Nemeroff C, Bissette G, Kalogeras K, Karonen SL, Linnoila M. 
Personality profiles and state aggressiviness in Finnish alcoholic, 
violent offenders, fire setters, and healthy volunteers. Arch Gen 
Psychiatry. 1994a;51:28–33. 
 
220. Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff 
C, Bissette G, Kalogeras K, Karonen SL, Linnoila M. CSF 
biochemistries, glucose metabolism, and diurnal activity rhythms in 
alcoholic, violent offenders, fire setters and healthy volunteers. Arch 
Gen Psychiatry. 1994b;51:20–7. 
 
221. Virkkunen M, Eggert M, Rawlings F, Linnoila M. A prospective follow-
up study of alcoholic violent offenders and fire setters. Arch Gen 
Psychiatry. 1996a;53:523–9. 
 
222. Virkkunen M, Goldman D, Linnoila M. Serotonin in alcoholic violent 
offenders. In: Genetics of criminal and antisocial behaviour (Bock GR, 
Goode JA, eds), pp 168–177. Chichester, UK: Wiley, 1996b. 
 
149
223. Virkkunen M, Rissanen A, Franssila-Kallunki A, Tiihonen J. Low non-
oxidative glucose metabolism and violent offending: An 8-year 
prospective follow-up study. Psychiatry Res. 2009;168:26–31. 
 
224. Volkow ND, Wang GJ, Fowler JS, Logan J, Hitzemann R, Ding YS, 
Pappas N, Shea C, Piscani K. Decreases in dopamine receptors but 
not in dopamine transporters in alcoholics. Alcohol Clin Exp Res. 
1996;20:1594–8. 
 
225. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, 
Hitzemann R, Pappas NR. Reinforcing effects of psychostimulants in 
humans are associated with increases in brain dopamine and 
occupancy of D(2) receptors. J Pharmacol Exp Ther. 1999;291:409–
15. 
 
226. Walther DJ, Bader M. A unique central tryptophan hydroxylase 
isoform. Biochem Pharmacol. 2003;66:1673–80. 
 
227. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: 
recent advances and challenges. J Neurosci. 2002;22:3332–7. 
 
228. Wang T, Franke P, Neidt H, Cichon S, Knapp M, Lichtermann D, 
Maier W, Propping P, Nöthen MM. Association study of the low-activity 
allele of catechol-O-methyltransferase and alcoholism using a family-
based approach. Mol Psychiatry. 2001;6:109–11. 
 
229. WHO. The ICD-10 classification of mental and behavioural disorders: 
Clinical descriptions and diagnostic guidelines. Geneva: World Health 
Organization, 1993. 
 
150
230. Xu K, Anderson TR, Neyer KM, Lamparella N, Jenkins D, Zhou Z, 
Yuan Q, Virkkunen M, Lipsky RH. Nucleotide sequence variation 
within the human tyrosine kinese B neurotrophin receptor gene 
(NTRK2): association with antisocial alcohol dependence. 
Pharmacogenomics J. 2007;7:368–79. 
 
231. Young RM, Lawford BR, Noble EP, Kann B, Wilkie A, Ritchie T, Arnold 
L, Shadforth S. Harmful drinking in military veterans with post-
traumatic stress disorder: association with the D2 dopamine receptor 
A1 allele. Alcohol Alcohol. 2002;37:451–6. 
 
232. Zhu G, Pollak L, Mottagui-Tabar S, Wahlestedt J, Taubman J, 
Virkkunen M, Goldman D, Heilig M. NPY leu7pro and Alcohol 
Dependence in Finnish and Swedish Populaitons. Alcohol Clin Exp 
Res. 2003;27:19–24. 
 
233. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe 
RA, Stohler CS, Goldman D. COMT val158met genotype affects mu-
opioid neurotransmitter responses to a pain stressor. Science. 
2003;299:1240–3.
Kuopio University Publications D. Medical Sciences 
 
 
D 434. Hassinen, Maija. Predictors and consequences of the metabolic syndrome: population-based 
studies in aging men and women.  
2008. Acad. Diss. 
 
D 435. Saltevo, Juha. Low-grade inflammation and adiponectin in the metabolic syndrome.  
2008. 109 p. Acad. Diss. 
 
D 436. Ervasti, Mari. Evaluation of Iron Status Using Methods Based on the Features of Red Blood 
Cells and Reticulocytes.  
2008. 104 p. Acad. Diss. 
 
D 437. Muukka, Eija. Luomun tie päiväkotiin: luomuruokailun toteutettavuus ja ravitsemuksellinen 
merkitys päiväkotilapsille.  
2008. 168 p. Acad. Diss.  
 
D 438. Sörensen, Lars. Work ability and health-related quality of life in middle-aged men: the role 
of physical activity and fitness.  
2008. 83 p. Acad. Diss.  
 
D 439. Maaranen, Päivi. Dissociation in the finnish general population.  
2008. 97 p. Acad. Diss.  
 
D 440. Hyvönen, Juha. Suomen psykiatrinen hoitojärjestelmä 1990-luvulla historian jatkumon 
näkökulmasta. 2008. 279 p. Acad. Diss.  
 
D 441. Mäkinen, Heidi. Disease activity and remission in rheumatoid arthritis: comparison of 
available disease activity measures and development of a novel disease sctivity indes: the mean overall 
index for rheumatoid arthritis (MOI-RA).  
2008. 129 p. Acad. Diss.  
 
D 442. Kousa, Anne. The regional association of the hardness in well waters and the incidence of 
acute myocardial infarction in rural Finland.  
2008. 92 p. Acad. Diss.  
 
D 443. Olkku, Anu. Glucocorticoid-induced changes in osteoblastic cells: cross-talk with wnt and 
glutamate signalling pathways. 
2009. 118 p. Acad. Diss. 
 
D 444. Mattila, Riikka. Effectiveness of a multidisciplinary lifestyle intervention on hypertension, 
cardiovascular risk factors and musculoskeletal symptoms. 
2009. 92 p. Acad. Diss. 
 
D 445. Hartmann-Petersen, Susanna. Hyaluronan and CD44 in epidermis with special reference 
to growth factors and malignant transformation. 
2009. 103 p. Acad. Diss. 
 
D 446. Tolppanen, Anna-Maija. Genetic association of the tenomodulin gene (TNMD) with 
obesity- and inflammation-related phenotypes. 
2009. 111 p. Acad. Diss. 
 
D 447. Lehto, Soili Marianne. Biological findings in major depressive disorder with special 
reference to the atypical features subtype.  
2009. 115 p. Acad. Diss.  
 
D 448. Nieminen, Jyrki. Effect of functional loading on remodelling in canine, and normal and 
collagen type II transgenic murine bone.  
2009. 107 p. Acad. Diss.  
 
D 449. Torpström, Jaana. Yliopistokoulutus ravitsemusasiantuntijuuden kehittäjänä.  
2009. 164 p. Acad. Diss.  
